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Investigation of biomarkers associated with 
hypergastrinaemia and their responses to 
CCK-2 receptor antagonism 
Katie Alexandra Lloyd 
Gastrin is a hormonal regulator of gastric acid secretion, but also regulates other cellular 
functions in the stomach such as proliferation, migration and apoptosis. Elevated serum 
concentrations of gastrin may dysregulate these processes and contribute to the 
development of gastric neuroendocrine tumours (NETs) and adenocarcinomas. The 
inhibition of gastrin or its subsequent downstream signalling pathways may therefore have 
therapeutic value in gastrin-related disorders including gastric NETs. The aims of this PhD 
were to investigate the role of gastrin in gastric tumour development and to identify 
potential biomarkers for the detection of gastrin-associated cellular phenotypical changes 
which may contribute to the development of gastric pathologies. I also investigated 
whether three novel cholecystokinin type-2 receptor (CCK2R) antagonists inhibited gastrin-
associated morphological changes in the stomach, in vitro. miRNA PCR arrays showed that 
gastrin significantly increased the expression of both miR-222 and miR-376c in human 
gastric cancer cells which express the cholecystokinin type-2 receptor (AGSGR). Of these 
two miRNAs, only the increase in miR-222 expression was confirmed using quantitative 
polymerase chain reaction (qPCR). Using chemical molecular pathway inhibitors, gastrin-
induced miR-222 overexpression was shown to occur via activation of the CCK2R and 
subsequent phosphokinase C (PKC) and phosphatidylinositol-3-kinase (PI3K) pathways. 
miR-222 expression significantly increased with age and further increased with 
Helicobacter felis (H. felis) infection in hypergastrinaemic INS-GAS mice. Similarly in 
patients with hypergastrinaemia and type-1 gastric NETs, miR-222 expression was 
increased at baseline relative to healthy control subjects and decreased whilst the patients 
were taking the CCK2R antagonist, netazepide. miR-222 overexpression caused p27 
mislocalisation to the cytoplasm and resulted in decreased p27 mRNA and protein 
expressions, in vitro. Functional analyses using small interfering RNAs (siRNAs) identified 
that this decreased p27 expression resulted in cell migration and structural remodelling in 
AGSGR cells. Previous cDNA microarray studies identified additional gastrin-regulated genes 
in gastric biopsies from hypergastrinaemic patients with type-1 gastric NETs being treated 
with netazepide. Of eight potential gene candidates, the tissue remodelling protein 
pregnancy-associated plasma protein-A2 (PAPPA2) was selected for further investigated in 
vitro due to its previous association with tissue remodelling in the placenta. Gastrin 
treatment increased PAPPA2 mRNA and protein expressions in AGSGR cells and this 
resulted in increased cell migration and cellular remodelling. Several CCK2R antagonists 
have previously been developed for the treatment of acid-peptic disorders and 
hypergastrinaemic conditions including gastric NETs. However oral bioavailability, receptor 
selectivity and/or drug potency still remain an issue. The inhibition of gastrin-induced 
cellular phenomena by the novel CCK2R antagonists TR1, TR2 and TR3 was therefore 
assessed using cell-based assays and their potencies were compared against the previously 
established CCK2R antagonists, YM022 and netazepide. All compounds caused significant 
reductions in gastrin-induced cellular processes such as cell growth, migration, structural 
remodelling and clonogenic survival. TR2 showed the highest potency, but was equally or 
less potent than both YM022 and netazepide in all assays. These data have therefore 
identified two potential novel gastrin-regulated biomarkers and a potential novel CCK2R 
antagonist which may be further developed for the detection and treatment of gastrin-
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1.1.1 History  
Primary studies led by Pavlov in 1888 17 provided fundamental knowledge of pancreatic 
physiology; prompting the first proposal of hormonal regulation of gut function 18. Since 
then, the role of gastrin 19-21 prompted the greatest debate due to the involvement of 
histamine 22 as some argued that pancreatic secretion could be a direct result of histamine 
release 23, 24. Some investigations concluded that only histamine-free (secretin) 
preparations significantly induced pancreatic secretions 25, however histamine-free gastrin 
was difficult to isolate. It wasn’t until R.A. Gregory and H.J. Tracy published a refined 
methodology of extracting gastrin from hog antral tissue 26, that adequate testing could be 
achieved with good reproducibility. It is now universally recognised that gastrin and 
histamine are two distinct gastrointestinal regulators involved in regulating the same 
physiological process of gastric acid secretion 27.  
1.1.2 Molecular structure of gastrin 
1.1.2.1 Transcription and translation 
Gastrins are a large family of peptide hormones that are predominantly secreted from 
gastrin (G) cells in the antrum of the stomach, and are less abundantly secreted in the 
duodenum, jejunum, colon and pancreas 28. The human gastrin gene (~4.2 kilobases in 
length) 29 is located on the long arm of chromosome 17 (q21.2) 30 and when transcribed 
into messenger RNA (mRNA), consists of 3 exons and 2 introns which encode the gastrin 
precursor, pre-progastrin  11 (Figure 1).  All gastrins are derived from this 101 amino acid 
(AA) pre-propeptide which contains a signal peptide (21 AA), N-terminal spacer sequence 
(37 AA), an active gastrin component (34 AA) and an extension peptide, carboxy-terminal 
flanking peptide (CTFP, 9 AA). Post-translational modifications and differential cleavages of 






















Figure 1. A schematic diagram representing the gene locus at chromosome 17 q21.2 from which the gastrin gene 
is transcribed. Preprogastrin mRNA contains 3 exons and 2 introns of which only exons 2 and 3 are spliced 
together and translated into the preprogastrin protein. The preprogastrin protein contains 4 domains: a signal 
peptide (21AA), an N-terminal spacer sequence (37AA), an active gastrin component (34AA) from which gastrins 
17 and 34 are derived and a  C-terminal flanking peptide (9AA). Figure adapted from Chao & Hellmich (2011) 
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Figure 2. A proposed pathway for the processing of progastrin (Pro-G).  Membrane bound signal peptidases remove the 
signal peptide in the rough ER whilst sulphation and phosphorylation by tyrosylprotein sulphotransferases (TPST) and 




 by prohormone convertase 




 by carboxypeptidase E (CPE). Subsequent cleavage at the 








 residues by 
prohormone convertase 2 (PC2) to form Gly-G17. Peptide carboxy-amidation by peptidyl-α-amidating monooxygenase 
(PAM) then generates various forms of biologically active gastrins (G17, G34 and G71) which may be secreted. Figure 
adapted from Bundgaard & Rehfeld (2010) 
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1.1.2.2 Post-translational modifications 
Post-translational modifications begin simultaneously with the translation of pre-
progastrin in the rough endoplasmic reticulum (ER) 31. The amino-terminal signal peptide 
interacts with a signal recognition particle (SRP) to temporarily pause translation of the 
mRNA by the ribosomes, whilst the SRP binds to a specific receptor on the cytoplasmic side 
of the ER. Pre-progastrin is directed through the translocon Ser61 channel on the 
cytoplasmic side of the ER by the signal peptide where translation is then resumed. Upon 
continuation, the signal peptide is cleaved by membrane-bound signal peptidases 
(between amino acids Ala21 and Ser22); generating the 80 AA progastrin (Pro-G) upon 
completion 32. Pro-G then progresses through the Golgi apparatus where phosphorylation 
followed by sulphation may occur in the trans-Golgi network (TGN). The sulphation and/or 
phosphorylation of Pro-G have been shown to increase protein-protein interactions and 
regulate cleavage that occurs later in the secretory pathway 33.  
1.1.2.3 Cleavage 
Following the trans-Golgi network, Pro-G is packaged into immature secretory vesicles 
where peptide activation and secretory granule maturation occur simultaneously in order 
to secrete the resulting products. The alternate splicing of Pro-G occurs in these immature 
secretory vesicles by exo- and endopeptidases typically at three di-basic residues: Arg36-
Arg37, Lys53-Lys54 and Arg73-Arg74 34 and is dependent upon the sulphation and 
phosphorylation states of the protein.  
In maturing secretory vesicles the first cleavage occurs after the Arg73-Arg74 residues 
specifically by prohormone convertase 1/3 (PC1/3) and this liberates the CTFP 35, 36, which 
has been shown to exert some independent biological functions 37. Post-cleavage 
exopeptidases (carboxypeptidase E) remove the residual C-terminal di-arginine residues 
leading to glycine extended gastrin-71 (Gly-G71) 




second di-arginine site (Arg73-Arg74) to cleave glycine extended gastrin-34 (Gly-G34). Gel 
chromatography of antral extracts from PC1/3-null mouse models indicated that PC1/3, 
but not PC5/6, is exclusively responsible for gastrin cleavage at both of the di-arginine sites 
which occur earlier in the processing pathway, as higher concentrations of progastrin (and 
early processing intermediates) were found in null-mice compared with wild type 
littermates 40.  
Glycine-extended gastrin-34 (Gly-G34) is then further processed into glycine-extended 
gastrin-17 (Gly-G17) by prohormone convertase 2 (PC2) via partial cleavage after the di-
lysine residues (Lys53-Lys54). PC2 has been shown to only be partially responsible for the 
Gly-G34 to Gly-G17 conversion as chromatography studies in mouse models with PC2 
deletion only showed 50% cleavage of di-lysine residues, whilst mice with a deletion of 
7B2, a PC2 chaperone protein, only showed 23% cleavage of the same residues indicating 
that both PC2 and its chaperone are required for the synthesis of Gly-G17 
41. The cleavage 
of the two pairs of arginine residues occurs relatively quickly after exiting the TGN into the 
secretory vesicles (t½~10mins), whereas cleavage of the di-lysine residues (Lys53-Lys54) has 
been shown to occur at a slower rate (t½~60mins). Using pulse-chase labelling experiments 
Varro et al. found that only ~50% of Gly-G34 is further processed to form Gly-G17 which may 
explain the slower cleavage rate of PC2 and its expression later in the secretory pathway 42.   
1.1.2.4 Amidation 
The final addition of a C-terminal amide functional group has been shown to be a 
prerequisite for the full biological activity of more than half of all peptide hormones 43, 44 
including gastrins, with tissue extracts suggesting that the main amidated forms of gastrin 
are G71, G34 and G17 
45. Peptide amidation has not been shown to be generated through 
transamidation and instead these peptides are transformed from glycine-extended 




which contains two catalytic domains peptidylglycine α-hydroxylating monooxygenase 
(PHM) and peptidyl-α-hydroxyglycine α-amidating lyase (PAL), during a two-step process. 
The first rate limiting step is catalysed by PHM which initiates the redox cycling of enzyme 
bound copper ions by utilising ascorbate and molecular oxygen to produce peptidyl-α-
hydroxyglycine and semidehydroascorbate by-products 46-48. Following the production of 
peptidyl-α-hydroxyglycine, which is relatively stable within the secretory granules (pH ~5) 
49-51, the second step is catalysed by the lyase domain PAL, which presumably contains a 
tightly bound zinc cation and occurs spontaneously at alkaline pH to convert the stable 
intermediate into the α-amidated product and glyoxylate 52-54.  
1.1.3 Tissue expression of the gastrin gene  
Gastrin gene expression is very tissue specific and differs significantly between human 
adults and neonates.  During foetal development, gastrin is predominantly expressed in 
pancreatic β cells and, to a lesser extent, the colon. Following the first 72hrs after birth this 
expression converts to adult expression patterns; becoming primarily located in the G cells 
of the antral mucosa with low-level expression in the small intestine, pituitary gland, 
reproductive organs, brain and lungs 55. This expression shift may be associated with the 
physiological role of gastrin in cell growth throughout the gastrointestinal tract that is 
essential for foetal development, in addition to stimulating gastric acid secretion 56.  
1.1.4 Regulation of gastrin expression 
1.1.4.1 Transcriptional 
Many physiological stimuli have been shown to be involved in the regulation of gastrin 
gene expression and subsequent peptide release, by binding to luminal receptors on the 
apical surface of antral G cells 57 resulting in the upregulation of transcription factors. Early 
studies identified high concentrations of biologically active epidermal growth factor (EGF) 




gastrin transcription 60. The upregulation of the gastrin gene by EGF has been shown to 
depend upon a 40 base pair cis-regulatory element of DNA between located upstream of 
the gastrin promoter region between -82 and -40 base pairs. This fragment of DNA 
contains the GC-rich gastrin EGF response element (gERE) motif located at 68 base pairs, 
which is the binding sites of two transcription factors: specificity protein-1 (Sp1) and 
activator protein-2 (AP2) 61, 62 and mediates the level of RNA polymerase-II transcription 
and subsequent gastrin gene expression in response to EGF receptor ligands 63.  
Gastrin transcription is also negatively regulated by other physiological conditions such as 
a reduced gastric luminal pH 64. During feeding, there is increased gastric acid secretion 
and a reduced intragastric luminal pH and as a consequence, somatostatin release is 
activated 65. Somatostatin is a cyclic tetradecapeptide that is released by various tissues 
such as the antral stomach to inhibit the release of peptide hormones in a paracrine 
manner. Somatostatin binds to a cis-regulatory element within the human gastrin 
promoter sequence between -82 and -69 base pairs, which is thought to be adjacent to the 
gERE, and inhibits EGF-stimulated gastrin transcription 66.  
1.1.4.2 Translational  
In addition to inhibiting gastrin mRNA transcription, somatostatin has been shown to 
translationally regulate gastrin by reducing gastrin mRNA stability 67-69. Studies by Bate et 
al. observed a 2-fold increase in gastrin mRNA translation in rats treated with the acid 
suppressing drug omeprazole for 5 days. In rats that had fasted for 24hrs there was a 40% 
decreased in gastrin mRNA translation, whilst gastrin mRNA abundance was unaffected 70. 
These data indicate that physiological factors such as luminal pH may control the rate of 





Cellular processing hormones involved in sulphation and phosphorylation have been 
shown to be important regulators of subsequent endoproteolytic cleavage of Pro-G. Serine 
phosphorylation has been shown to determine the rate of cleavage and has been shown to 
occur by trans-Golgi membrane bound kinases before sulphation in the secretory vesicles 
33, 71. Like many peptides, progastrin is phosphorylated upon progression through this 
secretory pathway 72 at a specific Arg-Arg-Ser-Ala-Glu-Glu/Asp domain, which contains a 
conserved recognition site (Ser-X-acidic residue) for calcium-dependent casein-like kinases. 
Site-directed mutagenicity studies have indicated that phosphorylation delays the further 
processing of progastrin 73-75 which subsequently influences the ratio of secreted peptide 
products. 
The sulphation of tyrosine residues has been shown to improve protein-protein 
interactions with specific sequences for sulphation proposed 76, 77. In mammals only 50% of 
progastrin is sulphated 78 in comparison to the structurally similar cholecystokinin (CCK) 
which exhibits complete sulphation 79. Studies by Bundgaard et al. indicated that the 
degree of sulphation determines the degree of proteolytic processing 80. Further 
examination revealed that glycine-extended gastrins contained a higher degree of 
sulphation in comparison to their respective amidated forms 81. Similar patterns of 
sulphation were observed in the rat 33 with identical sulphation patterns being observed in 
hog antral tissues 82 indicating that tyrosine sulphation regulates the subsequent post-
translational cleavage of gastrins at Lys53-Lys54 by PC2.    
In endocrine cells such as G cells a secretory vesicle pH of ~5.5 must be maintained, by 
vacuolar proton pumps (vH+/K+ ATPase) 83, 84, in order for adequate generation of gastrin 
products. The acidic intravesicular environment provides an optimal pH for processing 




for amine-proton exchangers. The expression of the two closely related human vesicular 
monoamine transporters (VMAT) -1 and -2 are primarily limited to endocrine and neuronal 
cells, respectively and also differ in substrate identification and drug inhibition. VMAT2 has 
a higher affinity for monoamines compared with VMAT1 and only VMAT2 transports 
histamine 87, 88. However, VMAT2 can also be found in the enterochromaffin-like (ECL) cells 
of the gastric mucosa, which is consistent with the ability for VMAT2, but not VMAT1, to 
transport histamine. It has previously been established that biogenic amines, particularly 
serotonin (5-HT) and dopamine, are decarboxylated in G cells and accumulate in the 
secretory vesicles 89, where they are utilised for peptide amidation. The basic properties of 
monoamines can also increase intravesicular pH which negatively regulates Pro-G cleavage 
15.  
Peptide amidation influences the ratio of secreted gastrins and the subsequent degree of 
biological activity, which can alter further post-translational processing of Pro-G. The 
concentration of amidating enzyme mRNAs have been shown to be regulated 
simultaneously with the control of its peptide substrate mRNA levels 90. The first step in 
peptide amidation is rate limiting due to the requirement of copper ions, ascorbic acid and 
molecular oxygen. In rats treated with a copper chelator diethyldithiocarbamate (DDC) 
there was a decrease in peptide amidation in situ, however there was a selective increase 
in amidating enzyme synthesis and increased gastric acid output 91. Similarly, the depletion 
of ascorbic acid has been shown to reduce the amidation of adrenocorticotrophic 
hormones (ACTH) 1-14 in the pituitary of the rat 92 and guinea pig 93. 
Changes in the gastric luminal pH have been shown to affect many physiological processes 
including the post-translational regulation of gastrin. In starved rats antral and serum 
gastrin, but not Pro-G, concentrations significantly decreased (~25%) and somatostatin 




counterparts. Refeeding with a nutritious diet caused a significant increase in gastrin 
mRNA levels which still remained 30% lower than freely fed rats, whereas somatostatin 
mRNA levels returned to baseline. These studies indicate that both gastrin gene expression 
and gastrin processing are regulated by luminal pH 94. 
The inhibition of gastric acid secretion by the proton pump inhibitor omeprazole and 
consequential increase in gastric luminal pH has also been shown to increase the 
transcription of genes encoding PC1/3 and PC2 95. In omeprazole treated rats, there were 
40% increases in G34 conversion to G17 through Lys
53-Lys54 cleavage and in the ratio of 
glycine extended gastrins (Gly-G34: Gly-G17), indicating that acid induced inhibition of G 
cells controls the post-translational processing of Pro-G 96. In other physiological studies it 
has been established that the cleavage of Pro-G into glycine-extended gastrins at Arg73-
Arg74, is temperature-dependent 71, 95 and a 15°C drop in temperature (from 37°C to 22°C) 
can cause cessation of these secretory processes. 
1.1.5 Regulation of gastrin secretion 
1.1.5.1 Physiological  
Although the in vivo mechanisms for the regulation of gastrin secretion by gastric luminal 
pH, amino acids and calcium are not fully understood, it has been suggested that there are 
both direct and indirect influences on the recipient G cell. The ingestion of a protein-rich 
diet, particularly L-isomers of tryptophan and phenylalanine, is a potent stimulator of both 
acid secretion and gastrin release 97-99 during the gastric phase of digestion. These aromatic 
L-amino acids are recognised by calcium-sensing receptors (CaR) that are widely 
distributed throughout the body including the stomach 100, pancreas 101 and brain 102 and 
their potencies are calcium-dependent, with Ca2+ concentrations <0.5mmol/L providing no 
biological response 103. CaRs located on antral G cells stimulate gastrin release 100 whereas, 




sensing mechanisms of CaRs, in combination with increased extracellular dietary calcium 
([Ca2+]o), have been shown to activate phospholipase-C (PLC) pathways which evoke the 
initial mobilisation of stored calcium and open non-selective cation channels (NSCCs) 
causing an influx of intracellular calcium ([Ca2+]i) followed by a sustained plateaux of [Ca
2+]i 
concentration, resulting in a concentration-dependent release of gastrin 100, 105.   
1.1.5.2 Neural and paracrine  
Luminal stimuli have also been shown to exert paracrine and neural signals which can 
regulate the secretion of gastrin. Intraluminal proteins stimulate cholinergic and two types 
of non-cholinergic gastric effector neurons, bombesin/gastrin releasing peptide (BN/GRP) 
and vasoactive intestinal polypeptide (VIP)- expressing neurons 106. Data have indicated 
that neurally-induced gastric acid secretion is mediated by the net effect of activated 
cholinergic neurons which can stimulate acid secretion from parietal cells and BN/GRP 
neurons that can indirectly inhibit the release of somatostatin from delta (D) cells with a 
subsequent increase in gastrin secretion 107.  
Partially digested proteins (peptones 0.5%) have been shown to potently stimulate the 
release of gastrin and inhibit somatostatin release 108. Atropine has been shown to partially 
inhibit (<50%) the release of gastrin which decreases somatostatin secretion, which in turn 
stimulates further release of gastrin (above basal levels). The subsequent increase in 
gastrin secretion due to the inhibition of cholinergic neurons, indicates that both 
cholinergic and BN/GRP neurons affect the release of gastrin in response to luminal 
proteins and the reduced somatostatin secretion caused by cholinergic neurons on D cells 
allows BN/GRP neurons and cholinergic neurons on G cells to stimulate appropriate gastrin 
secretion 109.   
Postprandial distension of the stomach can also activate both cholinergic and non-




distension causing an increase in cholinergic neuron recruitment, which increases gastrin 
secretion and decreases somatostatin secretion. As the stomach begins to empty there is a 
reduction in distension which evokes a mechanical reflex for the inhibition of gastrin 
secretion by preferentially activating VIP neurons to stimulate somatostatin release. 
Gastrin and somatostatin responses caused by both high and low grade distension can be 
reversed with the axonal blocker tetrodotoxin (TTX) indicating neural mediation 109.    
1.1.6 Degradation of gastrins 
The degradation and clearance of gastrins is essential for the cessation their biological 
function with excessive biological activity, particularly of G17, contributing to the 
development of gastric neoplastic conditions such as ECL cell hyperplasia 111 and gastric 
intestinal metaplasia 112.  
Currently the half-lives of G17, G34 and G71 have been determined in dogs, using a 
continuous infusion of human gastrin with results of approximately 3, 9 and 90mins 
respectively 113. However other studies have identified a longer half-life for G17 in humans 
(5-11mins) 114-116. Gastrin length has been shown to be the major determining factor for its 
rate of clearance, with studies in sheep suggesting that the larger the peptide, the longer 
the half-life as Pro-G had a significantly longer half-life (~42mins) than Gly-G17 (~11mins) 
117. The difference between the half-life of Pro-G and its derivatives is thought to reflect 
physiological application. The 3-fold increase in the half-life of G34 compared to G17 results 
in a higher ratio of G34:G17 in peripheral plasma than in antral tissue, which may be 
indicative of maintaining basal gastric acid secretions 118. Whereas the postprandial 
response to G17 rapidly increases gastric acid secretion to aid digestion and therefore the 




1.1.6.1 Clearance of G17  
Enzymatic metabolism of G17 by endopeptidase 24.11 is relatively slow in vitro with a half-
life of ~67mins, but local concentrations of endopeptidase 24.11 have proven adequate for 
the rate of degradation observed in vivo . Tyrosine sulphation has also been shown to 
decrease the hydrolysis of G17 by endopeptidase 24.11, in contrast to the increased 
hydrolysis of CCK by the same enzyme 119.     
1.1.6.1.1 Renal 
The major sites for the metabolism of gastrin are currently unknown. In vivo studies in 
dogs have provided evidence suggesting that the kidney extracts ~40% of circulating 
human gastrin from the renal artery 120 and radiolabelled human gastrin has been shown 
to accumulate in the renal cortex after intravenous injection 121. Due to the lack of gastrin 
present in the urine it has been suggested that the kidneys are a major site of gastrin 
degradation. However, in humans the role of the kidneys in gastrin clearance is less clear 
and although hypergastrinaemia has been associated with both acute and chronic renal 
failure 122, 123, there are few differences between arterial and renal gastrin concentrations 
124, 125 which would correspond to a half-life of over 7hrs. However as G17 has such a short 
half-life, renal extraction and metabolism may only provide part of the mechanism and 
other organs may also be involved.  
1.1.6.1.2 Hepatic 
Due to its paracrine nature, circulating gastrin must pass through the liver before reaching 
target tissues. Several studies have investigated whether the liver is a major site for gastrin 
degradation with conflicting results. Some showed a 40% reduction in gastric acid output 
in Heidenhain pouches of dogs after a portal injection, compared with caval injection, of 
human synthetic gastrin 126. Others found that hepatic inactivation of G17 was negligible in 




metabolises shorter gastrin fragments (<8 AA) with >90% inactivation of the C-terminal 
tetrapeptide of G17 (Trp-Met-Asp-Phe-NH2)  from the portal vein 
128, where it is deamidated 



















1.2 Gastrin receptor (CCK2R) 
1.2.1 Classification and structure of cholecystokinin receptors (CCKR) 
Amidated gastrins induce a biological response via their respective G-protein coupled 
receptor (GPCR), the cholecystokinin receptor (CCKR) 130 that is located on different target 
tissues. There are two types of CCK receptor (CCK1R and CCK2R) that have a high sequence 
homology (~50%) and are distinguished by structural peptide specificity for either CCK or 
gastrin (Figure 3). CCK1R requires the entire carboxyl-terminal heptapeptide-amide in its 
tyrosine sulphated form (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-PheNH2) for high affinity 
binding, whereas CCK2R recognises the carboxyl-terminal tetrapeptide (Trp-Met-Asp-
PheNH2) present in both CCK and gastrin. Thus, CCK1R binds sulphated CCK with a 500-
1000 fold greater affinity than gastrin or non-sulphated CCK, whereas CCK2R binds both 
peptides with almost equal affinity 131 and therefore, only CCK2R is termed a ‘gastrin 
receptor’.  
1.2.2 Tissue distribution of the CCK2R  
The tissue distribution of the CCKRs and their ligand affinities have been shown to 
determine receptor activation and differences in downstream signalling. CCK1Rs are 
located in specific regions of the brainstem and gastrointestinal tract, as the major function 
of CCK is to stimulate pancreatic exocrine secretion 132. However, CCK1R activation has also 
been associated with increased feeding-induced satiety 133 and intestinal lipids reduce 
gastric acid secretion and gastric emptying 134. By contrast, CCK2Rs are widely distributed 
throughout the central nervous system 12, 135, 136 and particularly on gastric parietal and ECL 
cells 137 as the main function of gastrin is to increase gastric acid secretion in response to a 
meal 138. As CCK and G17 bind with equal affinity for the CCK2R, the binding preference is 
determined by local concentrations of each hormone. G17 concentration is higher than CCK 





1.2.3 CCK2R regulation  
The gastrin/CCK2R is known to mediate several important biological functions within the 
stomach including acid secretion. However, less is known about the factors that regulate 
the receptor itself. The tight regulation of the CCK2R is essential for physiological 
homeostasis of gastrin/CCK2R signalling and CCK2R upregulation has been observed in 
many pathological conditions including colon 142 and stomach cancers 143. The CCK2R has 
been shown to undergo rapid ligand-induced endocytosis, in response to both CCK and 
gastrin 144, in which agonist-bound receptors are selectively phosphorylated. 
Phosphorylation promotes arrestin binding which terminates the downstream signalling 
cascade and initiates clathrin-dependent and independent internalisation of the receptor 
145, 146. Recent studies have suggested that the C-terminal end of the CCK2R is a critical 
determinant for β-arrestin recruitment and contains three potential phosphorylation sites 
147. Internalised receptors are then sorted for different routes of trafficking such as 
recycling to the plasma membrane (both slow and rapid) and lysosomal degradation. 
Internalisation and trafficking rates differ between receptors as a consequence of different 
ligand binding or method of internalisation indicating distinct regulatory mechanisms 148, 






















Figure 3. The deduced amino acid sequences of human CCK1 and CCK2 receptors were 428 and 447 amino acids respectively, with approximately 50% sequence homology. These sequences diverge 
predominantly at the amino-terminus and 3
rd
 intracellular loop, with the greatest homology occurring within the transmembrane spanning domains. Both CCK1R and CCK2R have conserved 




 extracellular loop that is consistent with tertiary structure stabilisation. Diagram was produced using  Protter  
5







1.3 Cellular/physiological effects of amidated gastrin 
1.3.1 Architecture of the stomach 
The human stomach forms part of the digestive system and is divided into five separate 
compartments: cardia, fundus, corpus, antrum and pylorus; with occasional functional 
overlap (Figure 4A). The stomach is responsible for the physical churning of chyme 
(partially digested food) and secretion of digestive enzymes which catalyse the breakdown 
of food for nutritional absorption and can act as a barrier for ingested bacteria 150. Like 
many organs, the gastric wall consists of multiple layers: the mucosa, submucosa and 
muscularis externa. The myenteric plexus separates the middle circular and outer 
longitudinal sections of the muscularis externa and is responsible for the innervation of 
peristalsis. Blood is supplied to the lesser curvature of the stomach from the aorta via the 
inferior and superior gastric artery. The greater curvature has a separate blood supply from 
the right and left branches of the gastroduodenal artery, which runs between the layers of 
greater omentum and converges with the splenic artery 151. The blood vessels (and lymph 
vessels) penetrate through the majority of layers in the stomach, however, they are mostly 
found in the submucosa due to the close proximity to gastric glands for increased 
endocrine function (Figure 4B).  
1.3.2 Architecture of gastric glands 
The corpus mucosa is organised into a glandular structures, with openings to gastric 
luminal contents (gastric pits or foveolae gastricae). Gland structures differ depending on 
their location in the stomach and can have one or more branches with distinct cellular 
compositions (Figure 5). Glands of the corpus mucosa are highly organised structures 
containing multiple cells types which include parietal cells and endocrine cells; the latter is 
comprised of many different types. Histamine-secreting ECL cells account for 35% of 
endocrine cell populations in humans compared with 65% in rats 152, 153. Progenitor stem 










Figure 4. Architecture of the stomach which divides the anatomical regions into the fundus, cardia, corpus, 








Figure 5. Architecture of a gastric gland located in the pylorus (A) or corpus (B) of the stomach, which contain a pit, 
progenitor region (isthmus), neck and base that are comprised of different cell types depending upon location. 






1.3.3 Gastric acid secretion 
Under normal physiological conditions, when digested food enters the stomach via the 
oesophagus, it distends the stomach walls activating mechanoreceptors (stretch receptors) 
which synapse on G cells to directly stimulate the release of gastrin releasing peptide (GRP) 
109. In addition to the distension, degraded proteins (particularly L-type amino acids) are 
potent stimulators of both direct and indirect gastrin and gastric acid secretion 97-99. 
Amidated gastrin diffuses into the local capillaries and acts in a paracrine manner on the 
ECL cells, proliferating cells and chief cells of the corpus via the CCK2R. Once activated, ECL 
cells synthesise and release histamine which binds to the H2 receptors on the parietal cells, 
combining with the signal from the gastrin-CCK2R complex, to secrete protons into the 
stomach lumen via the H+/K+ proton pump 155, 156. The decrease in gastric luminal pH 
stimulates the release of somatostatin from D cells which inhibits gastrin and further 
gastric acid secretion and provides a negative regulatory mechanism 157 (Figure 6).   
1.3.4 Cell proliferation  
Biosynthetic products of the gastrin precursor, such as amidated gastrin and glycine-
extended gastrins can stimulate cell growth within the gastric corpus mucosa 158, 159 and 
colon epithelium 160, 161 respectively, and several mechanisms of cell hypertrophy induced 
by amidated gastrin have been investigated. Self-replication has previously been observed 
in ECL cells obtained from the mouse mucosa, every 2 months 162 which suggests that 
hypergastrinaemia may directly stimulate MAPK mitogenic signalling via the CCK2R 163, to 
promote ECL cell hyperplasia and subsequent type-1 gastric NET formation 164. In addition 
to direct ECL cell hyperplasia, gastrin-stimulates the release of growth factors such as 
histamine and transforming growth factor (TGF)-α (known mitogens), and the regenerating 
(Reg) protein 165 which is a potent regulator of pancreatic β-cell proliferation 166, 167. Studies 
have suggested a positive correlation between Reg gene expression and gastric mucosal 




CCK2R, incubated with the Reg protein showed a potent and dose-dependent increase in 
proliferation 169. These data indicate both a direct and indirect method of gastrin-
stimulated proliferation of the corpus mucosa.       
1.3.5 Differentiation and maturation of parietal cells 
In the gastric mucosa of gastrin-deficient mice (GAS-KO), the development of the major cell 
types such as parietal cells, chief cells, mucous-secreting cells and endocrine cells, occur 
independent of gastrin secretion. However, gastrin is responsible for the functional 
maturation, particularly of parietal and ECL cells. Although immature parietal cells express 
proton pumps, which are a primary marker for the stage of differentiation of a cell, proton 
pump α and β subunit expressions are significantly decreased in GAS-KO mice. Other 
factors involved in acid secretion such as the KCNQ1 potassium channels, AQP4 water 
channels and creatine kinase B (a source of energy for the ATPase pump) are also 
significantly reduced in GAS-KO mice 170. Reduced gastrin production in these transgenic 
models has been associated with reduced parietal cell mass, but not number 171 possibly 
due to the reduced histamine concentrations (40%) in ECL cells and subsequent histamine 
secretion. Basal and stimulated gastric acid secretion 138, 172 can be partially restored by 
gastrin osmotic infusion (1µl/hr for 1 week). These data suggest that gastrin plays an 
important role in the differentiation and maturation of the gastric mucosa through 
regulating parietal and ECL cell physiology.   
1.3.6 Apoptosis  
Concise programming and regulation of cell death is essential for tissue maintenance and 
dysregulation of apoptosis is often observed in malignancy. In AGSGR cells treated with 
gastrin there was a 50-fold increase in plasminogen activator inhibitor-2 (PAI-2) expression 
which is a major component of the urokinase-type plasminogen activator (uPA) pathway 




models have also reported an increase in apoptosis in mice with elevated gastrin 
concentrations compared with normogastrinaemic controls, which is reversed upon 
treatment with a CCK2R antagonist 174-176. Similarly, in human biopsies taken from patients 
with hypergastrinaemia or Helicobacter pylori (H. pylori) infection, increased apoptosis was 
observed 175 possibly indirectly via increased circulating PAI-2 concentrations 173, 177. 
Alternatively, gastrin has shown to exert anti-apoptotic properties particularly in 
transformed cell lines such as AR42J, MKN-45 and AGSGR due to CCK2R signalling via the 
Akt pathway, increased Bax and decreased BCL-2 expression and increased Mcl-1 
expression, respectively 178-181. Together, these data indicate that gastrin regulates 
apoptosis in gastric epithelial cells dependent upon physiological and pathological 
conditions via CCK2R activation however the specific mechanisms remain largely unclear.    
1.3.7 Angiogenesis 
The development and maintenance of new blood vessels (angiogenesis) is an essential 
physiological function within the stomach and gastrin has been shown to play an important 
role in the formation of vascular structures. In cell culture models of angiogenesis, human 
umbilical vein endothelial cells (HUVEC) seeded onto fibroblast monolayers formed tubule 
structures when exposed to both amidated gastrin-17 (G17) and glycine-extended gastrin-
17 (Gly-G17) at optimal concentrations of 10nM. The angiogenic effect was modulated 
through the CCK2R, as administration of antiserum or CCK2R antagonists abolished the 
differentiating effects, EGFR signalling pathways that stimulate the release of heparin-
binding epithelial growth factor (HB-EGF) which is involved in cell proliferation 182, 
cyclooxygenase-2 (Cox-2) which is a rate-limiting cofactor in the biosynthesis of 
prostaglandins 183 and matrix metalloproteinases (MMPs)-2, -3 and -9 from neighbouring 
fibroblasts which allow structural remodelling. The proangiogenic properties of gastrin 
have also been observed in vivo with increased microvessel density (MVD) in the normal 




1.3.8 Structural remodelling  
The maintenance and structure of gastric epithelia has been shown to be regulated by 
gastrin through the increased expression of proteases such as uPA and its inhibitors PAI-1 
and PAI-2 185, 186. Increased expression of MMPs cause a breakdown of the extracellular 
matrix and reduced structural integrity is frequently observed in gastric neoplasia. The 
majority of MMPs are commonly expressed in stromal cells, except for MMP7, however 
there have also been reports of MMP1, -2 and -9 expression within the  parietal cells of the 
gastric mucosa 187. Gastrin-stimulated AGSGR cells have been shown to have increased 
MMP1 expression which is mediated by the PKC and MAPK pathways 188. In patients with 
MEN-1, usually associated with hypergastrinaemia, and in AGSGR cells there was an 
increase in MMP9 expression which stimulated epithelial cell invasion 189 which was also 
mediated by PKC-dependent and independent pathways. Similarly, MMP7 was shown to 
be upregulated in hypergastrinaemic patients (with and without H. pylori infection) via 
activation of GTPases, RhoA and Rac, which differentially stimulate the NFκB and AP-1 
transcription factors to increase cellular migration and epithelial-mesenchymal signalling 
190, 191. Reciprocal interaction between the epithelia and stroma determine gastric mucosal 
organisation and dysregulation has been associated with the development of gastric 
tumours due to chronic inflammation or injury 192.  
1.3.9 Actions of non-amidated gastrins 
Non-amidated gastrins including progastrin, glycine extended gastrins and CTFPs contain 
the less predominantly expressed forms of gastrin that were originally thought of as being 
biologically irrelevant. These isoforms are usually expressed in cells lacking the appropriate 
processing machinery. For example CPE-deficientfat/fat mice showed a slightly reduced 
expression of amidated gastrin and increased accumulation of progastrin intermediates 
such as glycine-arginine extended gastrins (86-fold) and glycine-extended gastrins (7-fold) 




effects on the colonic and gastric epithelia and to be involved in regulating physiological 
processes. Progastrin, Gly-G17 and CTFP are pro-proliferative and anti-apoptotic in both 
gastric and colonic cancer cell lines. Progastrin and its intermediates Gly-G17 and CTFP have 
been shown to independently promote cell growth in colon-derived cell lines in vitro 160, 194 
and in the colonic mucosa of mice overexpressing either human progastrin or Gly-G17 in 
vivo 37, 161, 195-198, in an autocrine manner. Whilst in AGS cells progastrin, Gly-G17 and CTFP 
have been shown to activate the PI3K pathway to reduce caspase-3 activity and decrease 
apoptosis 199; thus increasing the susceptibility for carcinogenesis. However, CTFP has also 























Figure 6. Paracrine, endocrine and neuronal stimulation of gastric acid secretion. Gastrin is secreted from antral G cells in response to dietary peptides and neuronal stimulation which 





 ATPase) secretions. CCK2R activation on ECL cells causes the release of histamine and paracrine stimulation of histamine type-2 receptors (H2Rs) of the parietal cells 
which also stimulate proton pump secretions. Increased luminal gastric acid and histamine stimulates the release of somatostatin from D cells which binds to somatostatin receptors 
(SST2R) located on antral G cells and parietal cells which inhibit gastrin and proton pump secretions respectively. Neuronal innervation has been shown to exert both inhibitory and 
stimulatory effects on D cells, G cells and parietal cells. Figure adapted from Schubert 2008 
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Hypergastrinaemia literally means excessive gastrin in the circulation however, most 
publications classify it as a fasting serum gastrin concentration of >100pg/ml or >48pM. 
Hypergastrinaemia is associated with the development of many conditions including 
gastric cancer and has many causes, which are currently characterised depending upon the 
pH within the gastric lumen.  
1.4.1 Causes 
1.4.1.1 Hypergastrinaemia associated with normal or hyperacidity  
1.4.1.1.1 Zollinger-Ellison syndrome (ZES) 
Elevated gastrin concentrations associated with low gastric luminal pH (≤2) are commonly 
caused by hormone-producing neuroendocrine tumours (gastrinomas) of the pancreas 
and/or duodenum. The first clinical report of gastrinomas was by Zollinger and Ellison in 
1955, who observed recurrent peptic ulceration, gastric acid hypersecretion and less 
commonly diarrhoea and steatorrhoea in patients with non-specific pancreatic islet cell 
tumours 201. This led to the term Zollinger-Ellison syndrome (ZES). However, studies by Roy 
et al. reported only 1 patient out of 1219 (235 National Institute of Health (NIH) patients 
and 984 cases in the literature) with ZES that exhibited basal hyperacidity 202.  
1.4.1.1.2 Antral gastrin cell hyperplasia (AGCH) 
A rare cause of hypergastrinaemia is antral gastrin cell hyperplasia (AGCH) that causes an 
increased serum gastrin response to a standard meal test, which differentiates these cases 
from gastrinomas 203. Antral-predominant H. pylori infection is present in 50% of AGCH 
cases and may contribute to increased antral inflammation which overstimulates G cell 
function, resulting in excessive gastrin production and hyperacidity 204. AGCH is reversed 




(<50pg/ml) and 92% reduction in gastric acid secretion 205, 206, however cases due to H. 
pylori infection should now be treated by eradicating this organism.  
1.4.1.1.3 Renal failure and uraemia  
Although the method of clearance for gastrin is still currently unclear, some studies have 
suggested that gastrin may be metabolised by the kidneys and liver in vivo 120 and by the 
lung, skeletal muscle and gastric mucosa in vitro 207-209. However, renal excretion of gastrin 
is thought to be the most efficient method as hypergastrinaemia is frequently observed in 
patients who have acute or chronic renal failure 122, 123, 210. In patients with renal failure, 
gastric ulceration and gastrointestinal bleeding has frequently been reported 211, 212, 
suggesting that the gastrointestinal bleeding and ulcer formation caused by gastric acid 
hypersecretion may be secondary to hypergastrinaemia due to the reduced gastrin 
clearance in renal failure patients 213.  
1.4.1.1.4 Post-gastric resection with intact antrum, particularly Billroth II 
partial gastrectomy 
Inadequate removal of all antral tissue during partial gastrectomy or gastrojejunostomy 
(Billroth II), has been shown to result in recurrent ulcer formation 214. Although this 
outcome is usually uncommon (0.5-6%), one possibility could be due to hypergastrinaemia 
as a result of continued parietal cell activity and a large study conducted in patients with 
recurrent peptic ulcer disease found that recurrence was caused by a retained gastric 
antrum in only 4% of patients 215. However, 2 cases reported by Webster et al. support the 




1.4.1.2 Hypergastrinaemia associated with hypoacidity (elevated gastric luminal 
pH ˃2) 
1.4.1.2.1 Chronic atrophic gastritis (CAG) 
Elevated gastrin concentrations associated with increased gastric luminal pH (>2) are more 
frequent than hyperacidic conditions, with chronic atrophic gastritis (CAG) being observed 
in <40% of the worlds’ general population 217. Atrophic gastritis is a premalignant condition 
that, in some cases, can progress to the development of gastric carcinoma and develops 
from chronic gastritis, which involves long-term inflammation of the antrum and/or corpus 
mucosa.  
Autoimmune conditions or chronic H. pylori infection (discussed in section 1.8 Helicobacter 
pylori (H. pylori)) are the main causes of CAG, types A and B respectively, by initiating the 
progressive destruction of the gastric mucosa. Absent or reduced parietal cell mass creates 
an achlorhydric stomach with optimal conditions for prolonged bacterial colonisation and 
consequential hypergastrinaemia being associated with premalignant disease. Although H. 
pylori usually remain in the gastric lumen, bacterial-cell interactions evoke an 
inflammatory response which over time can cause CAG. Without successful eradication of 
this bacterium, prolonged exposure may lead to epithelial cell damage, possibly due to the 
production of reactive oxygen species, loss of parietal and chief cells and glandular atrophy 
218. Studies by Kuipers et al. highlighted the negative impact that H. pylori infection has on 
healthy gastric mucosa as 36% of H. pylori positive patients that were initially CAG 
negative, developed the condition. Of these patients, 38% showed histological evidence of 
intestinal metaplasia and 6% developed an early onset of gastric cancer 219. 
On the other hand, autoimmune CAG is a disorder that selectively attacks acid secreting 
parietal cells and causes deficiency of intrinsic factor and in the more advanced stages 




epidemiological studies have suggested that similar to other autoimmune diseases, 
autoimmune CAG is more prevalent in the elderly, in females more than males 220, and can 
be detected by the presence of anti-gastric intrinsic factor and parietal cell cytoplasmic 
antibodies (PCA) in the serum 221, 222. 
1.4.1.2.2 Post-vagotomy 
Since peptic ulcer disease can arise as a result of corrosion of the gastric mucosa by acid, 
several methods were employed to either reduce gastric acid output or intragastric acidity 
including surgical intervention. Of the patients that received truncal vagotomy and 
pyloroplasty surgery, the mean basal serum gastrin concentration increased and mean 
basal gastric acid secretion decreased in both early postoperative studies and longer term 
studies (<4 years post-surgery) 223. Our improved understandings of the mechanisms that 
regulate gastric acid secretion have identified the vagus nerve as a minor contributing 
factor for gastrin and subsequent gastric acidity. Therefore, the removal or partial removal 
of the vagus nerve may induce hypergastrinaemia as a result of reduced gastric acid output 
224-226. 
1.4.1.3 Hypergastrinaemia associated with inhibitors of gastric acid secretion 
1.4.1.3.1 Histamine type-2 receptor antagonists (H2RAs) 
Histamine is a biologically active amine that binds to four distinct receptor subtypes (H1-4) 
located throughout various organs including the gut, lungs, heart and central nervous 
system, with the resulting agonism/antagonism depending upon tissue location 227-230. The 
dual signalling mechanism produced by H2Rs and their role in cell proliferation and 
differentiation provide additional targets for therapeutic intervention, particularly for the 
prevention and treatment of gastric carcinogenesis. 
H2RAs reversibly compete with histamine for binding to H2Rs on the basolateral surface of 




having no observed renal or haematological adverse effects in rats or dogs 232 and healthy 
subjects 233, H2RAs have been associated with hypergastrinaemia after both short 
234 and 
long term 235, 236 treatments. Whilst short term studies in humans observed an absence of 
gastric acid hypersecretion suggesting that parietal cell mass was unaffected 237, 238, 
histological analysis of experimental animal models receiving short and prolonged 
cimetidine treatment showed parietal cell hyperplasia 239, 240. However, these discrepancies 
may be due to the large doses used in these animal models which would be beyond the 
therapeutic range in man.   
1.4.1.3.2 Proton pump inhibitors (H+/K+ ATPase inhibitors) 
The development of proton pump inhibitors (PPIs), most notably omeprazole, provided a 
novel approach to the treatment of acid-relation conditions by blocking the final step in 
gastric acid secretion. Direct and irreversible inhibition of the H+/K+ ATPase pump 
embedded in the apical membrane of parietal cells blocks the exchange of protons against 
a high concentration gradient 241 and reduces acidification of the stomach. PPIs quickly 
surpassed the use of H2RAs due to an increase in the duration of action, potency, efficacy 
and low adverse effects. However, achlorhydric conditions of the stomach stimulate 
further gastrin secretion and the risk of potential hypergastrinaemia remains controversial.  
Short term studies in healthy patients and those with duodenal ulcer or ZES taking a single 
daily dose of 20-30mg omeprazole observed virtually complete elimination of gastric 
acidity after 6hrs and <70% reduction in stimulated gastric acid secretion after 24hrs which 
then stabilised. An increase in both resting and stimulated gastrin secretion was also 
observed secondary to the reduced intragastric acidity, which returned to basal levels 
approximately 14 days after cessation of treatment 242. Longer term studies have shown 
that omeprazole acutely increases serum gastrin concentrations which peak at 2-4 months 




a greater increase in gastrin concentrations being observed than with H2RAs due to 
increased drug efficacy 244. Although serum gastrin levels were elevated, most patients 
were not classified as hypergastrinaemic because the concentrations were within the 
normal range at <100pg/ml. Although omeprazole (and other subsequently developed 
PPIs) have been shown to increase serum gastrin concentrations 245 there is still conflicting 
evidence about whether the hypergastrinaemia that is associated with long term PPI 
treatment has any pathological consequences in man.    
1.4.1.4 Other causes of hypergastrinaemia 
1.4.1.4.1 Pernicious anaemia (PA) 
Destruction of the oxyntic mucosa, in particular parietal cells, reduces chlorhydric acid and 
intrinsic factor secretion 246. Intrinsic factor transports dietary vitamin B12 (cobalamin) to 
the terminal ileum for absorption 247 and vitamin B12 deficiency has been shown to induce 
a macrocytic anaemia known as pernicious anaemia (PA) (previously known as Biermer’s 
disease 248 and Addisonian anaemia 249). PA is currently considered an autoimmune 
condition due to the presence of intrinsic factor and parietal cell autoantibodies however 
PA is also the end-stage of autoimmune CAG 250.  
Some data have suggested the role of H. pylori-induced CAG in the pathogenesis of PA due 
to pathogen cross-activation of T or B cells 251. Pathogen-derived antigens have also been 
shown to evoke the host’s immune responses in rheumatoid arthritis which has been 
strongly associated with CAG 252. The gastric proton pump has previously been identified as 
an autoantigen in autoimmune CAG 253-255 and increased numbers of activated gastric CD4+ 
T cells (which recognise both gastric proton pump and H. pylori antigens) have also been 
observed 256, 257. However due to the low incidence of H. pylori seropositivity in patients 




1.4.1.4.2 Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic autoimmune condition that is characterised by 
inflammation of the synovial membranes, synovial hyperplasia and progressive destruction 
of affected joints. CAG has been previously observed in 62.5% of biopsies taken from 
patients with RA 252, which accounts for the high number of patients (<30%) that present 
with hypo- or achlorhydria. However, increased CAG has also been strongly associated with 
age and is commonly present in Sjögren's syndrome, which is often associated with RA 260 
and gastrin concentrations in RA have been variable with some studies recording levels as 
high as 1000pg/ml 261 whilst others have found no significant differences in comparison to 
healthy controls 262.  
1.4.1.4.3 Human immunodeficiency virus (HIV)/ Acquired immune deficiency 
syndrome (AIDS)  
There have been some reports that infection with the human immunodeficiency virus (HIV) 
may cause acid hyposecretion and subsequent hypergastrinaemia  263, 264, however the 
mechanism for acquired immune deficiency syndrome (AIDS)-related gastric disorders is 
complicated and still remains unclear. Some have suggested that increased parietal cell 
autoantibodies in immunocompromised patients may facilitate the development of 
atrophic gastritis 263, a known prerequisite for hypergastrinaemia. However this study 
provided little information about H. pylori or HIV positivity statuses. Other studies have 
reported conflicting results with only 1.6% of HIV-positive subjects analysed having 
increased serum parietal cell autoantibodies 265, suggesting a limited role for this 




1.4.2 Diseases associated with hypergastrinaemia 
1.4.2.1 Barrett’s oesophagus 
Barrett’s oesophagus is a premalignant disease that is a strong risk factor (125-fold 
increase) for the development of oesophageal adenocarcinoma 266, 267. Patients with 
Barrett’s oesophagus show metaplastic columnar epithelial cells in place of normal 
stratified squamous epithelial cells 268 as a result of chronic gastro-oesophageal reflux 
disease (GORD) 269, 270. Therefore, the majority of patients are prescribed acid suppressive 
therapies such as PPIs or H2RAs 
271 which contribute to increased gastrin secretion 272 and 
may promote tumour formation 273, 274. Gastrin binds to CCK2Rs, which are highly abundant 
in the mucosa of Barrett’s oesophagus, to induce the expression of EGF and trefoil factor 
family (TFF) peptides. The secondary signalling cascades activated can contribute to 
carcinogenesis via increased Cox-2 expression with further inflammatory responses and 
reduced apoptosis, and CCK2R activation has been shown to induce hyper-proliferation in 
oesophageal cancer cell lines 275-277. 
1.4.2.2 Cancer 
1.4.2.2.1 Gastric adenocarcinoma 
Gastric adenocarcinoma development and histological progression follows a specific 
pathway from normal mucosa to tumour formation through gastric atrophy, metaplasia 
and dysplasia and although many factors contribute to the predisposition for 
carcinogenesis it is strongly associated with chronic H. pylori infection 278. During H. pylori-
induced CAG there is a loss of parietal cell mass which subsequently reduces secretory 
signals that may control cell growth and differentiation. For example, the sonic hedgehog 
protein (SHH) is expressed in human and animal parietal cells 279 and physiologically 
regulates epithelial cell growth and function 280-282 and immunoregulation 283-285. Patients 
with CAG have decreased SHH expression and the development of gastric metaplasia has 




of chronic inflammation, primarily caused by H. pylori infection, increases the production 
of cytokines, reactive oxygen species (ROS) and reactive nitrogen species (RNS) which 
damage DNA. These oxidant products in conjunction with the loss of parietal cell 
regulatory mechanisms are necessary for progression towards gastric tumour formation 
287.  
Metaplastic cell lineages are progenitors for gastric metaplasia of which there are two 
types associated with gastric adenocarcinoma: intestinal metaplasia and spasmolytic-
polypeptide expressing metaplasia (SPEM). Intestinal metaplasia is the most recognised 
pre-neoplastic type of metaplasia and is characterised by the conversion of the normal 
mucosa to intestinal-type goblet cells 288. However, CAG can also promote the 
development SPEM which may originate from trans-differentiation of mature chief cells 289 
and is characterised by the development of an antral phenotype in the corpus, which 
expresses TFF-2 and muc-6 as physiological responses to injury 290. Both types of 
metaplasia are strongly associated with increased phenotypic and genotypic alterations 
observed in gastric adenocarcinoma 290-294 and in vivo studies have indicated that SPEM 
may be a precursor for intestinal metaplasia. Mongolian gerbils infected with H. pylori have 
been shown to develop SPEM after 3 weeks in association with CAG, followed by intestinal 
metaplasia after 24 and 39 weeks from areas of pre-existing SPEM, as both SPEM and 
intestinal metaplastic lineages were observed in a single gland 295. Similar histological 
progression of intestinal metaplasia has also been observed in humans 296.      
Unlike metaplasia which may be reversed by H. pylori eradication 297, 298, dysplasia is 
typically irreversible with hyper-proliferative and migratory properties and is strongly 
associated with the progression to gastric adenocarcinoma 299. The morphology of 
dysplastic tissues displays a breakdown of the glandular structure with increased 




gastric mucosa 300. Malignant transformation is a gradual process with morphological 
alterations continually occurring throughout the progression to carcinomatous tissue 292.     
1.4.2.2.2 Gastric neuroendocrine tumours (NETs) types-1 and -2  
Gastric carcinoids (neuroendocrine tumours, NETs) are rare tumours that originate from 
ECL cells in the oxyntic mucosa of the stomach 301-303 and are classified as three separate 
types (with an extremely rare fourth type) on the basis of pathological and morphological 
characteristics 304-306. Despite being rare, diagnoses of gastric NETs have become more 
common over the past 50 years as a consequence of increased endoscopic surveillance and 
improved pathological analysis 307.   
1.4.2.2.2.1 Type-1 gastric NETs 
Type-1 gastric NETs are the most common form (70-80%) and are associated with elevated 
serum gastrin concentrations. Previous studies have suggested that the associated 
pathological changes that occur in the stomach, may be, in part, due to the 
hypergastrinaemia which develops as a consequence of autoimmune CAG and achlorhydria 
302. Type-1 gastric NETs are typically small (0.5-1cm diameter), well-differentiated, 
multifocal tumours that are localised within the corpus mucosa and submucosa. In 
autoimmune CAG there is a loss of parietal cell mass which results in gastric acid 
hyposecretion with achlorhydria of the gastric lumen and decreased production of intrinsic 
factor (characteristic of pernicious anaemia). The lack of gastric acid in the stomach 
continually stimulates the release of gastrin from antral G cells and results in chronic 
hypergastrinaemia which promotes gastric mucosal ECL cell hyperplasia and contributes to 
tumourigenesis 308.  
1.4.2.2.2.2 Type-2 gastric NETs 
Type-2 gastric NETs are relatively rare (5-6%) tumours that are histologically similar to 




secreting tumours in Zollinger Ellison Syndrome and MEN-1 syndrome 309. MEN-1 
syndrome is usually caused by an inherited autosomal dominant menin gene mutation 
(MEN1), although somatic mutations of the MEN1 gene have frequently been observed in 
sporadic ZES cases that occur as a single tumour with no symptoms of MEN-1 310. Menin is 
a nuclear protein of dichotomous function as it can both positively and negatively regulate 
gene expression. In the majority of MEN-1 syndromes, the inherited MEN1 gene mutation 
causes a loss of heterozygosity (LOH), thus highlighting menin as a putative tumour 
suppressor protein within endocrine tissues 311, 312. In heterozygous MEN1 mutant and 
MEN1 knockout mice, phenotypic alterations mimic the MEN-1 syndrome observed in 
humans 313, 314 and complete deletion is fatal at E.11.5-13.5 in mouse embryos 315. 
Hypergastrinaemia has been shown to increase ECL cell hyperplasia as 30% of patients with 
autoimmune CAG or PA showed increased ECL cell proliferation, whilst only 7% developed 
gastric NETs 316, 317. However, gastric NETs are more frequently observed in patients with 
ZES associated with MEN-1 syndrome. In cases of ZES associated with MEN-1 but without 
gastrinoma, there have been reports of reduced gastric NET formation and in patients with 
ZES without associated MEN-1, gastric NETs were rare. These data suggest that 
hypergastrinaemia is sufficient for ECL cell hyper-proliferation but requires additional 
cofactors such as the MEN-1 tumour suppressor gene mutation, for the conversion of 
hyperplasia to neoplasia 318, 319.     
1.4.2.2.3 Gastric mucosa-associated lymphoid tissue (MALT) lymphomas 
Gastric mucosa-associated lymphoid tissue (MALT) lymphomas (now known as extranodal 
marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue) are the most 
common form of gastric lymphoma (70%) and are usually confined to the antrum and 
distal corpus of the stomach until an advanced stage of disease 320. Gastric MALT 




increased gastrin and CCK2R expression 322 and gastric atrophy 323. Low-grade histological 
features closely mimic the Peyer’s patch (B-cell component) observed in MALT and 
lymphoepithelial lesions have been frequently observed as lymphoma infiltrates spread 
into the mucosa surrounding the Peyer’s patch marginal zone 324, 325. Low grade tumours 
have been associated with better prognoses as localised therapy is often curative due to 
the relatively confined nature of the tumour and significant regression has been observed 
in many cases after H. pylori eradication 326, 327. In comparison high-grade tumours develop 
though increased numbers of transformed blast cells that form large sheets or clusters 
which induce glandular destruction 328, 329 and this has been shown to reduce the 10-year 
survival rate by 48% 330. Gene mutations in the NFκB signalling pathway have been 
implicated in the malignant transformation to high-grade tumours. However there is 
increasing evidence to suggest that oncogenesis may only occur when genetic aberrations 
are in combination with immunological stimulation (primarily caused by chronic H. pylori 
infection) 331.    
1.4.2.2.4 Pancreatic cancer 
Pancreatic cancer is one of the leading causes of cancer-related deaths with less than 1% 
survival rate (>10 years)332. The poor prognosis may be attributed to high levels of 
proliferation, metastasis and invasion resulting in advanced stage diagnoses. Exogenous 
gastrin has been shown to increase pancreatic cell growth in some studies 333, 334, but not in 
others 335 and the mechanism of the trophic effects of gastrin is currently unclear as the 
CCK2R is only abundantly expressed in drug-induced pancreatic cancer in rodents 336, 337. 
However, gastrin has been shown to increase proliferation in pancreatic cancer cells in 
vitro 338, 339 and in xenografted tumours in vivo 340. Studies have indicated that gastrin-
induced cell growth may occur in an autocrine manner as primary pancreatic cancer cells 
have been shown to express the CCK2R and synthesise gastrin 341-343. H. pylori 




major cause of hypergastrinaemia and has also been shown to double the risk of 
pancreatic cancer in humans 344, 345, indicating the potential role of gastrin in pancreatic 
carcinogenesis.   
1.4.2.2.5 Colon cancer  
Normal colonic epithelial cells have previously been shown to generally lack the CCK2R and 
the processing machinery required for the generation of amidated gastrins 346. However, 
studies have confirmed that non-amidated gastrins induce local epithelial cell proliferation 
in colon cancer 347, 348, in an autocrine and paracrine manner 349, 350. Transgenic hGAS mice 
(which overexpress human Pro-G) have been shown to have increased colonic proliferation 
and an increased susceptibility to colon carcinogenesis following DNA damage 198, 351, 352 or 
p53 gene mutation 195.  Previous studies have also reported an increase in Pro-G, but not 
G17 or Gly-G, in colorectal cancer patients 
353, 354.  
Non-amidated gastrins (Pro-G and CTFP) have been shown to possess anti-apoptotic 
properties due to the activation of the NFκB and Wnt signalling pathways 355, 356. High levels 
of Pro-G in primary colorectal cancer cells have also been strongly associated with 
increased tumour cell growth as larger tumours have been observed in 
CD133high/CD44high/Pro-Ghigh cells compared with CD133low/CD44low/Pro-Glow cells in severe 
chronic immunodeficiency (SCID) mice 357. In APCMin/+ mice, a model of human familial 
adenomatous polyposis (FAP) which is a rare autosomal-dominant colorectal cancer 
condition 358, 359, hypergastrinaemia alone has been shown to increase colonic proliferation 
and malignant potential but was not sufficient to cause carcinogenesis 360. In addition, 
hypergastrinaemic patients with ZES, PA or taking acid-suppressive drugs such as PPIs have 
not previously been shown to have an increased susceptibility to colon carcinogenesis 361, 





1.5 Mouse models used for the study of gastrin and gastric 
carcinogenesis 
The development of translational animal models is important in order to fully understand 
the molecular mechanisms involved in human gastric carcinogenesis, for preventative and 
therapeutic potential. Currently, limitations have occurred due to interspecies variability as 
anatomies differ between animals and humans. The human and mouse genome both 
contain ~30,000 protein coding genes 363 and therefore morphological and physiological 
differences are possibly due to alterations in both coding and non-coding sequences 364, 
duplicated sequences or gene deletions 365. Some morphological differences include the 
gastric fundus lining which contains squamous cells in mice rather than oxyntic mucosa like 
in humans and rodents rarely develop spontaneous gastric carcinogenesis, with the 
exception of cotton rats (Sigmodon hispidus) 366-368 and some strains of the common 
African rat (Mastomys natalensis) 369, 370. Therefore the induction of gastric cancer through 
chemical, bacterial or genetic methods has been explored.  
1.5.1 Chemical models 
Early studies suggested that aetiological factors such as high dietary salt and nitrate/nitrite 
intake may contribute to gastric carcinogenesis and therefore, early animal models utilised 
nitrosamines such as N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) in rats 371, 372 or N-
methyl-N-nitrosourea (MNU) in mice 373 in order to induce gastric tumours. 
1.5.2 Bacterial infection models 
Since the strong relationship between H. pylori and gastric cancer was discovered 374 and 
the bacterium was classified as a type-1 carcinogen in 1994  375, many different animal 
models have used H. pylori-associated bacterial infection to induce gastric tumours. Due to 
the successful manipulation of the mouse genome and relatively inexpensive housing 




a limited number of Helicobacter bacterial strains that can successfully colonise the mouse 
stomach and although successful colonisation of H. pylori has been reported in mice 376-378, 
infection with Helicobacter felis (H. felis) has been more extensively characterised 379-382.  
The isolation and culture of H. felis, a natural inhabitant of the gastric mucosa of adult cats 
383, allowed the first detailed investigations into bacterial colonisation of the gastric 
mucosa in small animal models. Although H. felis lacks cagA and vacuolating cytotoxin A 
(vacA) (the virulence factors associated with increased pathology in humans), chronic 
infection has shown to induce the progression from severe chronic gastritis to gastric 
cancer in germ-free mice 384-386, similar to the gastric trophism observed in H. pylori 
infected humans. Lee et al. also successfully adapted a strain of H. pylori (Sydney strain 
SS1) that is cagA and vacA positive with an increased ability for successful colonisation in 
mice, particularly in C57BL/6 mice but also at lower rates in BALB/c, DBA/2 and C3H/He 
mice, to provide a standardised model for H. pylori-associated disease 387.     
1.5.3 Genetic models of gastric cancer 
Transgenic animal models have significantly enhanced the understanding of many gastric 
conditions and the role that gastrin plays during carcinogenesis. Genetic manipulation of 
the mouse genome in early studies involved oncogenes such as the simian virus 40 large 
tumour antigens (SV40 Tag) 388, which controls viral infection and alters many biological 
processes 389. Stomach-specific SV40 Tag transgenic models using the H+/K+ ATPase β-
subunit promoter at nucleotides -1035 to +24 showed decreased maturation of parietal 
cells with subsequent hypochlorhydria 390. However, these models did not follow the 
classical pathway of healthy mucosa to gastric cancer via atrophy, metaplasia and 
dysplasia, and were not associated with CAG or H. pylori infection as seen in 
hypergastrinaemic conditions. Therefore, various transgenic mouse models have been 




1.5.3.1 Transgenic mice overexpressing amidated gastrin (INS-GAS) 
Pancreatic islet cells produce enzymes such as PCs which cleave progastrin into biologically 
active forms including amidated gastrins. Therefore, transgenic mice on the genetic 
background FVB/N which are homozygous for the INS1-GAS transgene, coding for the rat 
insulin-1 promoter (a gastrin regulator), express the human gastrin gene in pancreatic islet 
cells and produce an excess of human gastrin 391. This overexpression of gastrin causes mild 
hypergastrinaemia, increased parietal cell number and subsequent elevated gastric acid 
secretion by 12 weeks of age. After 12 weeks, morphological changes are seen within the 
gastric epithelium including atrophic gastritis and intestinal metaplasia. End-stage disease 
was found to occur after 20 months in this colony, characterised by invasive gastric 
adenocarcinoma formation. In comparison, wild-type FVB/N mice did not develop atrophic 
gastritis, metaplasia or gastric adenocarcinoma under similar conditions. Infection with H. 
felis has been shown to accelerate the development of gastric adenocarcinoma (≤8 
months) in 85% of infected INS-GAS mice, with submucosal and intravascular invasion 
observed in 54% and 46% of animal respectively 112. Similar pathology has also been shown 
in INS-GAS mice infected with H. pylori after 28 weeks of infection, with early antibiotic 
eradication of the bacteria (8 weeks post-infection) preventing the development of gastric 
pathology 392.   
1.5.4 Genetic models for the study of gastrin related peptides 
1.5.4.1 Gastrin deficient transgenic mice (GAS-KO) 
As previously reported, the majority of H. pylori infected patients do not exhibit significant 
hypergastrinaemia, however chronic atrophy may still develop which suggests a 
susceptibility to gastric cancer independent of circulating gastrin concentration. Several 
strains of gastrin-deficient mice (GAS-KO) have been developed to further examine the 
physiological role of gastrin in the stomach. Initial GAS-KO mice developed by Koh et al. 




numbers 393. Since then, independently developed 129/Sv GAS-KO strains have shown 
reduced gastric acid secretion and increased inflammation due to bacterial colonisation171. 
These mice developed gastric antral tumours when housed in non-specific pathogen free 
(non-SPF) environments394. In transgenic GAS-KO mice developed by Friis-Hansen et al. 
basal and stimulated gastric acid secretion were abolished, however this strain did not 
develop gastric antral tumours. Histological analysis confirmed gastric mucosal atrophy 
with an increase in parietal and ECL cell defects, which were partially restored with 6 day 
gastrin replacement therapy 138. These data indicate a differential role of gastrin in the 
physiological functioning and development of both the corpus and antrum.  
1.5.4.2 Transgenic mice overexpressing gastrin precursors  
1.5.4.2.1 Overexpression of progastrin (hGAS)  
Transgenic mice that overexpress the prohormone Pro-G (hGAS) have been developed 
using a 5.5kb complete human gastrin minigene construct that lacks 1kb of the first intron 
of gastrin. The lack of hepatic processing machinery results in elevated levels of Pro-G and 
G17 mRNA with normal concentrations of G17 and an accumulation of Pro-G peptides. 
Increased Pro-G in hGAS mice has been shown to increase colonic epithelial proliferation 
and increases the susceptibility to azoxymethane (AOM)-induced carcinogenesis 351, 352, 395. 
Histological examination of hGAS mice observed a significant increase in colon tumour size 
and number compared with wild-type mice on the same genetic background (FVB/N), with 
no obvious gastric phenotype as previously observed with INS-GAS mice 396.  
1.5.4.2.2 Overexpression of glycine- extended gastrin (MTI/G-Gly) 
Similar to hGAS mice, no obvious gastric phenotype is observed in mice that constitutively 
overexpress glycine-extended gastrins (MTI/G-Gly). PCR mutagenesis of human gastrin 
cDNA integrates two stop codons after Gly72 which is spliced into a metallothionein 




glycine-extended gastrins in both serum and the colonic mucosa. Gly-G have been shown 
to exert trophic effects, particularly proliferative, on both normal and malignant colonic 
cells with increased colonic mucosal hyperplasia observed in vivo 161.  
In both hGAS and MTI/G-Gly mouse models there was an overexpression and activation of 
the Src family of tyrosine kinases (SFKs), particularly p60-Src, and subsequent secondary 
signalling pathways 397 and  a significant upregulation of TGF-α which may provide a 
mechanism(s) for colonic carcinogenesis 398.   
1.5.4.3 Gastrin receptor (CCK2R) deficient mice 
The CCK2R has previously been shown to be an important regulator of cellular responses 
to G17, both physiologically and pathologically (see section 1.2 Gastrin receptor). CCK2R 
deficient mice exhibit gastric acid hyposecretion with subsequent hypergastrinaemia, 
abnormal organisation of oxyntic glands and increased gastric atrophy 399-401. As the CCK2R 
in these mice is non-functional, gastrin is prevented from stimulating gastric acid secretion 
and therefore the luminal pH remains elevated. Analysis of cell populations identified an 
increase in gastrin secreting G cells and a significant decrease in acid-secreting cells 
(parietal) and differentiation and function of ECL cells 402. These morphological changes are 
similar to those seen in INS-GAS mice which exhibit decreased parietal cell mass during 
atrophy 112 and are in contrast to other hypergastrinaemic models such as Praomys 
(Mastomys) natalensis or cotton rats (Sigmodon hispidus) which exhibit increased ECL cell 
number and density 370, 403.  However, there is no supporting evidence of gastric cancer 
development in CCK2R deficient mice, suggesting that the CCK2R is important for 






1.6 Cholecystokinin-2 receptor (CCK2R) antagonists 
1.6.1 Non-peptide gastrin receptor antagonists 
Over the past twenty years, various attempts have been made to identify compounds that 
inhibit the CCK receptor in order to selectively block pathological downstream signalling. 
Many classes of non-peptide receptor antagonists have been designed as novel 
therapeutic agents including amino acids, dipeptoids, pyrazolidinones, anthranilic 
sulphonamides, benzodiazepines and ureidobenzodiazepines, with varying degrees of 
success.  
1.6.1.1 Amino acids 
4-benzamido-5-(dipropylamino)-5-oxopentanoic acid (Proglumide) was the first clinically 
available CCKR antagonist 404, however it has since been demonstrated that proglumide 
does not clearly discriminate between the two CCK receptor subtypes 405. Chemical 
alterations of proglumide produced several glutamic acid derivatives, all of which had 
higher potencies than the parent drug (lorglumide > loxiglumide > proglumide) 406. 
Spiroglumide (CR-2194) was initially proposed as an anti-gastrin drug which was more 
potent (micromolar range) than proglumide in vitro and in vivo it dose-dependently 
inhibited pentagastrin-stimulated gastric acid secretion in rats  407 and humans 408. 
However due to a relatively low affinity for the CCK2R, new and improved analogues were 
pursued.  
CR-2622, a napth-1-ylamino containing spiroglumide derivative, showed nanomolar affinity 
for the CCK2R. Although CR-2622 was highly selective and showed good affinity for the 
CCK2R, the bulky nature of R-group modifications reduced its oral bioavailability 409. 
Simultaneously the Rotta group synthesised a basic compound (CR-2345) to investigate 
whether acidic properties were necessary for stereoselectivity. The substitution of the 




antagonistic activity and CR-2345 also inhibited acid secretion in the perfused rat stomach 
and in dogs with a Heidenhain pouch or gastric fistula 410. In addition, CR-2345 exhibited 
bacteriostatic activity in vitro for several H. pylori strains that had been isolated from 
patients with CAG 411. Although the minimum inhibitory concentrations (MICs) are much 
higher than current bactericidal antibiotics such as amoxicillin or clarithromycin 412, this is 
worthy of further investigation due to our current understanding about the role of H. pylori 
during gastric carcinogenesis. 
1.6.1.2 Dipeptoids 
Several dipeptoid derivatives have been previously developed based on two important 
amino acid residues (tryptophan and phenylalanine) of CCKR ligands that were potent and 
selective for the CCK2R 413. Of these compounds, CI-988 (previously known as PD-134,308) 
was the most recognised, with nanomolar affinity for the CCK2R 414. CI-988 has a 1,600-fold 
higher affinity for the CCK2R and inhibited pentagastrin-induced gastrin secretion in rats 
with no significant effect on basal gastric acid secretion 415. It also inhibited gastrin-CCK2R 
induced cellular proliferation 416. C-terminal modifications were attempted in the dipeptoid 
series of drugs in order to increase potency, selectivity and the pharmacokinetic profile 
such as oral bioavailability which led to the development of a highly potent (IC50: 0.08nM) 
and highly selective (940-fold) CCK2R antagonist 4-fluorophenyl dipeptoid 417. However, 
further studies in rats suggested that CI-988 and related compounds stimulate gastric 
(partially) and pancreatic (fully) secretions 418. This in combination with relatively poor oral 
bioavailability (due to high molecular weight) limited its clinical application for the 
treatment of gastric disorders.  
1.6.1.3 Pyrazolidinones  
Utilisation of ‘random drug screening’ techniques led to the discovery of a class of 




Follow-up structure-activity relationship (SAR) studies identified the compound LY262691 
with a binding affinity of 31nM for the CCK2R and 11,600nM for the CCK1R 419, 420. 
However, the potency of this drug was dependent upon absolute stereochemistry and 
LY288513 was quickly identified as the biologically active enantiomer of the compound 
with 19nM and 20,500nM binding affinities for the CCK2R and CCK1R respectively 420. 
However, studies examining the effects of LY288513 on gastrin stimulated histidine 
decarboxylase in rodents identified no inhibitory effects at any of the concentration tested 
( 0.1-30nM/kg/hr) 421.        
1.6.1.4 Benzodiazepines 
A different approach was adopted by researchers at Merck who identified the first 
compound to selectively antagonise the CCK2 receptor at nanomolar concentrations (the 
benzodiazepine analogue L-365,260). Oral bioavailability was increased by the addition of a 
phenyl ring 422. Bock et al. found that L-365,260 has 140- to 280-fold greater binding 
affinity for the gastrin CCK2R in the guinea pig compared with the rat pancreas and L-
365,260 inhibited 125I-gastrin binding to the gastrin receptor 423. However, due to poor 
affinity and the short term duration of action, it was concluded that effective clinical 
application would be difficult. Therefore, successive attempts at chemical substitutions 
were made to increase the affinity for the gastrin receptor in vitro 424, 425. 
1.6.1.5 Ureidobenzodiazepines 
Nishida et al. suggested another structurally similar 1, 4 substituted benzodiazepine 
analogue ([(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-
3-yl]-3-(3-methylphenyl) urea] or YM022) that had a 2-fold higher affinity for the CCK2R 
than the CCK1R. When orally administered, it dose-dependently reduced pentagastrin-
stimulated gastric acid secretion in pylorus-ligated rats 426. Yuki et al. confirmed that 




0.73nM and 136nM, for CCK2 and CCK1 receptors respectively 427. However, despite the 
significantly longer lasting effects on gastric acid secretion in vivo 428, insufficient oral 
bioavailability still remained a problem for this compound. To address this issue, Semple et 
al. substituted various functional groups (Figure 7), to produce a YM022 derivative called 
netazepide (YF476) 8. The substitution of the methylbenzene ring at position R1 for a 3-
methylgroup, the aromaticity of the pyridine ring at position R2, and the presence of a 3-
methylamino group at position R3 enhanced both aqueous solubility and potency, thus 
increasing oral bioavailability (ED50 21nmol/kg) in dogs 
429.  
Additionally, the 1,5 substituted benzodiazepine derived calcium bis[(R)-(―)-3-[3-(5-
cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]-
[1,4]diazepin-3-yl)ureido] benzoate] (Z-360) that has been developed by Zeria 
Pharmaceuticals Co. Ltd, also surpasses the potency for the CCK2R and oral bioavailability 
compared with YM022 and L-356,260 430. Z-360 showed increased displacement of [I125]-
G17 (0.15nM) binding from the CCK2R with an EC50 of 0.1nM 
431 and dose-dependently 
inhibited meal-induced gastric acid secretion in anaesthetised rats and vagus-innervated 
gastric pouch dogs, with the maximal effect (1mg/kg twice daily) comparable to the PPI 
omeprazole (30mg/kg once daily) 432.        
1.6.1.6 Anthranilic sulphonamides 
High throughput screening by Johnson & Johnson identified a novel class of small non-
peptide structures based around an anthranilic ring that had good potency and selectivity 
for the CCK2R, a promising half-life (0.35±0.03hrs) and a low plasma clearance rate 
(0.42±0.01 L/kg/hr) in rats 433. Further analogue studies increased the pharmacokinetic 
profile of the leading compounds in this class. For example, the substitution of the chlorine 
atom at the 4-position on the anthranilic ring for a bromine atom and similarly the 




binding affinity (10-fold) for the CCK2R and these became analogues of the initial 
compound. However, substitution of the sulphonamide moiety for an amide functional 
group or the sulphonamide moiety at the meta-position significantly inhibited biological 
activity. These data suggested that the sulphonamide group at the ortho-position and 
halogenation of the anthranilic ring were essential for the functionality of these 
compounds and contributed to the development and success of [(R)4-Bromo-N-[1-(2,4-
difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide (JNJ-26070109) as a 



























Figure 7. The basic 3D structure of a benzodiazepine derivative (B) and the functional group differences between two 
benzodiazepine-derived, highly potent and selective CCK2R antagonists YM022 and netazepide (A, C and D).  Figure 






1.6.2 Effects of current CCK2R antagonists  
1.6.2.1 In vitro 
In humans, the CCK2R is ubiquitously expressed throughout the brain and the 
gastrointestinal tract and increased expression has been observed in various tumour cell 
lines including stomach, lung, colon and lymphoma 436-440. Gastrin has been shown to exert 
trophic effects on CCK2R bearing tumours both in vitro and in vivo 441, 442 in a paracrine and 
potentially in an autocrine manner, as some CCK2R bearing cells additionally synthesise 
gastrin 350. YM022 and netazepide have been shown to competitively displace [125I] 
radiolabelled gastrin-I from the CCK2R with higher potencies than previously developed 
CCK2R antagonists 426, 429. Gastrin-induced cellular responses such as DNA synthesis, 
phosphoinositide hydrolysis, histamine secretion and calcium mobilisation were dose-
dependently inhibited following either YM022 or netazepide treatment, indicating that the 
current CCK2R antagonists YM022 and netazepide may intervene in the activation of the 
CCK2R to reduce gastrin stimulated trophic effects in human cancer cells 443-447.  
1.6.2.2 Animal models 
Excessive proliferation of the colonic epithelium has previously been identified as a risk 
factor for the development of colon cancer 448. The human gastrin precursor Pro-G is a 
trophic growth factor for CCK2R bearing colonic epithelial cells located on basal colonic 
crypts 396. Previous studies in transgenic hGAS mice have suggested that Pro-G increases 
CCK2R expression and Pro-G has been strongly associated with an increased susceptibility 
to drug-induced colon carcinogenesis in both short and long term studies 351, 352, 395. 
Inactivation of the CCK2R with YM022 has been shown to inhibit Pro-G stimulated 
hyperproliferation and increases apoptosis of the colonic epithelium which reduces 
mucosal thickness and the aberrant crypt foci (ACF) associated with neoplastic progression 




Numerous in vivo studies have suggested that persistent H. pylori infection causes CAG 
which may progress to gastric adenocarcinoma in susceptible individuals 218, 292, 375. 
Transgenic INS-GAS mice develop mild inflammation, moderate hyperplasia and severe 
mucosal atrophy with intestinal metaplasia and dysplasia after 36 weeks, which is 
exacerbated by infection with H. felis 112. These preneoplastic changes have been shown to 
be reduced with administration of YM022 or netazepide, alone or in combination with 
antimicrobial treatments, in both infected and uninfected INS-GAS mice 450, 451. Similarly, 
subcutaneous injection of netazepide (500μmol/kg) has been shown to reduce chronic 
mucosal inflammation and atrophy in Mongolian gerbils with and without H. pylori 
infection (<18 month treatment), with no significant differences in H. pylori colonisation 
being found between groups 452. Netazepide at a concentration of 500μmol/kg has also 
been shown to inhibit ECL cell hyperproliferation and the development of type-1 gastric 
NETs that spontaneously arise in African cotton rats (Sigmodon hispidus) 368, 453 and 
Mastomys rodents (Praomys natalensis) 454.  
Equally, the recent development of the anthranilic sulphonamide class of CCK2R 
antagonists identified JNJ-26070109 as one of the most selective human CCK2R 
antagonists (<1200 fold higher affinity for CCK2R than CCK1R) with high oral bioavailability. 
Chronic administration of JNJ-26070109 has been shown to reduce pentagastrin-
stimulated gastric acid secretion and PPI-induced gastric acid rebound in a dose-dependent 
manner in rodents and canines 434, 455. These data indicate that JNJ-26070109 is a promising 
novel CCK2R antagonist for clinical investigation into the treatment of acid related 
disorders. 
1.6.2.3 Human clinical pharmacology 
In support of the animal studies, netazepide has been shown to be a well-tolerated and 




netazepide cause dose-dependent inhibition of pentagastrin-stimulated or food-stimulated 
gastric acid secretion 456-458. In two non-randomised trials, oral administration of 
netazepide (50mg daily for 12 weeks with a 12 week follow-up) reduced the abundance of 
gastric biomarkers such as chromogranin A (CgA), histidine decarboxylase (HDC) and MMP-
7 which returned to baseline after cessation of treatment and reduced tumour size and 
number by 30% in patients with autoimmune chronic atrophic gastritis, hypergastrinaemia 
and type-1 gastric NETs 459, 460.  
Due to the expression of the CCK2R on various tissues, CCK2R antagonists also have the 
potential to inhibit the trophic effects of gastrin associated with the development of other 
tumours such as pancreatic adenocarcinoma. The benzodiazepine-derivative Z-360 
(120mg/day) has been shown to inhibit gastric acid secretion and was well tolerated with 
minimal adverse effects in phase 1a clinical trials (healthy subjects) at concentrations of 
<480mg/day for 8 days (quoted as unpublished by Meyer et al. 461). Despite the increased 
oral bioavailability and tolerability, a phase Ib/IIa clinical trial investigating chemotherapy 
regimens for patients with advanced pancreatic carcinoma found no significant difference 
between co-administration of Z-360 and gemcitabine, either drug alone or the placebo. 
However, increased plasma gastrin concentrations at <240mg Z-360 treatment indicated 
successful inhibition of the CCK2R 461.    
1.6.2.4 Human disease 
In vivo studies have previously demonstrated the importance of CCK2R intracellular 
signalling in hypergastrinaemic conditions such as PA, CAG (both autoimmune and H. 
pylori-induced), acid suppression and gastrinomas 462, 463. Elevated gastrin concentrations in 
the circulation stimulate the proliferation of CCK2R bearing gastric ECL cells and contribute 
to the development of hyperplasia, with subsequent progression to gastric NETs in some 




NETs and 10-30% of patients with type-2 gastric NETs develop metastases 466. Gastrin is an 
essential regulator of gastric acid secretion via activation of proton pumps on the 
basolateral membrane of parietal cells 467. However, gastrin also exerts trophic effects on 
parietal cells and increased parietal cell mass has been strongly associated with increased 
gastric acid output which is essential for the development of peptic ulcers 130, 226, 411. In 
contrast, corpus colonisation of H. pylori  has been shown to decrease parietal cell mass 
and integrity which reduces gastric acid secretion and results in CAG; a known precursor 
for gastric adenocarcinoma development 219. Therefore the development of highly potent 
and selective CCK2R antagonists particularly YM022 and netazepide, have identified areas 
for therapeutic intervention which may, alone or in combination with other treatments, 















1.7 MicroRNAs (miRNAs) 
1.7.1 Significance of miRNAs 
MicroRNAs (miRNAs) are a large family of endogenously expressed single stranded non-
coding RNAs, 19-25 nucleotides in length, that control post-translational gene expression 
via binding to the 3’ untranslated region (3’UTR) of numerous mRNAs. Since the first 
miRNA (lin-4) from the Caenorhabditis elegans lin-14 gene 468  was discovered over 20 
years ago, the number of known mature miRNAs has risen into the thousands and is 
continually increasing. According to previous literature, miRNA genes may contribute to 
~1% of the total human genome with a large proportion (<40%) stemming from introns 469, 
formerly referred to as ‘junk’ sequences. This highlights the possibility that the number of 
miRNA sequences and subsequent mature miRNAs may be greater than first thought. As 
only a partial sequence of complementary target mRNA is required for binding to a miRNA, 
there is a potential for one miRNA to regulate several different mRNAs and vice versa for 
one mRNA to be regulated by multiple miRNAs. This provides an additional layer of 
complexity for the functional characterisation of identified miRNAs and their targets 470.     
1.7.2 Biogenesis 
The biogenesis of mature miRNAs is a complex multistep process (Figure 8). RNA 
Polymerases-II 471 or -III 472 initially transcribe a long primary sequence pri(mary)-miRNA, 
which may contain numerous miRNA transcripts. The RNA binding protein DiGeorge 
syndrome chromosomal region-8 (DGCR8)/Pasha facilitates the cleavage of pri-miRNA to 
hairpin-like miRNA precursors 473 by the class 2 RNAse-III enzyme Drosha, before being 
exported through the nuclear pore via the exportin-5/Ran-GTP 474. The human 
immunodeficiency trans-activating response RNA binding protein (TRBP) along with the 
endoribonuclease Dicer, process the ~70 nucleotide lengths of pre-miRNA by removing the 
stem-loop at the 3’ end to generate a small double stranded RNA duplex (miRNA:miRNA*), 




complementary strand. Only mature miRNA strands are incorporated into the RNA-
induced silencing complex (RISC) and associate with the catalytic subunit Argonaute 2 
(Ago2) 475; which directs the complex to mRNA targets with complementary base pairing 
sequences, leaving the complementary miRNA* strand to be cleaved.   
1.7.3 Physiological functions 
MicroRNAs are a class of endogenous non-protein coding short RNAs that post-
transcriptionally regulate approximately 30% of the human genome 470, 476, however their 
regulatory mechanisms are poorly understood. Mature miRNA sequences have been highly 
conserved throughout evolution in most investigated organisms including humans 477, 
suggesting a fundamental role during the maintenance of cell physiology.  
1.7.4 Target mRNA downregulation 
1.7.4.1 Translational repression 
It was originally suggested that miRNAs mediate mRNA repression after the initiation of 
translation for a particular protein, but the point at which this occurred remained unclear. 
This hypothesis was based on the miRNA lin-4 and its larval mRNA targets (lin-14 and lin-
28) that were isolated from Caenorhabditis elegans (C. elegans) 468. Lin-14 and lin-28 mRNA 
have been shown to be accumulate in the polysomes (processing bodies) whilst protein 
concentration is downregulated in late L2 to early L3 larval stages of C. elegans 
development (periods where miRNA mediated repression occurs) which suggest that 
translation repression occurs downstream of its initiation 478, 479. However, this hypothesis 
was challenged by Pillai et al. who examined miRNA repression in human cells using 
luciferase reporters at 3 sites of the 3’UTR of target mRNAs which are mediated by 
endogenous let-7. After 48hr DNA transfection, luciferase expression was decreased 80-
90%, with a 20% reduction in reporter mRNA expression. Moreover sucrose gradient 




initiation occurring 480. Although there are a few discrepancies between experimental 
methods there is little evidence to contradict either theory, therefore is it possible that 
inhibition of translation may occur through multiple mechanisms, as the biological 
outcome of miRNA-mRNA interactions depends on many factors including base pairing, 
RNA secondary structures, target site accessibility in addition to cellular context 481-484.           
1.7.4.2 Target mRNA degradation 
Perfect complementary base pairing of miRNAs-mRNAs has been shown to induce 
endonuclease cleavage of the target mRNAs (also known as ‘slicer’ activity) 485-487. Although 
the majority of perfect base pairing has been shown to direct endonucleolytic cleavage, in 
some cases this may not be adequate and other factors such as the presence of the Ago2 
protein in the RISC complex, are needed for cleavage to occur 488, 489.  Additionally, some 
imperfect base pairing in plants has also been shown to still induce endonucleolytic 
cleavage of target mRNAs 490, 491, indicating the importance of specific and catalytically 
active ribonucleoprotein binding for the cleavage of mRNAs. The cleaved fragments of 
mRNAs are incorporated into general mRNA degradation pathways which are initiated by 
deadenylation of the 3’ poly(A)-tail 492 followed by either exonuclease activity within the 
exosome, or processed by decapping enzymes (Dcp) 1/2 followed by exoribonuclease 
(Xrn1p) degradation 493. Studies have also suggested that miRNAs may target mRNAs for 
slicer-independent degradation via AU-rich 3’UTR regulatory elements (AREs) 494 which 
commonly control mRNA decay 495, however the mechanism for ARE-mediated 
degradation remains unknown.  
1.7.5 Target mRNA upregulation 
It is generally assumed that mRNA regulation by miRNAs always results in decreased 
expression of the target mRNA through degradation or translational repression. However, 




process and evidence suggested that some miRNAs may stimulate mRNA upregulation 
through direct mediation or the inhibition of repression 496.  
1.7.5.1 Direct upregulation of target mRNAs 
Post-transcriptional upregulation has been shown to occur in response to specific cellular 
states for instance, different phases of the cell cycle. During the G0 phase the GW182 
protein, which is essential for translational repression, is downregulated allowing Ago2 
(which loses ‘slicer’ activity in this phase) to interact with the Fragile-X mental retardation 
protein-1 (FXR1) in microRNA ribonucleoprotein (miRNP) complexes, which are recruited 
for the initiation of ARE-mediated translation to maintain quiescence 497, 498. In contrast, 
during the late S/ early G2 phase of the cell cycle some miRNAs have been shown to 
additionally repress translation in proliferating cells 499, 500, suggesting that miRNAs may 
oscillate between activating and inhibiting mRNA translation as a regulatory function of the 
cell cycle.   
1.7.5.2 Indirect upregulation of target mRNAs 
The indirect upregulation of target mRNAs involves the removal of inhibitory 
miRNA/miRNP complexes 501 which have frequently been observed in response to cell 
stress such as increased hypoxia, radiation and salt concentrations 502-504. For example, the 
cationic amino acid transporter-1 (CAT-1) mRNA has been shown to be upregulated in 
response to amino acid deprivation by the binding of the human antigen R (HuR) protein to 
AREs, which delays mRNA decay and increases miR-122 dissociation. The removal of 
repressive miRNPs facilitates CAT-1 incorporation into stress granules 502 which causes 
polysome recruitment to increase CAT-1 expression and maintains hepatocellular protein 
synthesis 505.  
Alternatively, endogenous miRNA ‘sponge’ RNAs have been associated with the indirect 




miRNAs and prevent the binding of specific miRNPs to the target mRNA 506, 507. In prostate 
cancer cells (DU145), retroviral overexpression of the miRNA sponge PTENP1 has been 
shown to derepress the tumour suppressive PTEN gene in a Dicer-dependent manner from 
the oncogenic miR-17~92 cluster, as miR-17~92 has been shown repress PTENP1 and PTEN 
with equal magnitude. Copy number losses at the PTENP1 genomic locus have also been 
frequently observed in sporadic human colon cancers compared with normal colon tissues 





Figure 8. The canonical pathway for miRNA biogenesis in human cells. RNA polymerase-II transcribes the 
primary miRNA transcript(s) (pri-miRNA) located within exons or introns, or in intergenic regions of DNA.  
Multiple miRNAs located on the same gene are transcribed as clusters. The microprocessor complex 
(Drosha/DCGR8) crops the pri-miRNA into precursor miRNA (pre-miRNA) hairpin loops which are exported into 
the cytoplasm via exportin-5 (EXP5). The majority of pre-miRNAs are further cleaved by Dicer/TRBP which 
generates mature miRNA strands that can be incorporated into the miRNP complex and directed to target 
mRNAs. Figure adapted from Lodish et al. (2008)
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1.7.6 Regulation of miRNAs 
1.7.6.1 Transcription 
In humans, miRNA loci are located within multiple genomic regions including coding and 
non-coding introns and exons. Several miRNAs have been shown to be located in close 
proximity and are transcribed together as cluster miRNAs (polycistrons) such as the miR-
17~92 and miR-221~222 clusters 509. However, polycistronic miRNAs can also be 
individually post-transcriptionally regulated. miRNA transcription is regulated by multiple 
RNA polymerase-II associated transcription factors such as p53 and Myc 510, 511 and 
epigenetic factors such as DNA methylation and histone modification 512, which determine 
positive or negative miRNA expression.  
1.7.6.2 miRNA processing 
In the nucleus, the microprocessor (Drosha and DGCR8 complex) is essential for the 
cropping of pri-miRNAs (~11bp of the lower stem) into pre-miRNA hairpin loops. The 
microprocessor can be auto-regulated as DGCR8 stabilises Drosha whilst Drosha 
destabilises DCGR8 mRNA 513, 514 or regulated by post-translational modifications which 
increase protein stability and nuclear localisation or either enhance or inhibit processing 
activity 515-517. Post-translational modifications such as protein phosphorylation are 
controlled by RNA-binding proteins such as p53, p72, p68, mothers against 
decapentaplegic homologs (SMAD) 1-3 or -5 518-520. miRNAs are exported into the 
cytoplasm via exportin-5 (EXP5) (a RAN-GTP-dependent binding protein) that is 
ubiquitously expressed within the cell. However, it has been suggested that EXP5 can be 
post-transcriptionally induced by PI3K pathway activation upon entry into the cell cycle (G1 
phase) 521. Increased nuclear export of miRNAs has also been associated with increased 
DNA damage due to Akt pathway activation 522 which is a common feature in many cancers 
and increased nuclear accumulation of miRNAs has been associated with XPO5 mutation 




into mature miRNA:miRNA* duplexes, of which the mature miRNA can then be 
incorporated into RISC complexes and directed to target mRNA 524. Human Dicer has been 
shown to interact with TRBP and the double-stranded RNA-binding protein (PACT) and it 
has been suggested that TRBP regulates the processing of certain pre-miRNAs as MAPK-
mediated phosphorylation of TRBP has been shown to increase growth-promoting miRNAs 
and decrease tumour suppressive miRNAs such as let-7 525. In contrast, the expression of 
the TARBP2 gene (which encodes for the TRBP protein) has been shown to be mutated in 
cancer and it has been suggested that reduced TRBP expression may destabilise Dicer and 
alter miRNA processing 526. Therefore the role of these cofactors in the regulation of 
miRNAs remains unclear as purified Dicer has also been shown to retain a similar 
processing activity to the RNA binding protein-Dicer complexes 527. 
1.7.6.3 miRNA sequence/structure 
miRNA transcript sequence and/or structure can be altered in numerous ways and this has 
been shown to interfere with mature miRNA expression and target binding. Single 
nucleotide polymorphisms (SNPs) are changes in miRNA base sequences which can alter 
the transcription of a particular miRNA. For example, SNPs have been identified in the 
tumour suppressive pri-miR-15a~16-1 cluster transcript (CNNC to TNNC) and have been 
shown to reduce the processing activity of the microprocessor which subsequently 
decreases the expression of mature miR-16 528. The addition of untemplated nucleotides to 
the 3’ end of the pri-miRNA (RNA tailing) such as adenylation or uridylation has been 
shown to interfere with Drosha and Dicer processing to either stabilise the miRNA or 
facilitate miRNA decay 529-532. In addition to RNA tailing, the post-transcriptional 
substitution of an adenosine to inosine (RNA editing catalysed by adenosine deaminases 
(ADARs)) in pri-miRNA sequences and the O-methylation of pre-miRNA sequences, such as 
pri-miR-142 and pre-miR-145 respectively, have been shown to reduce the binding affinity 




miRNAs can also be regulated by exonucleases and target mRNAs. For example in 
melanoma cells the human polynucleotide phosphorylase (PNPT1) has been shown to 
degrade miRNAs, specifically miR-221, miR-222 and miR-106 535. Target mRNAs have also 
been shown to regulate mature miRNAs by either decreasing 536, 537 or increasing stability 
538. However, the physiological relevance of miRNA stabilisation by target mRNAs still 
needs to be explored.  
1.7.7 Dysregulation in disease 
As the binding of miRNAs has been shown to inhibit the translation, increase cleavage or 
induce the degradation of target mRNAs depending upon complementary miRNA-mRNA 
binding 539, 540, altered gene regulation can result in many consequential disease states 
including neurodegenerative diseases such as  Alzheimer’s 541 and cancers 542-544.  
1.7.7.1 miRNAs and cancer 
As miRNAs control a large proportion of the genome, their expression patterns are tissue-
specific and dysregulation has been observed in the majority of malignancies 545, 
suggesting the potential for miRNAs to be biomarkers of cancer diagnosis, prognosis and 
response to therapies. One gene can be regulated by many miRNAs and likewise one 
miRNA can regulate several genes, including tumour suppressor genes and oncogenes. This 
adds an additional layer of functional complexity as miRNAs can act as both ‘oncomiRs’ to 
promote tumour development or ‘anti-oncomiRs’ to suppress tumour development, 
depending upon their tissue expression 546. However, >50% miRNA genes are located 
within fragile sites and genomic regions associated with deletion, translocation and 
amplification in cancers, further indicating their significance during carcinogenesis 547. 
OncomiRs are usually upregulated during tumour pathogenesis and inhibit tumour 
suppressor genes or genes associated with cell cycle regulation or apoptosis. There are 




direct evidence to suggest that miRNA dysregulation can induce carcinogenesis identified 
the overexpression of miR-155 and the miR-17-92 cluster (miR-17-3p, miR-17-5p, miR-18a, 
miR-19a, miR-20a, miR-19b-1 and miR-92a-1) 548 in various B-cell lymphomas 549-552 due to 
the amplification of the chromosomal region in which the miRNAs are located. However, 
these miRNAs have also been shown to be overexpressed in solid tumours of the breast, 
lung, colon, pancreas, prostate and stomach 542, 553-557.  
miRNAs of the miR-17-92 polycistron cluster have been shown to be transactivated by c-
Myc, a proto-oncogene that is aberrantly expressed in several types of malignancy 558. 
Distinct parts of the cluster have been shown to inhibit the expression of tumour 
suppressor genes such as PTEN (miR-19) thus promoting c-Myc-induced B-cell 
lymphogenesis 559, in part through a c-Myc-E2F1 reciprocal activation cycle 560. By contrast 
other parts of the cluster (miR-17-5p and miR-20a) negatively regulate E2F1 gene 
translation to potentially control this putative positive feedback loop 561.       
In contrast the downregulation of anti-oncomiRs, which inhibit oncogene translation to 
prevent tumour development, is more frequently observed in cancers. miR-15 and miR-16 
are involved in the physiological regulation of cell growth and apoptosis and target the 
anti-apoptotic B-cell lymphoma 2 (BCL2) gene 562. Translocation of the BCL-2 protein into 
mitochondria has been shown to inhibit the mitochondrial/intrinsic pathway and release of 
cytochrome c, which prevents the apoptotic caspase cascade 563. However in 68% of B-cell 
chronic lymphocytic leukaemias (B-CLL), the chromosome 13q14 region, where the miR-15 
and miR-15 genes are located, is deleted 564 causing a downregulation of these anti-
oncomiRs and allowing the initiation of tumour formation. 
The let-7 family was one of the first recognised classes of miRNAs to be shown to 
orchestrate cell proliferation, migration and differentiation in C. elegans 565, 566. Let-7 




which activate mitogenic MAPK/ERK signalling pathways that are commonly overexpressed 
in human malignancy 568. Similar to miR-15 and miR-16, the let-7 gene has been mapped to 
human genomic locations that are frequently deleted in lung cancer, resulting in reduced 
tumour suppressive function of let-7 569. Although specific members of the let-7 family are 
downregulated in cancers (e.g. let-7a and -7c in lung cancer  567), miRNA expression 
patterns are highly tissue specific and some members of the let-7 family maintain a high 
level of expression (e.g. let-7f in breast cancer 570 and let-7b and let-7i in lymphoma 571), 
indicating the potential for tumour-specific biomarkers.   
1.7.7.2 miRNAs and H. pylori 
In addition to transcriptional regulation, H. pylori infection has been shown to post-
transcriptionally regulate host cellular responses such as cell cycle progression, 
inflammatory responses, the inhibition of apoptosis, cell invasion and cell migration 
through dysregulated miRNAs 572. Epigenetic alterations induced by altered miRNA 
expression have been shown to enhance tumourgenicity of H. pylori-associated gastric 
cancer.  
H. pylori-associated dysregulation of miRNAs has been shown to contribute to gastric 
cancer pathogenesis. Ectopic expression of miR-101 has been shown to have tumour 
suppressive functions, in part, through the modulation of the cancer epigenome by 
inhibition of enhancer of zeste homologue-2 (EZH2), Cox-2, Mcl-1 and v-fos FBJ murine 
osteosarcoma viral oncogene homologue (Fos) 573-578. However miR-101 is reported to be 
downregulated in H. pylori-associated gastric cancer and this has been shown to promote 
tumour cell proliferation, metastasis, angiogenesis and the inhibition of apoptosis 573.   
Aberrant DNA methylation or histone modification is induced by H. pylori-infection in the 
gastric mucosa 579 and has been shown to contribute to increased inflammation 580. cagA 




of let-7 miRNAs through DNA methylation and histone modification in chronic gastritis and 
gastric cancer tissues 567, 581. This in turn activates the Ras/MAPK/ERK pathway which 
contributes to the malignant phenotype 582. 
Acute infection with cagA+ H. pylori in vitro and in vivo also significantly increases the 
expression of oncomiRs such as miR-1289 compared with uninfected or cagA- infected 
controls. miR-1289 post-transcriptionally inhibits the translation of H+/K+ ATPase-α subunit 
(HKα) mRNA to further control hypochlorhydric conditions 583. In both cagA-transfected 
and H. pylori-infected human gastric adenocarcinoma (AGS) cells, miR-1290 expression was 
upregulated in an ERK1/2-dependent manner and miR-584 was upregulated in an NFκB-
dependent manner and indirectly by mIR-1290. Both miR-584 and miR-1290 were shown 
to target the Foxa1 gene which significantly promoted epithelial-mesenchymal transition. 
In knock-in mice, miR-584 and miR-1290 overexpression induced gastric mucosal 
remodelling to intestinal metaplasia 584. The miRNA clusters miR-17~92 and miR-
106b~93~25, miR-194, miR-21 and miR196 were all significantly increased in intestinal 
metaplasia compared with healthy adjacent tissues and miRNA dysregulation was not 
reversed upon eradication of H. pylori during long term colonisation 585.       
Zhang et al. showed that oncogenic miR-21 was overexpressed in vitro in H. pylori infected 
cells and in vivo in gastric cancer tissues compared with healthy uninfected controls, 
suggesting that the increased miR-21 expression may be due to H. pylori infection. In AGS 
cells, an increase in cell survival, proliferation and cell invasion was induced by miR-21 
overexpression via the inhibition of reversion inducing cysteine rich protein with kazal 
motifs (RECK), a known tumour suppressor of gastric cancer 586.      
1.7.8 miRNAs as potential biomarkers of cancer 
miRNAs are promising candidates as biomarkers of disease, particularly cancer, due to 




miRNAs has been shown to remain intact under severe conditions including freeze-
thawing, boiling, low/high pH (1 or 13) or long term storage and ~50% of miRNAs have also 
been shown to remain intact after 3hr exposure to RNase enzymes 589. miRNAs have been 
shown to be expressed in distinct tissue-specific patterns that can determine 
clinicopathological features.  
1.7.8.1 Diagnostic, prognostic and predictive uses of miRNA profiles for cancer 
It has been previously observed that cancers derived from different cell lineages express 
distinct miRNA profiles that can determine cancer origin and subtype. For example, studies 
by Ferracin et al. were able to correctly identify the origin of 100% of primary tumours and 
78% of metastatic tumours from 101 formalin fixed paraffin embedded (FFPE) biopsies 
using a microarray platform. Further verification in 16 independent tumour samples of 
unknown origin initially indicated >90% prediction accuracy for most cases 590. Some 
specific miRNA profiles have also been shown to possess reproducible results for the early 
detection of cancers, for example increased expression of miR-21 is indicative of pancreatic 
ductal neoplasia 591. Earlier diagnosis of cancer and the identification of the primary 
tumour site would significantly enhance the specificity and effectiveness of cancer 
treatment and could significantly increase overall patient survival for many cancers. 
In addition to earlier diagnosis and the identification of tumour origin and type, miRNAs 
have been shown to accurately predict prognosis of disease-free survival and may enhance 
cancer therapy management. A unique thirteen miRNA signature has been identified in 
chronic lymphocytic leukaemia (CLL) patients and has been shown to accurately determine 
abnormal levels of prognostic factors, such as increased 70kDa zeta-associated protein 
(ZAP-70) and a reduced number of mutations in the immunoglobulin heavy-chain variable-
region gene (IgVH) 
592 which have been associated with a more aggressive form of cancer 




been identified for lung cancer prognosis as high expression of miR-221 and let-7a has 
been associated with increased tumour suppressive function with a good prognosis, whilst 
increased miR-137, miR-372 and miR-182 has been associated with enhanced metastasis 
594. Similarly, a seven miRNA signature (miR-21, miR-10b, miR-223, miR-338, let-7a, miR-
30a and miR-126) has been shown to predict overall survival and disease-free relapse in 
gastric cancer patients 595. Notably, single miRNAs have also been shown to accurately 
predict disease outcome. For example, an increase in miR-210 expression has been 
associated with an increased risk of relapse and poor clinical outcome in breast cancer, 
with similar accuracy to a 76 gene mRNA profile (GENE76) 596. The surveillance of specific 
miRNA profiles may also allow accurate prediction of patient response to cancer therapies, 
which is of great importance due to the development of chemoresistance; a major 







1.8 Helicobacter pylori (H. pylori) 
1.8.1 Potential routes of transmission 
Due to the high incidence of H. pylori infection, it is possible that there is more than one 
route for transmission of this bacterium which may include zoonotic, environmental and 
interpersonal. H. pylori-infected gnotobiotic pigs exhibited gastric pathological features 
similar to human infection 600 and higher incidences of H. pylori seropositivity have been 
observed in adults after occupational exposure to sheep 601, 602. Four independent studies 
have also suggested that the isolation of H. pylori is possible from both drinking and 
wastewater 603-606 and recent animal models found that contaminated drinking water 
increased H. pylori infection and gastric mucosal inflammation 607. Whilst some 
epidemiological studies have suggested that contraction from environmental sources is 
possible 607 there is more supporting evidence to suggest that interpersonal transmission is 
more probable 608-610, however the most important mechanism in humans still remains 
unclear. 
1.8.2 Role in pathogenesis  
The H. pylori bacterium is well adapted for survival and colonisation of the human gastric 
mucosa for the lifetime of the host 611 and spontaneous eradication is relatively uncommon 
(0.1-1.1% per year) 612. There are frequently no visible symptoms in H. pylori infected 
patients, with the majority not progressing to clinical disease 613. However for some 
patients, H. pylori infection stimulates the development of chronic gastritis which has 
previously been associated with peptic ulcers and gastric adenocarcinoma in humans 614, 
615. Environmental, genetic and bacterial virulence factors influence the outcome of 




1.8.2.1 Environmental  
Many environmental factors have previously been shown to actively contribute to H. 
pylori-induced gastric carcinogenesis. Diet plays a major role in the colonisation and 
persistence of H. pylori, as a synergistic relationship was identified between the bacterium 
and dose-dependent salt intake. High dietary salt intake has also been shown to induce 
gastric mucosal damage, in addition to independently increasing cell proliferation and DNA 
damage, which may result in tumourigenesis 616. In contrast, an increased intake of 
antioxidants and vitamins such as vitamin C (ascorbic acid) exhibit a cytoprotective 
function in acute H. pylori infection 617.  
1.8.2.2 Genetic 
As H. pylori infection is asymptomatic for the majority of people, the host’s genetics have 
been shown to determine susceptibility and severity of H. pylori infection. Inflammation of 
the gastric mucosa (chronic gastritis) occurs after successful colonisation of H. pylori and 
can be observed in all confirmed cases. H. pylori-induced gastritis commonly develops as a 
consequence of a Th1-polarised immune response with increased secretion of pro-
inflammatory cytokines (IL-1β, TNFα and IL-8) and reactive oxygen/nitrogen species 618-620. 
Administration of H. pylori-infected unfractionated splenocytes has been shown to result in 
gastric pathologies including gastritis, delayed-onset of hypersensitivity and metaplasia in 
uninfected mice 621.  
Single nucleotide polymorphisms (SNPs) within genes involved in immune and 
inflammatory responses have been shown to increase the risk of H. pylori-related gastric 
pathogenesis 622-625. Studies by El-Omar et al. identified that SNPs within the loci of the IL-1 
gene cluster, which encode the IL-1α, IL-1β and IL-RN genes, were strongly associated with 




sequence of TNF-α (TNF-α-308*A) and IL-8 (IL-8-251*A) have also been shown to promote 
gastric atrophy and to increase the risk of gastric cancer development 627, 628.  
In addition, chronic H. pylori infection has been shown to induce the accumulation of 
latent somatic gene mutations. For example, whole-exome sequencing and deep 
sequencing of tumour-associated genes in H. pylori-infected patients identified numerous 
mutations (predominantly C:G>T:A transitions) in the tumour suppressive TP53 gene, in 
cancerous and non-cancerous gastric biopsies 629. The progressive accumulation of somatic 
mutations within the TP53 gene may cause dysregulation of the cell cycle and initially drive 
tumour formation.  
1.8.2.3 Bacterial virulence factors 
In addition to host genetic factors, bacterial virulence genes have also been shown to 
determine the clinical outcome of chronic H. pylori infection. Previous evidence has 
suggested that H. pylori evolved simultaneously with humans as bacterial genetic diversity, 
which varies due to point mutations, gene insertions and/or deletions 630, 631, has been 
reported within the same host 632, 633. Although the majority of H. pylori bacteria reside 
within the gastric lumen, approximately 20% have been shown to interact with the gastric 
epithelia 634-636 and different bacterial genotypes have been shown to induce differential 
epithelial responses, some of which have been shown to increase the risk of gastric 
tumourigenesis 637.  
The most extensively characterised virulence factors are cagA and vacA genes which have 
been associated with malignant phenotypes 579, 638. However, some studies have reported 
cases of gastric cancer with cagA-negative strains of H. pylori 639, indicating the potential 
role of other virulence factors during the development of gastric neoplasia. The cagA gene 
is located within the 31 gene cag pathogenicity island (cagPAI), which also encodes for the 




T4SS facilitates the deployment of bacterial products such as the cagA gene product (CagA) 
and peptidoglycan, into the host epithelial cell cytoplasm 641. CagA has been shown to 
subsequently interact with multiple secondary messenger proteins which activate the 
MAPK, PI3K-Akt and NFκB pathways 642 which contribute to increased mucosal 
inflammation and susceptibility for gastric cancer 643-646. cagA+ strains can also 
independently increase the transcription of activation-induced cytidine deaminase (AID) in 
the gastric mucosa which causes mutations in immunoglobulin DNA 647. 
The vacA gene is not located within the cagPAI and encodes for the vacuolating cytotoxin-
A protein (VacA). The bacterial toxin VacA  has been shown to suppress T-cell activation 
and disrupt the epithelial cell barrier, primarily through the induction of cytoplasmic 
vacuolation, in vitro 648 and causes epithelial cell damage and ulcer formation in vivo 649. 
Almost all H. pylori strains contain the vacA gene, however variations within the 5’ terminal 
(s), middle (m) or intermediate (i) regions, of which the ‘s’ and ‘m’ regions are further 
divided into subtypes s1a, s1b, s1c/s2 and m1/m2, have been shown to influence 
cytotoxicity 650. In vitro, vacA s1/m1 strains have been shown to produce higher 
concentrations of cytotoxin with increased vacuolating activity being observed compared 
with s1/m2 or s2/m2 strains 651. Similarly in vivo, infection with H. pylori vacA s1/m1 strains 
have been associated with increased risk of peptic ulcer 652-654 or gastric cancer 655-657. VacA 
and CagA are functionally associated, as both have been shown to downregulate the 
effects of the other on the gastric epithelium, to potentially limit mucosal destruction and 
allow bacterial-cell interaction 658. 
Helicobacter outer membrane (Hop) proteins are the largest of the outer membrane 
protein (OMP) families which encode ~4% of the H. pylori genome 635. Hop proteins include 
adhesins such as blood-group antigen-A (BabA/ HopS) 659, sialic acid-binding adhesion 




the bacteria and success of long-term infection. Bacterial adhesins have also been strongly 
associated with increased H. pylori density, neutrophil infiltration and high levels of 
chemokines such as interleukin (IL-8) 662, which correlate with a more intense inflammatory 



















Figure 9. The environmental, genetic and bacterial virulence factors which contribute to H. pylori associated pathogenesis in humans. Single nucleotide polymorphisms and 
accumulated gene mutations have been shown to contribute to the development of gastritis and glandular atrophy. Environmental factors such as poor diet and smoking have also 
been associated with increased glandular atrophy which has been shown to be reduced with increased vitamin C intake. Bacterial virulence factors also contribute to early stage 
pathogenesis by the disruption of tight junctions, gene mutations, increased cell damage, invasion and metastasis and increased immune and inflammatory responses. The 
accumulation of all three risk factors has been shown to severely increase the development and progression of gastric adenocarcinoma. Figure adapted from Conteduca et al. (2013) 
10
, 
Monack et al. (2004) 
14
 and Wadhwa et al.(2013) 
16





Gastrin induces differential expression patterns of genes associated with gastric 
premalignant changes such as cellular proliferation, migration and structural remodelling, 
which can be reversed with CCK2 receptor antagonism. This could provide mechanistic 
insight into gastrin-associated carcinogenesis and may provide potential novel biomarkers 
for the early detection of gastric tumours.  
1.10 Aims 
1. To assess differentially expressed miRNAs within human gastric adenocarcinoma 
cell lines that have been transfected with the human CCK2 receptor (AGSGR) with 
and without gastrin treatment 
2. To identify possible activated pathways that may alter the transcription of the 
chosen miRNA(s) 
3. To identify and verify protein targets of the miRNA(s) and assess the functional 
consequences of their dysregulation in vitro and in vivo, in both hypergastrinaemic 
INS-GAS mice and humans with type-1 gastric neuroendocrine tumours 
4. To assess whether gastrin affects the expression of PAPPA2 mRNA and protein in 
AGSGR cells 
5. To evaluate the functional consequences of gastrin-induced alterations in PAPPA2 
expression in AGSGR cells 
6. To assess whether three novel CCK2 receptor antagonists reduce/reverse gastrin-





























Amidated gastrin (G17) was from Bachem (St.Helens, UK), Ro-32-0432, PD-98059 and LY-
294002 were from Calbiochem (Nottingham, UK) and YM022 was from Tocris Bioscience 
(Bristol, UK). Netazepide (YF476) and compounds TR1, TR2 and TR3 were gifts from Trio 
Medicines Ltd (London, UK). All other routine supplies were from Sigma (Poole, UK) unless 
otherwise stated.  
Human PAPPA2 and GAPDH qPCR primer pair sequences were purchased from Eurogentec 
(Southampton, UK) (Table 1). Human miR-222 (MS00007609), RNU62 (MS00033740) and 
CDKN1B (p27) primers (QT00998445) were purchased from Qiagen (Sussex, UK).  
Human PAPPA2 siRNA, human CDKN1B (p27) siRNA and non-targeting control siRNA were 
purchased from GE Dharmacon (Lafayette, USA) as a combination of 4 pooled siRNA 
sequences (SMARTpool: ON-TARGETplus™ PAPPA2 siRNA, SMARTpool: ON-TARGETplus™ 
human CDKN1B (p27) siRNA and SMARTpool: ON-TARGETplus™  Non-targeting Pool siRNA) 
for maximal gene silencing (Table 1). DharmaFECT 1 transfection reagent (GE Dharmacon, 
Lafayette, USA) was used for effective siRNA transfection in AGSGR cells.  
Chemically synthesised miR-222 mimic (MSY0000279), miR-222 inhibitors (MIN0000279), 
miR-1 mimic positive control (MSY0000416) and miScript negative control (1027271) were 









Table 1. Primer and small interfering RNA (siRNA) sequences.  
 
 
Target gene Primer sequences Purchased from 








Target gene siRNA sequences Purchased from 





















2.2 Cell lines 
A human gastric adenocarcinoma cell line (AGS) and a transfectant stably expressing the 
human CCK-2 receptor (AGSGR) 
173, 663, provided by Prof. A. Varro (Liverpool, UK) were 
cultivated in nutrient mixture F-12 Ham’s medium supplemented with 10% Foetal Bovine 
Serum (Gibco, Paisley, UK), 2mM L-Glutamine and 1% combined antibiotics streptomycin 
and penicillin (complete media). Cells were maintained in a humidified atmosphere of 5% 
CO2/ 95% O2 in Galaxy R (Wolf Laboratories, Newton, MA) incubators at 37°C and AGSGR 
cells sustained antibiotic selection with 2µg/ml puromycin for 7 days before 
experimentation.  
Rat exocrine pancreatic tumour cells (AR42J) that constitutively express the gastrin-CCK2 
receptor were purchased from the European collection of cell cultures (ECACC, Salisbury, 
UK). Cells were routinely cultivated in Dulbecco’s modified Eagle medium supplemented 
with 10% foetal bovine serum and 1% combined antibiotics streptomycin and penicillin 
(complete media) and maintained at 5% CO2/ 95% O2 in Galaxy R incubators (Wolf 
Laboratories, Newton, MA) at 37°C.  
All cells were harvested with 1× trypsin-EDTA solution (0.05% trypsin (v/v), 0.02% EDTA 
(w/v) in PBS) at 70-80% confluency and only cells at passage numbers between 1 and 30 
were used. All cells were serum starved for 24hrs before treatment.  
2.3 Animals 
All in vivo experiments were carried out under UK Home Office project licence numbers 
40/3392 and 70/8457, granted after ethical approval. Animals were housed in specific 
pathogen free facilities with access to food and water ad libitum at the University of 
Liverpool. Male wild-type FVB/N mice were purchased from Charles River Laboratories 
(Margate, UK) and male INS-GAS mice on the genetic FVB/N background were generated 




promoter (a gastrin regulator), which produced an excess of human gastrin 28. This 
overexpression resulted in mild hypergastrinaemia, increased parietal cell number and 
subsequent elevated gastric acid secretion within 12 weeks of birth. After 12 weeks, 
morphological changes were seen within the gastric epithelium including atrophic gastritis 
and intestinal metaplasia. End-stage disease occurred after about 40 weeks in this colony, 
characterised by invasive gastric adenocarcinoma formation 396. All mice were pathogen 
free and maintained under normal housing conditions for a minimum of 1 week prior to 
experimentation. Whole stomachs were taken and opened via the greater curvature then 
washed in sterile PBS. Whole stomach mucosal scrapings were obtained using sterile glass 
slides and preserved in either 500µl RNA later for RNA extraction or 200µl RIPA buffer for 
protein extraction. All blood samples were collected via cardiac puncture and separated by 
centrifugation by Dr. Bryony Parsons and H. felis bacteria for mouse infection studies was 
provided by Dr. Bryony Parsons.   
2.4 Human samples 
Human serum and gastric corpus biopsies were obtained by Dr. Andrew Moore from 8 
patients enrolled on studies 1 and 2 of the phase-2 clinical trial for the assessment of 
netazepide in subjects with autoimmune atrophic gastritis, hypergastrinaemia and multiple 
type-1 gastric neuroendocrine tumours, as previously described 460. Control samples were 
obtained from 10 patients who had a normal upper GI endoscopy, normal gastric antral 
and corpus biopsies, no evidence of H. pylori infection, were not taking proton pump 
inhibitors and who had fasting serum gastrin concentrations <40pM. All human sample 
collection had appropriate ethical approval and informed patient consent. 
2.5 Sample preparation 
1x106 AR42J, AGS or AGSGR cells were seeded into T75 vented cap cell culture flasks 




Treatments were applied accordingly in serum free media. Following treatment, cells were 
detached with trypsin and harvested into 15ml centrifuge tubes (Corning, Sunderland, UK). 
Cell suspensions were then centrifuged in the Heraeus Multifuge 3 S-R (Thermo Fisher 
Scientific, Hemel Hempstead, UK) at 1500rpm for 5mins and the precipitate-free liquid 
removed. The remaining pellet was re-suspended in 10ml phosphate buffered saline (PBS) 
and centrifuged at 1500rpm for a further 5mins, discarding the supernatant. The pellet was 
re-suspended again in 1ml PBS, transferred into a 1.5ml Eppendorf tube and spun in a 
HAWK 15/05 refrigerated microcentrifuge (Sanyo/MSE, London, UK) a final time at 4°C, 
5000rpm for 15mins. The upper layer of PBS was aspirated and discarded without 
disturbing the pellet which was stored at -80°C prior to use. 
2.6 RNA isolation and reverse transcription  
Total RNA was isolated from cells and tissues using the miRNeasy Mini Kit and from serum 
using the miRNeasy Serum/Plasma kit (both from Qiagen, Sussex, UK) according to the 
manufacturer’s instructions. The concentration of RNA was determined using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Hemel Hempstead, UK) and each sample was 
diluted to a final concentration of 2.5ng per reaction. Using the miScript RT II Kit (Qiagen, 
Sussex, UK) with the HiFlex buffer enabled cDNA synthesis of mRNA and with the HiSpec 
buffer enabled cDNA synthesis of mature miRNAs only. Samples were stored as undiluted 
cDNA at -20°C prior to real-time PCR. 
2.7 MicroRNA PCR Array  
The synthesised cDNA was prepared using the miScript SYBR Green PCR Kit (Qiagen, 
Sussex, UK) according to the manufacturer’s instructions. The mixture was then loaded 
into each well of the 96-well miScript miRNA PCR array plate (Qiagen, Sussex, UK) and run 
in a real-time LightCycler 480 (Roche, Sussex, UK). miScript miRNA PCR arrays contained 84 




biologically relevant pathway-focused panels with 8 endogenous control miRNAs. Data was 
analysed using the ΔΔCT method for relative quantification using the miScript miRNA PCR 
array data analysis software (Qiagen, Sussex, UK). Normalisation was against the average 
threshold cycle of the entire plate minus Ct values >35 (the maximum threshold value) and 
4 control genes (2x miRTC and 2xPPC) that were separately used to assess reverse 
transcription and PCR performance.  
2.8 Quantitative polymerase chain reaction (qPCR) primer assays  
Mature miRNAs were assessed using primer assays with SYBR green for miR-222 with 
endogenous RNU62 or spike-in exogenous C. elegans miR-39 used for normalisation 
according to the miScript miRNA Primer Assay Handbook (Qiagen, Sussex, UK). Messenger 
RNA was assessed using primer assays for CDKN1B (p27) with GAPDH for normalisation 
according to the Quantitect Primer Assay Handbook (Qiagen, Sussex, UK) and run in a real-
time LightCycler 480 (Roche, Sussex, UK). Each sample was run in quadruplicate and 
analysis used the ΔΔCT method for relative quantification.  
2.9 Small interfering RNA (siRNA) transfections 
AGSGR cells were transfected with SMARTpool: ON-TARGETplus™ human CDKN1B (p27) 
siRNA (L-003472-00-0005) or SMARTpool: ON-TARGETplus™ Non-targeting Pool siRNA (D-
001810-10) (both from GE Dharmacon) for 48hrs according and using DharmaFECT 1 
transfection reagent. AGSGR cells were seeded onto 24 well plates (3x10
4/well) in complete 
media and left to adhere for 24hrs. In separate 1.5ml Eppendorf tubes, the siRNA and 
transfection reagent (GE Dharmacon, Lafayette, USA) were diluted in serum free media to 
a final volume of 50μl per reaction and incubated for 5mins at room temperature. The 
diluted 50μl of siRNA was added to the 50μl transfection reagent, mixed by gentle 
pipetting and incubated for 20mins at room temperature. The transfection reaction was 




culture media was aspirated from the cells and 500μl of the appropriate transfection mix 
was added to each well. Cells were incubated at 37°C in a humidified atmosphere of 5% 
CO2/ 95% O2 for 24-72hrs, media was replaced with fresh complete media every 24hrs to 
reduce cytotoxicity. Cell culture medium was then changed to serum-free medium when 
10nM G17 treatment was applied. 
2.10    MicroRNA (miRNA) mimic and inhibitor transfections  
AGSGR cells (3x10
4/well) were seeded into 24 well plates in 500µl complete media and left 
to adhere for 24hrs before being transfected. The chemically synthesised miR-222 mimic 
(MSY0000279) or inhibitor (MIN0000279), miR-1 positive control (MSY0000416) or 
miScript negative control (1027271) (all from QIAGEN) were diluted in 100µl serum-free 
media. The HiPerfect transfection reagent (301704) (QIAGEN) was then added (3-4.5µl) 
and incubated for 10mins at room temperature to allow the formation of transfection 
complexes. The complexes were then added dropwise onto the cells and incubated for 24-
72hrs. Cell culture medium was then changed to serum-free medium when 10nM G17 
treatment was applied. 
2.11    Sulforhodamine-B (SRB) assay 
AGSGR cells (2x10
3/well) were seeded in 96 well plates and grown for 48hrs in complete 
media, with fresh media applied every 24hrs. Cells were treated with TR1, TR2 and TR3 in 
the absence and presence of G17 10nM in complete media at 24hr intervals for a further 
48hrs. DMSO (1%) and G17 10nM treatments were used as negative and positive controls 
respectively, with YM022 and netazepide (100nM) treatments used as positive inhibition 
controls.  After 48hrs, cells were fixed using methanol/acetic acid, stained with 0.4% SRB in 
1% glacial acetic acid and absorbance was read at 570nm using a Sunrise plate reader 




2.12    Haemocytometer count assays 
AGSGR cells (2x10
5/well) were seeded in 6 well plates and left to adhere for 48hrs in 2ml 
complete media; fresh media was applied every 24hrs. Cells were treated with TR1, TR2 
and TR3 in the absence and presence of G17 10nM in complete media at 24hr intervals for a 
further 48hrs. Untreated and G17 10nM alone treatments were used as negative and 
positive controls respectively, with YM022 and netazepide (100nM) treatments used as 
positive inhibition controls. After treatment, the media was removed and floating cells 
were counted. Adherent cells were washed twice with PBS and trypsinised until all cells 
were in suspension and these were then counted using a haemocytometer.  
2.13   Cell migration assays 
Monolayers of AGSGR cells were grown on 24 well plates in complete media before a cell-
free region was created using a 2μl pipette tip. Cells were washed twice in PBS followed by 
two washes in serum free media before the treatment was applied. Whole cells that had 
migrated into the denuded region were counted and scratch wound width was measured 
using a graticule at 0hrs and 8hrs post-treatment. Representative images were taken at 
these times using a Zeiss Aviovert 25 microscope (Carl Zeiss Microscopy, New York, USA).   
2.14  Cell morphological assays 
AGSGR cells (1x10
4/well) were seeded in 24 well plates in complete media and left to 
adhere for 24hrs before treatment. After treatment, cells were fixed using 3:1 methanol: 
acetic acid and stained with 0.3% crystal violet. The number of cells that presented long 
processes were counted as a percentage of total cells in 3 reference fields (>100 cells) per 
treatment and representative images were taken using the Zeiss Aviovert 25 microscope 




2.15    Clonogenic survival assays 
AGSGR cells were seeded at a low density (500 cells/well in 2ml of complete media) in 6 
well plates and left to adhere for 24hrs. Cells were pre-treated for 20mins with or without 
compounds TR1, TR2 or TR3 at a range of concentrations. Cells were then treated with or 
without 10nM G17 for 6hrs, followed by treatment with or without 8μM etoposide for 1hr. 
Fresh complete media was applied after etoposide treatment and the cells were left to 
form colonies. After 10-12 days, cells were washed and fixed using 3:1 methanol/acetic 
acid and stained with 0.3% crystal violet for 10mins. Colonies containing at least 100 cells 
were counted.  
2.16    Immunofluorescence visualisation  
AGSGR cells were seeded onto 13mm diameter coverslips (VWR international Ltd, 
Leicestershire, UK) in 24 well plates (Costar, High Wycombe, UK) at a density of 1x104/well 
in complete media and left to adhere for 24hrs before treatment was applied. After 
treatment, cells were washed twice with PBS and fixed with 4% paraformaldehyde for 
30mins. Following the removal of the fixative, cells were washed a further two times with 
PBS and permeabilised with 0.2% PBT (0.03g BSA, 10ml PBS and 20μl Triton-X 100) at room 
temperature for 30mins.  
For immunocytochemical analysis cells were blocked in 10% swine serum (Dako, 
Cambridgeshire, UK) for PAPPA2 antibody or 10% rabbit serum (Vectorlabs, Peterborough, 
UK) for p27 antibody for 45mins at room temperature before overnight incubation with 
either rabbit polyclonal anti-Plac3 (PAPPA2) primary antibody (Thermo Fisher Scientific, 
Hemel Hempstead, UK) or mouse monoclonal anti-p27 antibody (BD Biosciences, Oxford, 
UK) diluted 1:500 in PBS in a humidified chamber at 4°C. For enhanced specificity salt 
washes were applied to cells before incubation with swine anti-rabbit FITC conjugated 




secondary antibody (Vectorlabs, Peterborough, UK) diluted 1:500 in 1% BSA in PBS for 1hr, 
protected from light. For phalloidin staining, after fixation and permeabilisation cells were 
incubated with either Alexa Fluor™ 488 or Alexa Fluor™ 594 phalloidin diluted 1:500 in PBS 
in a humidified chamber for 1hr at room temperature protected from light.  
Cells were washed three times in PBS for 10mins each, still protected from light, before 
mounting with Vectashield® mounting media with DAPI (Vectorlabs, Peterborough, UK) 
onto glass slides for visualisation. Images were captured using the Olympus BX51 
fluorescence microscope (Olympus, Sussex, UK) at 6 reference fields (>100 cells) per 
treatment and relative intensities of nuclear and cytoplasmic staining  was analysed using 
AxioVision Rel. 4.8 software. Cells stained with secondary antibody alone were used as 
non-specific binding controls.  
2.17    EdU incorporation assays 
AR42J cells (1x104/well) were seeded onto 13mm diameter coverslips in 24 well plates, in 
1ml complete media and left to adhere for 24hrs. Cells were pre-treated in serum free 
media for 20 mins with or without compounds TR1, TR2, TR3, YM022 or YF476 at the 
minimum concentration which fully inhibited the effects of 10nM G17 in AGSGR cells, and 
this was followed by treatment with or without 0.1nM G17 for 8hrs. Cells were visualised 
using the Click-iT® EdU Imaging Kit (Life Technologies, Paisley,UK) as follows: after 6hrs of 
0.1nM G17 treatment, cells were additionally treated with 10μM EdU in DMSO for a further 
2hrs. Cells were then fixed using 1ml 3.7% formaldehyde in PBS for 15mins at room 
temperature. The fixative was then removed and cells were washed twice with 1ml of 3% 
BSA in PBS. Cells were then permeabilised in 1ml 0.5% Triton X-100 in PBS for 20mins at 
room temperature, followed by two washes in 1ml 3% BSA in PBS. The Click-iT® reaction 
cocktail was prepared as per the manufacturer’s instructions and 500μl was added to each 




Once the reaction cocktail was removed, cells were washed once with 1ml 3% BSA in PBS 
and once with 1ml PBS. For nuclear staining, 1ml Hoechst 33342 (component G) 1:2000 in 
PBS was added to each well and cells were incubated for 30mins at room temperature, 
protected from light. After nuclear staining, cells were washed twice with 1ml PBS and 
mounted onto slides using Vectashield® mounting medium (Vectorlabs, Peterborough, UK). 
Images were obtained using an Olympus BX51 fluorescence microscope and analysed using 
ImageJ. Cells demonstrating EdU fluorescence were scored as a percentage of total cells in 
three separate fields (>100 cells) per treatment. 
2.18  Protein extraction and western blotting 
Cell lysis was achieved by suspending harvested cell pellets on ice in radio 
immunoprecipitation (RIPA) buffer containing 425mM NaCl, 1% v/v Igepal CA-630, 1mM 
EDTA, 0.5% w/v sodium deoxycholate, 50mM Tris, 0.1% w/v SDS, 10mM NaF and 0.5mM 
sodium orthovanadate. Suspensions were centrifuged at 13,000rpm for 15mins at 4°C and 
the supernatant, which contains the protein, and transferred to fresh Eppendorf tubes 
which were stored at -80°C prior to use.  
Protein concentrations were quantified by Quick start™ Bradford protein assay (Bio-Rad, 
Hertfordshire, UK) using standard concentrations of bovine serum albumin (BSA). Protein 
samples were denatured in Laemmli buffer at 95°C for 10mins and electrophoresed on 
12% SDS-polyacrylamide gels, followed by transfer onto 0.45μm pore nitrocellulose 
membrane (mdi; membrane technologies INC, Ambala Cantonment, India). Nonspecific 
antibody binding was blocked by incubating the membrane in 5% non-fat milk in PBS with 
0.1% Tween-20. Membranes were incubated with the following primary antibodies: mouse 
monoclonal p27 antibody (BD Biosciences, Oxford, UK) at a dilution of 1:5000 or mouse 
monoclonal anti-actin antibody (Neomarkers, Freemont, CA) at a dilution of 1:2500. The 




immunoglobulins from Dako (Cambridge, UK) at a dilution of 1:2000. Membranes were 
developed using Supersignal (Pierce, Tattenhall, UK) and chemiluminescence was detected 
using a Bio-Rad ChemiDoc XRS+ (Bio-Rad, Hertfordshire, UK). Densitometry was performed 
using ImageLab software and results were normalised to the expression of actin. 
2.19    Statistics 
Data are presented as means or percentage of control ±SEM. All experiments were 
repeated in at least triplicate and either one-way ANOVA or two-way ANOVA with Sidak 
post-hoc test was used to establish statistical significance where appropriate. P<0.05 was 
considered significant. A Mann Whitney-U test was used to assess statistical differences 
between independent healthy patient samples and baseline samples of patients taking 
netazepide. A Wilcoxon signed ranked test with Bonferroni correction was subsequently 
used to determine significant differences between repeated samples from the same 
patients as not all data were normally distributed and P<0.0125 was considered significant 















































Elevated circulating concentrations of the hormone gastrin contribute to the development 
of gastric adenocarcinoma and types-1 and -2 gastric neuroendocrine tumours (NETs). 
MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate 
proteins which in turn influence various biological processes. We hypothesised that gastrin 
induces the expression of specific gastric miRNAs within CCK2 receptor (CCK2R) expressing 
cells and that these mediate functionally important actions of gastrin. miRNA PCR arrays 
were used to identify changes in miRNA expression following G17 treatment of human 
gastric adenocarcinoma cells stably transfected with CCK2R (AGSGR). miR-222 was further 
investigated using primer assays and samples from hypergastrinaemic mice and humans. 
Chemically synthesised mimics and inhibitors were used to assess cellular phenotypical 
changes associated with miR-222 dysregulation. Gastrin increased miR-222 expression in 
AGSGR cells, with maximum changes observed at 10nM G17 for 24hrs. Signalling occurred 
via CCK2R and the PKC and PI3K pathways. miR-222 expression was increased in the serum 
and gastric corpus mucosa of hypergastrinaemic INS-GAS mice and miR-222 expression 
was further increased in gastric corpus biopsies of INS-GAS mice with H. felis infection. 
miR-222 expression decreased in the serum and gastric corpus biopsies of 
hypergastrinaemic patients with autoimmune atrophic gastritis and type-1 gastric NETs 
following treatment with the CCK2R antagonist netazepide. Gastrin-induced miR-222 
overexpression resulted in reduced expression and cytoplasmic mislocalisation of p27, 
which in turn caused actin remodelling and increased migration in AGSGR cells. These data 
indicate a novel mechanism contributing to gastrin-associated gastric tumour 
development. miR-222 may also be a promising biomarker for monitoring gastrin induced 






Elevated circulating concentrations of the gastric antral hormone gastrin are found in 
patients who are hypochlorhydric as a result of atrophic gastritis. Autoimmune atrophic 
gastritis predisposes to the development of type-1 gastric neuroendocrine (carcinoid) 
tumours (NETs) 664, 665. Hypergastrinaemia is crucial for the development of these tumours, 
as surgical antrectomy to remove the source of hypergastrinaemia 666 or treatment with 
gastrin/CCK2 receptor antagonist drugs can reverse tumour development 459, 460. H. pylori 
induced atrophic gastritis also results in hypergastrinaemia and this is thought to act as a 
co-factor during gastric adenocarcinoma development. This is supported by animal studies 
which have demonstrated accelerated H. pylori induced gastric carcinogenesis in 
transgenic hypergastrinaemic INS-GAS mice 667, 668. 
Gastrin contributes to gastric tumour development via several cellular mechanisms. These 
are in addition to its well established role in regulating gastric acid secretion and include 
alterations in cell proliferation, apoptosis, migration, differentiation and angiogenesis 
(reviewed in 669, 670). Moreover several proteins including Reg 671, MMP7 191, MMP1 188 and 
members of the urokinase plasminogen activator family of proteins 185 show increased 
expression in the stomach or serum of patients with hypergastrinaemia. Many of these 
proteins are thought to contribute to gastric tumourigenesis by altering key functions 
including cell migration and differentiation. Some may also have utility as biomarkers of 
tumour development. Gastrin exerts its effects in the stomach predominantly as a result of 
binding to the CCK2 receptor (CCK2R) on ECL cells. Downstream signalling occurs via a 
number of pathways, including protein kinase C (PKC), MAP kinase (MAPK), and 
phosphatidylinositol (PI) 3-kinase (PI3K) 669. 
MicroRNAs (miRNAs) are a class of endogenous non-protein coding short RNAs that post-




translation, increase cleavage or induce the degradation of target mRNAs depending upon 
complementary RNA-RNA binding 540. As miRNAs control a large proportion of the genome, 
their expression patterns are tissue-specific and dysregulation has been observed in many 
malignancies 545, suggesting the potential for miRNAs to be biomarkers of cancer diagnosis, 
prognosis and response to therapies. One gene can be regulated by many miRNAs and 
likewise one miRNA can regulate several genes, including tumour suppressor genes and 
oncogenes. This adds an additional layer of functional complexity, as miRNAs can act as 
both ‘oncomiRs’ to promote tumour development or ‘anti-oncomiRs’ to suppress tumour 
development, depending upon their tissue expression 546. Moreover, >50% miRNA genes 
are located within fragile sites and genomic regions associated with deletion, translocation 
and amplification in cancers, further indicating their significance during carcinogenesis 547. 
I hypothesised that gastrin may exert some of its pro-tumourigenic effects in the stomach 
by altering the expression of specific microRNAs, which in turn alter the expression of 
downstream proteins regulating key cellular processes involved in gastric tumour 
progression. I therefore investigated which miRNAs showed altered expression following 
G17 treatment of a CCK2 receptor expressing gastric epithelial cell line. One of the 
upregulated miRNAs, miR-222, was further investigated using samples obtained from 
hypergastrinaemic mice and humans and upstream and downstream signalling pathways 





3.1.3 Gastrin induces miR-222 expression in AGSGR cells 
miScript miRNA PCR arrays were used to identify differentially expressed miRNAs between 
AGSGR cells treated with and without 10nM G17 for 24hrs (N=6, n=2). Three miRNAs showed 
increased expression and three miRNAs showed decreased expression beyond the 2-fold 
threshold (Figure 10A). However, only miR-376c and miR-222 proved significant with fold 
changes of 5.2 (P<0.01) and 2.3 (P<0.0001) respectively (for all miRNA expression profiles 
see Table 2. in 6. Supplementary data).  
Further validation by qPCR primer assays was performed to confirm these differences and 
normalised against endogenous RNU62 expression. As miR-376c was of relatively low 
abundance in both the control and gastrin-treated cells, miR-222 was chosen for further 
investigation. In parental AGS cells (not stably transfected with the CCK2R), gastrin 
treatment had no significant effect on miR-222 expression at concentrations of 0-100nM 
for 2-48hrs. However in AGSGR cells which express the CCK2R, miR-222 expression 
increased dose and time dependently following gastrin treatment and this was maximal 















Figure 10. In AGSGR cells treated with 10nM G17 compared with untreated controls, miScript miRNA PCR arrays (N=6, 
n=2) showed 3 miRNAs that increased and 3 miRNAs that decreased in expression beyond the 2-fold threshold (of 
the 84 biologically relevant arrayed miRNAs), with only miR-222 (P<0.0001) and miR-376c (P<0.01) proving 
significant (A). qPCR primer assays showed that miR-222 expression increased dose and time dependently in AGSGR 
cells and was maximal following treatment with 10nM G17 for 24hrs in serum free media (P<0.0001, N=3, n=4). 
However, miR-222 expression did not significantly change following G17 treatment of untransfected AGS cells (B, C).  
Statistical significance was determined using student t-test (A) or two-way ANOVA (B, C) with Sidak post-hoc test 





3.1.4 Activation of the CCK2 receptor by gastrin leads to increased miR-222 
expression via the PKC and PI3K pathways in AGSGR cells 
In order to investigate the signalling mechanisms downstream of CCK2R that were 
responsible for the observed increase in miR-222 expression, we used known inhibitors of 
these pathways. AGSGR cells were pre-treated with the following signalling pathway 
inhibitors: Ro-32-0432 (PKC inhibitor), LY294002 (PI3K inhibitor), PD98059 (inhibitor of 
MAPK activation) and netazepide or YM022 (both CCK2R antagonists) for 20mins prior to 
treating the cells for 24hrs with 10nM G17. miR-222 expression was evaluated using qPCR 
primer assays. As miRNAs are regulated by many mRNAs and vice versa, miRNAs may be 
involved in multiple signalling pathways. Small nuclear RNAs, such as the housekeeping 
gene RNU62 used for normalisation, may therefore also be regulated by the particular 
pathways investigated. Therefore, an exogenous spike in control (C.elegans miR-39) was 
added to each sample at a known concentration () and used for normalisation. Untreated, 
10nM G17 treated and 1% DMSO treated cells were used as negative, positive and vehicle 
controls.   
Gastrin-induced miR-222 overexpression was almost fully reversed when AGSGR cells were 
pre-treated with Ro-32-0432 (1µM) (P<0.0001), LY294002 (20µM) (P<0.0001), YM022 
(100nM) (P<0.0001) and netazepide (100nM) (P<0.0001) suggesting that miR-222 
expression is increased via activation of the CCK2 receptor and subsequent PKC and PI3K 
pathways. However, there was only a partial reversal caused by the inhibitor of MAPK 
activation (P<0.001), indicating that this is not the major pathway for miR-222 expression 
(Figure 11A) (N=3, n=4). Further investigation of downstream signalling was performed by 
pre-treating AGSGR cells with and without PKC and PI3K inhibitors followed by activation of 
PKC via PMA 100nM for 24hrs. The activation of PKC stimulated a significant increase in 




pre-treatment with the PI3K inhibitor (P<0.05). These data indicate that gastrin-CCK2 
receptor activation increases miR-222 expression via both the PKC and PI3K pathways in 





Figure 11. In PCR primer assays, LY294002 (20μM), YM022 (100nM), netazepide (100nM) and Ro-32-0432 (1μM) all 
completely reversed while PD98089 (20μM) partially reversed the miR-222 overexpression caused by 10nM G17 
treatment of AGSGR cells for 24hrs (A) (N=3, n=4). Ro-32-0432 (1μM) also completely reversed while LY294002 
(20μM) partially reversed the miR-222 overexpression induced by 100nM PMA treatment of the same cell line for 
24hrs (B) (N=3, n=4). Statistical significance was determined using two-way ANOVA with Sidak post-hoc test and 




3.1.5 miR-222 expression increases with age and further increases with 
Helicobacter felis (H. felis) infection, in hypergastrinaemic INS-GAS mice  
As previously reported, miRNAs are highly stable in both blood and tissues 587, 588. miR-222 
expression was therefore assessed by qPCR in male FVB/N and transgenic INS-GAS mice on 
the same genetic background. Mice were culled at 12 and 30 weeks of age (n=10 per 
group) and gastric corpus mucosal scrapings and serum were used for primer assays. miR-
222 expression was significantly increased in both the gastric mucosal scrapings (P<0.01) 
and serum (P<0.0001) of 30 week old INS-GAS mice compared with age-matched FVB/N 
wild-type, with no significant differences being observed between 12 week and 30 week 
old FVB/N wild-type mice. There was also a statistically significant difference between 12 
week INS-GAS and FVB/N wild type mice (P<0.05) in the serum (Figure 12A and 12B) (N=3, 
n=4).  
miR-222 expression was additionally assessed in INS-GAS mice that had been infected with 
H. felis for 6 weeks. At 6 weeks of age, mice were given 3 doses of H. felis via oral gavage 
48hrs apart and culled after a further 6 weeks. Gastric corpus mucosal scrapings were used 
for miR-222 primer assays. H. felis infection further increased miR-222 expression 
compared with age-matched uninfected FVB/N (0.0001) and INS-GAS mice (P<0.01) (n=9 







Figure 12. qPCR primer assays showed that miR-222 expression was significantly increased in mucosal scrapings 
taken from the gastric corpus (A) and in the serum (B) of 30 week old male hypergastrinaemic INS-GAS mice 
relative to age and sex-matched FVB/N mice, with significant differences also being observed between 12 week 
INS-GAS and FVB/N mice in the serum (n=10 per group) (N=3, n=4). miR-222 expression was further significantly 
increased in 6 week H. felis infected INS-GAS mice compared with age-matched FVB/N and INS-GAS uninfected 
mice (n=9 per group) (C) (N=3, n=4). Statistical significance was determined using either one-way (C) or two-way 
ANOVA (A, B) with Sidak post-hoc test and P<0.05 was considered significant (*P<0.05, **P<0.01 and 




3.1.6 miR-222 expression is increased in the serum and gastric corpus of 
patients with hypergastrinaemia and type-1 gastric neuroendocrine 
tumours, and is significantly reduced by netazepide treatment 
We also assessed miR-222 expression by qPCR in both gastric corpus biopsies and serum 
samples from patients with autoimmune atrophic gastritis, hypergastrinaemia and type-1 
gastric NETs who had been enrolled on a phase-2 clinical trial to assess the short and long 
term effects of the CCK2R antagonist netazepide 459. In addition to the initial 12 week trial, 
the results of which have been reported, patients were treated for an additional 12 
months and showed ongoing histological and biochemical evidence of tumour regression 
(manuscript in preparation). 
In both the short-term (12-week treatment with 12-week follow-up) and longer-term (12-
month treatment) regimens, there was a significant but small increase in miR-222 
expression in the gastric corpus biopsies of hypergastrinaemic patients before taking 
netazepide relative to normogastrinaemic controls (P<0.001 short term, P<0.0125 long 
term), which significantly decreased whilst patients were taking 50mg netazepide daily 
(P<0.0125) and returned to baseline after cessation of treatment, (Figure 13A and 
13B)(N=8, n=3).  
miR-222 expression was also significantly increased in the serum of the same 
hypergastrinaemic patients with a 5.7 fold increase in the short-term study (P<0.0001) and 
a 5-fold increase in the longer study (P<0.0001), when compared to healthy controls. 
Similarly, whilst patients were taking netazepide, serum miR-222 expression significantly 
decreased and returned towards baseline after cessation of treatment (Figure 13C and 





Figure 13. In both gastric corpus biopsies (A, C) and serum samples (B, D) from patients with hypergastrinaemia and type-1 
gastric neuroendocrine tumours (n=8), qPCR miR-222 expression was significantly higher at baseline compared with 
normogastrinaemic healthy controls who had a normal stomach at endoscopy (n=10). miR-222 expression decreased whilst 
patients were taking netazepide and returned to baseline after cessation of treatment, in short (12 weeks, A and B) and 
long (1 year, C and D) term studies. Statistical significance was determined using a Mann Whitney U test between healthy 
controls and baseline, and by Wilcoxon signed rank test with Bonferroni correction between treatment visits. P<0.0125 





3.1.7 miR-222 overexpression decreases proliferation and increases migration 
and the extension of long processes in AGSGR cells  
Gastrin has been shown to both stimulate and inhibit AGS cell proliferation and previous 
studies by Varro et al. suggested that the expression of the cell surface receptor CCK2R has 
been associated with reduced cell growth in AGSGR cells 
663. Chemically synthesised miR-
222 mimics at concentrations >10nM also significantly reduced AGSGR cell proliferation 
after 48hrs transfection in a dose dependent manner (Figure 14A) (N=3, n=3). 
Alternatively, chemically synthesised miR-222 inhibitors (>50nM) significantly reversed the 
anti-proliferative effects of 24hrs G17 treatment after 72hrs transfection in AGSGR cells, 
again in a dose-dependent manner (Figure 14B) (N=3, n=3).  
Gastrin has previously been shown to increase the migration of AGSGR cells dose 
dependently after 8hrs treatment with concentrations of 30pM to 3nM G17 
672. Incubation 
of AGSGR cells with 10nM G17 for 8hrs significantly stimulated cell migration in scratch 
wound assays (Figure 15A) when compared to untreated AGSGR cells. Chemically 
synthesised miR-222 mimics at concentrations 10-100nM also significantly increased AGSGR 
cell migration dose dependently (Figure 15B) (N=3, n=3). By contrast, chemically-
synthesised miR-222 inhibitors significantly reversed 10nM G17-induced AGSGR cell 
migration at concentrations 50-100nM and completely reversed gastrin-stimulated (10nM) 
migration at a concentration of 500nM (Figure 15C) (P<0.0001, N=3, n=3). 
Incubation of AGSGR cells with 1nM G17 has also previously been shown to induce cell 
scattering and the extension of long processes which were maximal after 6hrs treatment 
673. Similar responses were observed in AGSGR cells treated with 10nM G17 for 6hrs (Figure 
16A), with visible morphological changes observed with the extension of long processes 
(arrows). Chemically synthesised miR-222 mimics dose dependently increased the 




(Figure 16B) (P<0.0001, N=3, n=3). Chemically synthesised miR-222 inhibitors dose 
dependently reversed the extension of long processes induced by 10nM G17 in AGSGR cells, 
which was significant after treatment with concentrations >50nM (Figure 16C) (P<0.001, 
N=3, n=3).  
AGSGR cells transfected with miR-1 (10-100nM) also showed a significant increase in the 
extension of long processes (P<0.01 and P<0.001), compared with untreated controls. 
However, miR-1 is physiologically expressed at low levels in AGSGR cells and has previously 
been associated with cell differentiation in cardiomyocytes  674 and skeletal muscle  675, 





Figure 14. Haemocytometer counts showed that transfection (48hrs) with a chemically synthesised miR-222 mimic 
significantly reduced AGSGR cell growth in a dose dependent manner after 10nM concentration (A) (N=3, n=3). 
Chemically synthesised miR-222 inhibitors (72hrs) dose dependently reversed the anti-proliferative effects of 10nM 
G17 for 24hrs which was significant after 50nM concentration (B) (N=3, n=3). The miR-222 mimic and miR-222 
inhibitor were not cytotoxic as the number of floating cells did not differ from the untreated controls. Statistical 
significance was determined using two-way ANOVA with Sidak post-hoc test and P<0.05 was considered significant 





Figure 15. Scratch wound assays were performed to assess cell migration (A) following G17 treatment of 
AGSGR cells (scale bar 50μm). Chemically synthesised miR-222 mimics significantly increased migration (B) in 
a dose dependent manner with statistical significance determined using one way ANOVA with Sidak post-hoc 
test (N=3, n=3). Whereas miR-222 inhibitors significantly reduced the migration (C) that were stimulated by 
10nM G17 treatment of AGSGR cells, in a dose dependent manner and statistical significance was determined 
using two-way ANOVA with Sidak post-hoc test (N=3, n=3). P<0.05 was considered significant (**P<0.01 and 































Figure 16. Scattering assays were performed to assess the expression of long processes (A) following G17 
treatment of AGSGR cells (scale bar 100μm). Chemically synthesised miR-222 mimics significantly increased 
the extension of long processes (A) in a dose dependent manner with statistical significance determined 
using one way ANOVA with Sidak post-hoc test (N=3, n=3). Whereas miR-222 inhibitors significantly 
reduced the extension of long processes (C) that were stimulated by 10nM G17 treatment of AGSGR cells, in 
a dose dependent manner and statistical significance was determined using two-way ANOVA with Sidak 
post-hoc test (N=3, n=3). P<0.05 was considered significant (**P<0.01, ***P<0.001 and ****P<0.0001 vs 




3.1.8 Gastrin-induced miR-222 overexpression decreases the expression of 
p27 in vitro and in vivo, via the PKC and PI3K pathways 
In AGSGR cells, qPCR primer assays showed that p27 mRNA expression decreased in dose 
(Figure 17A) and time (Figure 17B) dependent manners following G17 treatment, which was 
maximal after 10nM G17 for 24hrs (P<0.0001, N=3, n=4). Western blots indicated that 
AGSGR cells incubated with G17 also showed dose (Figure 17C) and time (Figure 17D) 
dependent decreases in p27 protein expression. This was again significant after treating 
cells with 10nM G17 for 24hrs (P<0.05, N=3).  
Immunofluorescence visualisation showed a dose dependent increase in cytoplasmic 
abundance of p27 that was significant at a concentration 0.1nM G17 for 24hrs. A reciprocal 
dose dependent decrease in nuclear p27 expression was also observed after 0.1nM G17 for 
24hrs (Figure 18A) (P<0.001, N=3, n=6). p27 shuttling between the nucleus and cytoplasm 
was observed <6hrs after 10nM G17 (P<0.001). After 8hrs 10nM G17, there was a significant 
decrease in the nuclear abundance and increase in the cytoplasmic abundance of p27 in a 
time-dependent manner (Figure 18B) (P<0.0001, N=3, n=6). Representative images were 
taken at 8hrs and 24hrs after 10nM G17 treatment for visual comparisons (Figure 19). 
Western blotting showed thatthe decreased p27 protein expression caused by 10nM G17 
for 24hrs was completely reversed by pre-treatment of cells with Ro-32-0432 (1µM), 
LY294002 (20µM), YM022 (100nM) and netazepide (100nM) and partially reversed by 
PD98059 (20µM) (Figure 20) (P<0.05, N=5).  
AGSGR cells transfected with a chemically synthesised miR-222 mimic showed a dose 
dependent decrease in p27 protein expression (Figure 21A); this was significant at miR-222 
mimic concentrations >50nM (P<0.01, N=3). The chemically synthesised miR-222 inhibitor 
at 500nM concentration also significantly reversed the decrease in p27 protein expression 




In 30 week old male hypergastrinaemic INS-GAS mice, p27 mRNA expression was also 
significantly decreased relative to age and sex-matched FVB/N wild-type mice (P<0.05), 
with no significant differences shown between 12 week INS-GAS and FVB/N mice (n=10 per 
group) (Figure 22). These data suggest that gastrin stimulates CCK2R activation leading to 
increased miR-222 expression which in turn decreases p27 mRNA and protein expression 





























Figure 17. Representative western blots for p27 (A) and after stripping and re-probing the same blot for actin 
(B)  which confirm correct band sizes. p27 mRNA expression significantly decreased dose (C) and time (D) 
dependently in AGSGR cells treated with gastrin (N=3, n=4). p27 protein expression dose (E) and time (F) 
dependently decreased following gastrin treatment of AGSGR cells (N=3). p27 decreased expression was 
maximal after 10nM G17 for 24hrs. Statistical significance determined using one way ANOVA (C, E) with Sidak 
post-hoc test and P<0.05 was considered significant (*P<0.05 and ****P<0.0001 vs untreated control) or two-
way ANOVA (D, F) with Sidak post-hoc test and P<0.05 was considered significant (*P<0.05, ***P<0.001 and 








Figure 18. Immunofluorescence staining of  AGSGR cells= showed that the nuclear expression of p27 decreased 
and cytoplasmic expression of p27 increased dose dependently with G17 treatment, which was significant after 
0.1nM concentration 24hrs (A) (N=3, n=6). 10nM G17 treatment of AGSGR cells (2-6hrs) showed the shuttling of 
p27 with a significant increase in cytoplasmic mislocalisation of p27 after 8hrs, in a time-dependent manner (B) 
(N=3, n=6). Statistical significance determined using two-way ANOVA with Sidak post-hoc test and P<0.05 was 












Figure 19. Representative images were taken of cellular p27 localisation by immunofluorescence staining with 
mouse monoclonal anti-p27 antibody (1:500) followed by FITC conjugated rabbit anti-mouse horseradish 
peroxidase secondary (1:500) antibody (green) in AGSGR cells with and without 10nM G17 treatment for 8hrs 
and 24hrs. Nuclear staining with DAPI was used as an intensity control (blue) (scale bar 100μm) (N=3, n=6). 
Incubation with rabbit anti-mouse FITC conjugated HRP secondary antibody alone was used as a non-specific 

























Figure 20. Western blot analysis indicated that LY294002 (20μM), YM022 (100nM), netazepide (100nM) and Ro-32-
0432 (1μM) all completely reversed while PD98089 (20μM) partially reversed the reduction in p27 expression caused 
by 10nM G17 treatment for 24hrs. Statistical significance was determined using two-way ANOVA with Sidak post-hoc 













Figure 21. Using primer assays, a chemically synthesised miR-222 mimic significantly reduced p27 
expression (A) after 50nM concentration, whereas a chemically synthesised miR-222 inhibitor (500nM) 
significantly reversed the reduced p27 expression that was caused by 10nM G17 treatment for 24hrs (B) in 
AGSGR cells. Statistical significance was determined using one way ANOVA (A) with Sidak post-hoc test and 
P<0.05 was considered significant (**P<0.001 and ****P<0.0001 vs scrambled 10nM) or two-way ANOVA 














Figure 22. qPCR analysis of p27 mRNA expression also significantly decreased with age in the gastric corpus 
mucosa of 30 week old hypergastrinaemic INS-GAS mice compared with age-matched FVB/N wild-type mice, 
with no significant differences between 12 week old INS-GAS and FVB/N mice (n=10 per group). Statistical 





3.1.9 The reduced p27 expression induced by gastrin decreases proliferation 
and increases migration and the extension of long processes in AGSGR 
cells 
AGSGR cells were transfected with CDKN1B (p27) siRNA at concentrations between 10-
50nM using 0.25μl-2.5μl transfection reagent for 24-72hrs for optimisation and confirmed 
by western blotting to determine the function of gastrin-inhibited p27 protein expression. 
Optimised western blots confirmed that p27 expression was significantly decreased after 
48hrs transfection with 25nM siRNA using 0.5µl transfection reagent by ~75%, in a dose 
dependent manner (Figure 23) (P<0.0001, N=3). Therefore, a p27 siRNA concentration of 
25nM (using 0.5µl transfection reagent) for 48hrs was used in future cell based assays.  
The reduced p27 protein expression induced by 25nM p27 siRNA significantly inhibited 
AGSGR cell growth (Figure 24A) (P<0.0001, N=3, n=3)  and increased cell migration (Figure 
24B and 24D) (P<0.0001, N=3, n=3) and the extension of long processes (Figure 24C and 
24E) (P<0.0001, N=3, n=3) that were assessed using haemocytometer counts, scratch 






















Figure 23. Western blot analysis confirmed that p27 25nM siRNA knockdown for 48hrs resulted in decreased 
protein expression. Statistical significance was determined using two-way ANOVA with Sidak post-hoc test and 







Figure 24. p27 25nM siRNA knockdown for 48hrs significantly decreased cell growth (A) and increased cell migration (B,D) 
and the extension of long processes (C,E) in AGSGR cells (scale bar 50μm). Statistical significance was determined using one 
way ANOVA with Sidak post-hoc test and P<0.05 was considered significant (****P<0.0001 vs scrambled 25nM) (scale bar 






In summary I have demonstrated that miR-222 expression is increased in AGSGR cells 
following G17 treatment and that the abundance of this miRNA is also increased in the 
gastric mucosa and serum of hypergastrinaemic mice and humans, with a further increase 
observed in H. felis infected INS-GAS mice. Increased gastrin-induced miR-222 expression 
leads to decreased proliferation and increased migration and the extension of long 
processes in AGSGR cells, of which increased migration and morphological changes are 
associated with gastric tumour development. miR-222 exerts these effects at least in part 
by decreasing p27 expression and causing this protein to be mislocalised in the cytoplasm 
(Figure 25). 
There are few previous reports of the regulation of microRNAs by gastrin. However miR-
449 expression was shown to be significantly downregulated in the antrum of gastrin 
knockout mice relative to wild-type counterparts 676. The transcription factor E2F1 
promotes miR-449 transcription which inhibits the oncogenic genes CDC25A and CDK6. 
Reduced expression of CDC25A and CDK6 causes dephosphorylation of the retinoblastoma 
protein (pRB), which arrests the cell cycle and reduces further E2F1 release 677, 678. 
Dysregulation of the miR-449/pRB-E2F1 regulatory loop therefore increases E2F1 activity 
and promotes cell cycle progression and inhibits apoptosis in gastric cancer. miR-146a 
expression is also up-regulated in the stomach of gastrin-knockout mice and also in 73% of 
tested gastric cancers. It targets CARD10 and COPS8, resulting in reduced expression of NF-
κB 679. 
Several microRNAs have, however, been shown to be dysregulated in gastric 
adenocarcinoma and in the H. pylori infected stomach (reviewed in 572, 680, 681). These 




including apoptosis, proliferation and metastasis. Moreover certain miRNAs have also 
shown promise as biomarkers of both diagnosis and prognosis in gastric cancer. 
Among the miRNAs dysregulated in gastric cancer is miR-222. miR-221 and miR-222 are 
encoded in tandem from a gene cluster located on chromosome Xp11.3. Overexpression of 
miR-222 occurs in several other malignancies including breast, lung, papillary thyroid, 
prostate and glioblastoma 682-686. In the GI tract, miR-222 is upregulated in cancers of the 
oesophagus, stomach, colon, liver and pancreas and shows decreased expression in 
cholangiocarcinoma and gastrointestinal stromal tumours (reviewed in 687). miR-222 
expression is increased in the plasma of patients with gastric cancer relative to patients 
with chronic active gastritis and healthy controls. Higher levels are associated with more 
advanced disease 688 and reduced 5 year survival 689. miR-222 expression is also increased 
in gastric cancer tissue-derived mesenchymal stem cells 690 and in the stomachs of H. pylori 
infected individuals 691, 692. 
miR-222 has several downstream mRNA targets including p27kip1, p57, PUMA, PTEN, Bim 
and MMP1 (reviewed in 693). Specifically in the stomach, increased miR-222 expression in 
H. pylori infected AGS cells post-transcriptionally regulates RECK and promotes cancer-cell 
growth and invasion 692, 694. miR-222 also targets the tumour suppressor PTEN in SGC7901 
gastric cancer cells 695. This negatively regulates the Akt pathway and promotes 
progression through the cell cycle via the inhibition of p27 and p57 689. miR-222 
overexpression is also associated with reduced expression of VGLL4 in human gastric 
cancer cell lines and tissues suggesting that miR-222 inhibits the translation of VGLL4 and 
promotes YAP-TEAD activation, which is sufficient to increase tumour proliferation, 
epithelial-mesenchymal transition and invasion 694.  
One of the best characterised downstream targets of miR-222 is p27kip1 (p27). Several 




development. There are few data linking p27 expression in the stomach specifically to 
gastrin, but several investigators have previously studied the importance of p27 during H. 
pylori induced gastric carcinogenesis. H. pylori infection decreases the expression of the 
cell cycle inhibitor protein p27 at both transcriptional and post-translational levels. H. 
pylori modulates the G-protein coupled delta opioid receptor (DOR) which regulates the 
histone acetylation of the p27 gene (CDKN1B) 696. In addition CagA+ H. pylori strains 
decrease the transcription of p27 through activation of the PI3K/Akt pathway 697. H. pylori 
infection also promotes the threonine/serine phosphorylation of p27 allowing its 
accumulation in the cytoplasm 698. This impairs the ubiquitination of p27 which accelerates 
its degradation via a proteasome-dependent pathway during cell cycle progression 699. p27-
null mice show increased susceptibility to H. pylori induced gastric preneoplastic pathology 
700. Patients with H. pylori-induced chronic gastritis also show decreased gastric expression 
of p27, which is reversed following eradication of the bacterium 701, 702. Long-term 
exposure to H. pylori in animal 703 and cell culture 704 models has also been shown to 
promote an apoptosis-resistant phenotype associated with decreased p27 expression 705.  
p27 has a number of well described functions that may influence tumour development 
(reviewed in 706). When located in the nucleus it is predominantly a cell-cycle inhibitor. The 
AGSGR cells used in this study show an unusual response to gastrin stimulation with direct 
inhibition instead of the expected stimulation of proliferation 663. Similarly, in other cell 
lines such as Chinese Hamster Ovary (CHO) and human pancreatic cells (Panc-1 and 
MiaPaca-2) there is decreased proliferation in response to gastrin treatment 707, 708. The 
CCK2R is coupled to heterotrimeric G-proteins709 and other G-protein coupled receptors 
(GPCRs) such as m3 muscarinic acetylcholine receptors, which have also been associated 
with both positive and negative effects on cellular proliferation in response to mitogenic 
stimuli. Carbachol has been shown to stimulate proliferation in mouse embryonic 




(NIH3T3/m3) during cell quiescence and inhibit cell growth if the cells were in the G1 phase 
of the cell cycle 710. These data suggest that CCK2R coupling, downstream signalling and 
subsequent biological response are specific to cell-type and environment.  
Varro et al. has previously suggested that the proliferative response of AGS cells was 
attributable to the activation of the epidermal growth factor receptor (EGFR) due to the 
release of growth factors, such as heparin-binding epidermal growth factor (HB-EGF), 
during epithelial structural remodelling via the activation of the PKC pathway. However 
activation of this pathway can also be induced by phorbol esters, such as phorbol-12-
myristate-13-acetate (PMA) which mimics the action of diacyl-glycerol (DAG), and causes 
cell cycle arrest in the G1 phase 
663. In AGSGR cells PKC activation appears to predominantly 
induce cell cycle inhibition, which is consistent with the reduced cell growth observed in 
this study and therefore the decreased expression of p27 caused by gastrin may have a 
negligible effect on the cell-cycle, in this context.   
When p27 is located in the cytoplasm it has been shown to regulate cell migration and 
invasion in a cell cycle independent manner 706. Thr198 phosphorylation of p27 increases its 
cytoplasmic localisation, inhibits RhoA (Ras homolog gene family, member A) activation 
and increases cell motility 711. Our observation of cytoplasmic mislocalisation of p27 
following gastrin treatment is therefore consistent with the increase in migration and 
change in morphology that was observed in AGSGR cells following treatment with gastrin 
and a miR-222 mimic. 
In conclusion, gastrin induced the expression of miR-222 in CCK2R bearing cells. Increased 
amounts of miR-222 were also detected in the gastric mucosa and sera of 
hypergastrinaemic patients with type-1 gastric NETs and in H. felis infected INS-GAS mice. 
This miRNA therefore has potential utility as a biomarker of hypergastrinaemia and of 




monitoring the response to treatment with CCK2R antagonists such as netazepide. Further 
work is however needed to investigate whether increased serum miR-222 abundance is 
specific to patients with type-1 gastric NETs or whether it is also increased in patients who 
have other causes for hypergastrinaemia such as long-term proton pump inhibitor use. 
Gastrin-induced miR-222 upregulation appears to be functionally important. Increased 
miR-222 expression results in decreased abundance of p27 mRNA and protein and causes 
p27 mislocalisation into the cytoplasm. This mechanism appears to contribute to the 
increased migration and actin remodelling observed in AGSGR cells following G17 treatment 
(Figure 25). It is therefore possible that similar mechanisms may also be important during 







Figure 25. A schematic diagram of the signalling pathways that are activated by gastrin-CCK2R binding. miR-
222 transcription is increased via the PKC and PI3K pathways and partially via the MAPK pathway. The 
pri(mary)-miR-222 transcript is cleaved by the RNAse-II enzyme Drosha into a hairpin structure (pre-miR-222) 
which is transported from the nucleus to the cytoplasm via exportin-5. Pre-miR-222 is cleaved by a second 
RNase II enzyme, Dicer, into mature miR-222 which associates with RISC to target imperfect complementary 
mRNA sequences. Mature miR-222 inhibits the translation of p27 which increases cell migration and 



















Microarray studies that investigated differentially expressed genes in patients with 
hypergastrinaemia and type-1 gastric neuroendocrine tumours (NETs) previously identified 
pregnancy associated plasma protein (PAPP)-A2 as a potential gastrin regulated gene 4. 
PAPPA2 has been shown to increase the bioavailability of insulin-like growth factors (IGF) 
types-I and –II in the circulation 712. IGFs are important for cell growth and development 713, 
however altered circulating concentrations have also been observed in numerous 
pathologies including gastric cancer 714, 715.  
Gastrin-induced activation of the CCK2R has been shown to contribute to epithelial-
mesenchymal transition (EMT) which includes the transformation of gastric epithelial cells, 
increased proliferation, migration and metastasis 189, 191 and hypergastrinaemia has also 
been strongly associated with an increased risk of developing type-1 gastric NETs 180, 463, 716.  
Therefore changes in PAPPA2 expression may correlate with the extent of tissue 
remodelling, increased cell growth and/or migration that has previously been associated 
with chronic hypergastrinaemia. Using qPCR and immunofluorescence staining we 
examined whether gastrin stimulated the expression of PAPPA2 in AGSGR cells. Functional 
analyses were performed using PAPPA2 siRNAs to examine the potential role of PAPPA2 as 
a biomarker of gastric carcinogenesis.  
Gastrin treatment dose and time dependently increased PAPPA2 mRNA and protein 
expression in AGSGR cells, which was maximal after 10nM G17 for 24hrs. The knockdown of 
PAPPA2 expression (both mRNA and protein) via siRNA significantly increased the anti-
proliferative effects and decreased the migratory response and the extension of long 
processes caused by 10nM G17 in AGSGR cells. These data indicate that the upregulation of 
the protease PAPPA2 is partially dependent on gastrin and may have a role in the 




increasing the bioavailability of IGFs. Therefore, PAPPA2 provides promise as a novel 
biomarker of gastrin-associated conditions and the monitoring of structural remodelling of 
the gastric mucosa. However, further studies within the circulation would strength the 






The peptide hormone gastrin exerts many of its biological activity through the activation of 
gastrin receptors (CCK2R) located on enterochromaffin-like (ECL) cells within the stomach. 
The gastrin/CCK2 receptor signalling pathway has been extensively investigated with 
respect to acid secretion 717-719 however less in known about the mechanisms by which 
gastrin exerts other trophic effects in the stomach such as cell migration and tissue 
remodelling.  
In a previous cDNA microarray and qPCR study from our group, differentially expressed 
genes were identified in gastric corpus biopsies taken from hypergastrinaemic patients 
with type-1 gastric NETs who were treated daily with the gastrin/CCK2 receptor antagonist 
netazepide (50mg) for both short (12 weeks with a 12 week follow up) and long term 
regimens (1 year) (Figure 26). Gastrin receptor antagonism with netazepide caused a 30% 
reduction in tumour size and number, suggesting that gastrin/CCK2R activation is strongly 
associated with the development of gastric NETs 459. In these patients, PAPPA2 expression 
was initially high at baseline (before treatment), but this decreased upon treatment with 
netazepide, with levels returning to baseline upon cessation of the drug, indicating a 
possible correlation between gastrin/CCK2 receptor activation and PAPPA2 expression 4.   
Pregnancy-associated plasma protein A2 (PAPPA2/pappalysin) is an insulin-like growth 
factor-binding protein (IGFBP) protease that is predominantly expressed in the placenta, 
but is also found at low levels in the gall bladder, kidney and stomach720. Evidence suggests 
that PAPPA2 is upregulated as a consequence of hypertensive disorders including 
preeclampsia 721, 722, HELLP (Haemolytic anaemia, Elevated Liver enzymes, and Low Platelet 
count) syndrome 721-723 and cancers of the uterus 724 and lung 725. In human placental 




with 47-fold and a 6-fold increases in expression respectively 726. These are factors that are 
known to be highly expressed as a consequence of placental pathology.  
The PAPPA2 enzyme primarily cleaves insulin-like growth factor binding protein-5 (IGFBP5), 
and to a lesser extent IGFBP3. This extends the half-life and reduces the turnover rate of 
insulin-like growth factors (IGFs). IGFs are responsible for several important biological 
processes including bone formation 727 and the growth and permeability of the placenta 
728. The latter is crucial during pregnancy and therefore the observed increased expression 
of IGF regulatory proteins such as PAPPA2 is to be expected. However, the increased 
bioavailability of IGFs and subsequent signalling cascades have also been previously 
associated with various pathological conditions including breast 729, colorectal 730, 731, 
prostrate 732, 733 and stomach cancers 714, 715.  
Previous studies by Varro et al. have suggested that some matrix metalloproteinases 
(MMPs), particularly MMP7 also cleave IGFBP5 and are significantly increased in both 
hypergastrinaemic mice and humans in order to facilitate the expansion of the 
extracellular matrix surrounding ECL cell populations in type-1 gastric neuroendocrine 
tumours (NETs) 191. Other studies have also suggested that MMP7 abundance increases as 
a consequence of H. pylori infection 190, 734, 735; a known cause of hypergastrinaemia. 
Interestingly, during epithelial-mesenchymal transition (EMT) and stromal remodelling, 
which have been shown to be stimulated by high concentrations of gastrin, there is an 
increased abundance of myofibroblasts which release IGFBP5 734, 736. Different substrate 
bioavailability for proteases such as PAPPA2 during early gastric pathological changes may 
cause different levels of PAPPA2 expression and this is a potential biomarker of 
carcinogenesis in the stomach.  
Therefore, I have further investigated the relationship between PAPPA2 expression and 




carcinogenesis such as cell migration, the extension of long processes and proliferation. 
Using gastric adenocarcinoma cells that express the CCK2R (AGSGR) with and without 
gastrin treatment, I assessed both PAPPA2 mRNA and protein expression as they may 
provide a potential biomarker for the detection of gastric neoplastic conditions and/or 


















Figure 26. The abundance of several potential novel biomarkers in gastric corpus biopsies, relative to GAPDH 
expression. Statistical significance was determined using a Wilcoxon signed rank test. *P<0.05 compared to 
baseline, *P=0.055 compared to baseline (**P<0.01 compared to baseline, #P<0.05 compared to 2
nd
 baseline, 
and ##P<0.01 compared to 2
nd






3.2.3 Gastrin increases PAPPA2 mRNA and protein expression in AGSGR cells 
Previous studies have identified PAPPA2 as a potential biomarker of type-1 gastric NETs as 
PAPPA2 mRNA expression was high before treatment in patients with hypergastrinaemia 
and type-1 gastric NETs, reduced whilst patients were taking 50mg oral daily dose of the 
CCK2R antagonist netazepide and returned to baseline after cessation of treatment 4. To 
investigate whether gastrin affects PAPPA2 expression, dose response and time-course 
experiments were initially assessed using qPCR in AGSGR cells treated with and without 
gastrin.  
PAPPA2 mRNA dose (Figure 27A) and time (Figure 27B) dependently increased with gastrin 
treatment (N=3, n=4). Further validation using immunocytochemical staining confirmed 
that PAPPA2 protein expression was primarily nuclear in AGSGR cells and was significantly 
increased in a dose  and time dependent manner (Figure 30) in response to gastrin 
treatment. Representative immunofluorescence images were taken for visual comparisons 
between untreated and 10nM G17 treatment 24hrs (Figure 28) and untreated and 10nM 
G17 treatment for 6hrs and 24hrs in AGSGR cells (Figure 29) (N=3, n=6). Incubation with 
swine anti-rabbit FITC conjugated HRP secondary antibody alone was used as a non-








































Figure 27. Gastrin increases PAPPA2 mRNA expression in as dose (A) and time (B) dependent manner which is 
maximal after 10nM G17 treatment for 24hrs in AGSGR cells. Statistical significance was determined using one-way 
ANOVA (A) with Sidak post-hoc test and P<0.05 was considered significant (**P<0.01 and ***P<0.001 vs untreated 
control) or two-way ANOVA (B) with Sidak post-hoc test and P<0.05 was considered significant (**P<0.01, and 































Figure 28. Representative immunofluorescence staining with rabbit anti-plac3 (PAPPA2) antibody (1:500) followed 
by swine anti-rabbit FITC conjugated HRP secondary antibody (1:500) showed an increase in primarily nuclear 
PAPPA2 protein expression (FITC: green) with 10nM G17 treatment compared to untreated controls in AGSGR cells 
after 24hrs. Nuclear staining (DAPI: blue) was used as an intensity control between treated and untreated AGSGR 
cells (scale bar 100μm). Incubation with swine anti-rabbit FITC conjugated HRP secondary antibody alone was used 










Figure 29. Representative immunofluorescence staining with rabbit anti-plac3 (PAPPA2) antibody (1:500) followed 
by swine anti-rabbit FITC conjugated HRP secondary antibody (1:500) showed an increase in primarily nuclear 
PAPPA2 protein expression (FITC: green) with 10nM G17 treatment after 6hrs that was maximal after 24hrs 
compared to time-matched untreated controls in AGSGR cells. Nuclear staining (DAPI: blue) was used as an intensity 
control between treated and untreated AGSGR cells (scale bar 100μm). Incubation with swine anti-rabbit FITC 






Figure 30. Relative fluorescence intensities measured using AxioVision Rel. 4.8 software showed that PAPPA2 
protein expression (primarily nuclear) increased dose (A) and time (B) dependently in AGSGR cells treated with 
gastrin (N=3, n=6). Statistical significance was determined using two-way ANOVA with Sidak post-hoc test and 





3.2.4 PAPPA2 siRNA significantly reduces gastrin-induced PAPPA2 mRNA and 
protein expression in AGSGR cells, by 90% and 80% respectively.  
Immunofluorescence and qPCR were used to confirm the optimal conditions for the 
successful knockdown of PAPPA2 mRNA and protein in AGSGR cells, in order to assess the 
functional consequence(s) of gastrin-induced PAPPA2 expression in the stomach.  
AGSGR cells that had been transfected with a non-targeting scrambled (25nM 48h) siRNA 
followed by 10nM G17 for 24hrs showed a significant increase in PAPPA2 mRNA (Figure 31A 
P<0.001, Figure 32A P<0.0001 and Figure 33A P<0.0001) and protein (Figure 31C P<0.0001, 
Figure 32C P<0.0001 and Figure 33C (P<0.0001, 33E P<0.0001 and 33G P<0.0001) 
expression and were used as a positive control.  
PAPPA2 siRNA (25nM 48hrs) successfully reduced gastrin-induced PAPPA2 mRNA 
expression by >90% at all volumes of transfection reagent (TFR) (0.25-2.5μl) (Figure 31B) 
(P<0.0001, N=3, n=4). However, PAPPA2 protein expression was only significantly reduced 
with 0.5μl TFR (Figure 31D) (P<0.0001, N=3, n=6) as higher volumes resulted in limited 
numbers of adherent AGSGR cells which indicated cytotoxicity (data not shown).  
PAPPA2 siRNA at concentrations of 10nM (for 48hrs with 0.5μl TFR) significantly reduced 
gastrin-induced PAPPA2 mRNA expression (P<0.05) which was maximal at 25nM with a 
reduction of 87% (Figure 32B) (P<0.0001, N=3, n=4). PAPPA2 siRNA dose-dependently 
reduced PAPPA2 protein expression which was significant at 25nM (for 48hrs with 0.5μl 
TFR) with an 80% reduction (Figure 32D) (P<0.0001, N=3, n=6) in AGSGR cells.  
PAPPA2 siRNA (25nM with 0.5μl TFR) significantly reduced gastrin-induced PAPPA2 mRNA 
expression by 88% after 48hrs (Figure 33B) (P<0.0001, N=3, n=4) and also reduced protein 





Representative immunofluorescence images were taken for visual comparisons between 
AGSGR cells transfected with and without PAPPA2 siRNA using 0.5μl TFR for 48hrs (Figure 
34) (N=3, n=6). Incubation with swine anti-rabbit FITC conjugated HRP secondary antibody 






Figure 31. PAPPA2 mRNA (A) and protein (C) expression were significantly increased in AGSGR cells transfected 
with and without a non-targeting scrambled control siRNA (25nM) for 48hrs followed by 10nM G17 treatment for 
24hrs. Transfection with PAPPA2 25nM siRNA alone did not significantly affect basal PAPPA2 mRNA or protein 
expression. PAPPA2 25nM siRNA that had been transfected with all volumes of transfection reagent (TFR) (0.25μl-
2.5μl) decreased gastrin-induced PAPPA2 mRNA expression (B) (N=3, n=4) and 0.5μl TFR significantly reduced 
gastrin-induced PAPPA2 protein expression (D) (N=3, n=6).  Statistical significance was determined using one-way 
ANOVA (A and B) or two-way ANOVA (C and D) with Sidak post-hoc test and P<0.05 was considered significant 






Figure 32. PAPPA2 mRNA (A) and protein (C) expression were significantly increased in AGSGR cells transfected 
with and without a non-targeting scrambled control siRNA (25nM) for 48hrs followed by 10nM G17 treatment 
for 24hrs. Transfection with PAPPA2 25nM siRNA alone did not significantly affect basal PAPPA2 mRNA or 
protein expression. AGSGR cells that had been transfected with 10nM PAPPA2 siRNA significantly decreased 
gastrin-induced PAPPA2 mRNA expression (B) (N=3, n=4) and PAPPA2 25nM siRNA significantly reduced gastrin-
induced PAPPA2 protein expression (D) (N=3, n=6).  Statistical significance was determined using one-way 
ANOVA (A and B) or two-way ANOVA (C and D) with Sidak post-hoc test and P<0.05 was considered significant. 






Figure 33. PAPPA2 mRNA (A) and protein (C,E and G) expression were significantly increased in AGSGR cells 
transfected with and without a non-targeting scrambled control siRNA (25nM) for 24-72hrs followed by 10nM 
G17 treatment for 24hrs. Transfection with PAPPA2 25nM siRNA alone did not significantly affect basal PAPPA2 
mRNA or protein expression. AGSGR cells that had been transfected with PAPPA2 25nM siRNA significantly 
decreased gastrin-induced PAPPA2 mRNA expression after 48hrs (B) (N=3, n=4) and protein expression in a 
time-dependent manner which was significant after 24hrs (D, F and H) (N=3, n=6).  Statistical significance was 
determined using two-way ANOVA with Sidak post-hoc test and P<0.05 was considered significant 





























Figure 34. Representative immunofluorescence staining with rabbit anti-plac3 (PAPPA2) antibody (1:500) followed 
by swine anti-rabbit FITC conjugated HRP secondary antibody (1:500) showed an increase in primarily nuclear 
PAPPA2 protein expression (FITC: green) after 48hrs transfection with a non-targeting scrambled siRNA (25nM) 
followed by 10nM G17 for 24hrs in AGSGR cells. Cells transfected with PAPPA2 25nM siRNA (0.5μl TFR for 48hrs) 
showed significantly decreased gastrin-induced PAPPA2 protein expression. PAPPA2 25nM siRNA transfection 
without gastrin treatment did not significantly affect basal levels of PAPPA2 protein expression. Nuclear staining 
(DAPI: blue) was used as an intensity control between treated and untreated AGSGR cells (scale bar 100μm). 
Incubation with swine anti-rabbit FITC conjugated HRP secondary antibody alone was used as a non-specific 




3.2.5 PAPPA2 siRNA significantly inhibits the anti-proliferative effects of 
gastrin in AGSGR cells  
PAPPA2 is a member of a large family of matrix metalloproteinases that are essential for 
postnatal tissue and bone development in mice 737. Therefore we assessed phenotypical 
changes associated with gastrin induced PAPPA2 expression using PAPPA2 siRNA 
knockdown in AGSGR cells.  
Cell proliferation was significantly inhibited by 10nM G17 treatment for 24hrs in AGSGR cells 
(P<0.0001), with minimal cytotoxic effects being observed as the number of floating cells 
(indicative of apoptosis) was not affected. The knockdown of PAPPA2 using  PAPPA2 25nM 
siRNA (with 0.5μl TFR) for 48hrs prior to 10nM G17 treatment, significantly reversed the 
inhibition of AGSGR cell growth induced by gastrin after 24hrs (P<0.05) with no observed 





























Figure 35. Haemocytometer counts showed that 10nM G17 for 24hrs inhibited AGSGR cell growth compared 
with untreated controls. AGSGR cells transfected with a non-targeting scrambled siRNA (25nM) or PAPPA2 
siRNA (25nM) alone showed no significant effect on cell proliferation.  AGSGR cells transfected with a non-
targeting scrambled siRNA (25nM) for 48hrs followed by 10nM G17 for 24hrs showed significantly inhibited 
cell growth. PAPPA2 25nM siRNA (48h) significantly reduced the anti-proliferative effects of 10nM G17 for 
24hrs in AGSGR cells. No significant differences were observed between floating cell number for any 
treatment, indicating negligible cytotoxic effects (N=3, n=3). Statistical differences were determined using 
two-way ANOVA with Sidak post-hoc test and P<0.05 was considered significant (*P<0.05 and ****P<0.0001 




3.2.6 PAPPA2 siRNA significantly inhibits the extension of long processes 
induced by gastrin in AGSGR cells 
Previous studies have suggested that IGFBPs, particularly IGFBP-5, are substrates for 
PAPPA2 and are cleaved to release IGFs 712, which have been shown to regulate many 
cellular processes including tissue remodelling and cell differentiation. Gastrin has 
previously been shown to induce the remodelling of the actin cytoskeleton via the 
extension of long processes in gastric cancer cells 673 and the loss of gastric gland structure 
in vivo has been associated with the development of premalignant gastric atrophy 292. 
Therefore we investigated the effects of gastrin-induced PAPPA2 expression on gastric 
epithelial cell morphology in AGSGR cells.  
Gastrin (10nM for 6hrs) induced the extension of long processes in AGSGR cells and was 
therefore used as a positive control. AGSGR cells transfected with 25nM PAPPA2 siRNA for 
48hrs showed a significant decrease in the proportion demonstrating extension of long 
processes following treatment with 10nM G17 for 6hrs (P<0.0001). PAPPA2 siRNA 25nM 
alone did not cause any significant effects on cell morphology (Figure 36A) (N=3, n=3).  
Representative images were taken of AGSGR cells transfected with and without scrambled 
25nM siRNA or PAPPA2 25nM siRNA with and without 10nM gastrin treatment 6hrs for 















Figure 36. AGSGR cells treated with 10nM G17 for 24hrs and cells transfected with a non-targeting scrambled 
siRNA (25nM) for 48hrs before 10nM G17 for 6hrs showed an increase in the extension of long processes. The 
gastrin-induced extension of long processes was significantly reduced by PAPPA2 25nM siRNA transfection for 
48hrs prior to gastrin treatment. Cells transfected with a non-targeting scrambled siRNA (25nM) or PAPPA2 
siRNA (25nM) alone showed no significant change in cell morphology (A). Cells were stained with 0.3% crystal 
violet after 6hrs G17 treatment and representative images were taken (scale bar 150μm) (N=3, n=3). Statistical 
significance was determined using two-way ANOVA with Sidak post-hoc test and P<0.05 was considered 




3.2.7 PAPPA2 siRNA significantly inhibits the migratory response stimulated 
by gastrin in AGSGR cells 
The expression of IGFBP-4 and -5 have been shown to be increased during the first 
trimester of pregnancy and are involved in the regulation of cell migration 738, suggesting 
an important role for this protein in cell growth and development. An increase in IGFBPs 
(PAPPA2 substrate) may cause an increase in PAPPA2 expression during periods of tissue 
reorganisation, which may occur during the development of gastric neoplasia. Therefore, 
we assessed whether gastrin-stimulated PAPPA2 expression was positively associated with 
AGSGR cell migration.  
Gastrin treatment alone (10nM) stimulated AGSGR cell migration after 8hrs and was 
therefore used as a positive control. Transfection with PAPPA2 siRNA 25nM for 48hrs had 
no effect on AGSGR cell migration, however PAPPA2 siRNA at a concentration of 25nM for 
48hrs significantly reduced the migratory response of AGSGR cells caused by 10nM G17 
treatment for 8hrs (Figure 37A) (P<0.0001, N=3, n=3).  
Representative images were taken of AGSGR cells transfected with and without scrambled 
25nM siRNA or PAPPA2 25nM siRNA with and without 10nM gastrin treatment 8hrs for 
visual comparisons of cell morphology, at 0hrs and 8hrs post-gastrin treatment  (Figure 
































Figure 37.  Gastrin (10nM for 8hrs) increased cell migration in AGSGR cells that were transfected with or without 
a non-targeting scrambled siRNA (25nM) for 48hrs prior to treatment. Transfection with PAPPA2 25nM siRNA 
for 48hrs significantly reduced the migratory response caused by 10nM G17 for 8hrs. Cells transfected with a 
non-targeting scrambled siRNA (25nM) or PAPPA2 siRNA (25nM) alone showed no significant alteration in cell 
migration (A). Representative images of scratch wound assays were taken at 0hrs and 8hrs after gastrin 
treatment for visual comparison (scale bar 50μm) (B and C) (N=3, n=3). Statistical significance was determined 
using two-way ANOVA with Sidak post-hoc test and P<0.05 was considered significant (****P<0.0001 vs 





In the current study we have evaluated whether PAPPA2 has a potential role as a novel 
biomarker for gastric neoplasia. This study is based on a previous microarray study by 
Moore et al. 4 which identified 8 genes that were increased in hypergastrinaemic patients 
with type-1 gastric NETs one of which was PAPPA2. This increased PAPPA2 mRNA 
expression subsequently reduced when the patients were taking the CCK2R antagonist 
netazepide and returned to baseline upon cessation of treatment indicating that PAPPA2 
expression may be associated with CCK2R activation.  The findings of this study support 
this hypothesis as PAPPA2 mRNA and protein expression significantly increased with 
gastrin treatment in AGSGR cells; this was maximal at 10nM G17 for 24hrs. After confirming 
the microarray results with qPCR and immunofluorescence, functional analysis was 
undertaken using short interfering RNAs (siRNAs) and suggested that gastrin-induced 
PAPPA2 overexpression may contribute in part, to the cellular morphological changes, 
migration and invasion that are associated with gastric carcinogenesis.  
PAPPA2 is a homologue of PAPPA which is 1542 amino acids in length and comprises a 
putative pre-propeptide, an elongated zinc-binding motif (HEXXHXXGXXH) 739, a strongly 
conserved Met-turn740 and a lin-notch repeat (LNR) module 741. The proteolytic domain 
consists of five complement control protein modules (CCP1-5) 742, 743 and selectin, and two 
more LNR modules 741 which mediate cell surface adhesion and regulate tissue 
differentiation, respectively. Although PAPPA and PAPPA2 are encoded on different 
chromosomes (9 and 1 respectively), studies have identified a high sequence homology 
(44% identical and 62% similar amino acids) suggesting that the two proteins are a related 
subfamily of metzincin metalloproteinases that are distinct from other metalloproteinases 
such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase family 




Matrix metalloproteinases (MMPs) are essential for the maintenance of the extra cellular 
matrix and structural integrity of cells by regulating the turnover of connective tissue such 
as collagens, proteoglycans and accessory ECM proteins. Recent studies have also 
suggested a potential role for MMPs in the release of growth factors, chemokines and 
cytokines 746 which contribute to vascular remodelling and immune and inflammatory 
responses. MMPs have been shown to cleave IGFBPs and to liberate IGFs, increasing their 
bioavailability. Liberated IGFs bind to their corresponding cell surface receptors (IGFRs) 
which activate the PI3K/Akt pathway 747 and are associated with malignant transformation 
748, 749. IGFBP5 upregulation has previously been observed in rhabdomyosarcoma 750, 
prostate cancer 751, smooth-muscle derived uterine leiomyoma 752, and in ~50% of gastric 
cancers714, indicating a potential role in neoplastic development.  
Previous studies have suggested that infection with H. pylori increases the production and 
secretion of MMP7 from gastric epithelial cells 190, 735, 753. Secreted MMP7 liberates IGF-II 
from IGFBP5, which has been shown to be released from sub-epithelial cells, and 
stimulates the expansion and migration of the surrounding gastric microenvironment 734, 
736. Subsequent studies suggested that hypergastrinaemia also causes increased MMP7 
expression, as well as MMP1 188 and MMP9 189, in vitro 191, 734, 736 and in mice and humans in 
vivo  112. Patients with increased gastric MMP7 expression secondary to hypergastrinaemia 
(>100pM) have been shown to possess an increased risk of developing type-1 gastric NETs 
754 and this has also been associated with poorer prognosis 755-757, possibly due to increased 
tissue remodelling, cell migration and invasion. Additionally in colonic myofibroblasts, 
MMP7 has been shown to increase the abundance of other MMP precursors and active 
enzymes including MMP3 and MMP8 736 which may contribute to a negative clinical 




Metalloproteinase activity is tightly regulated by tissue inhibitors of metalloproteinases 
(TIMPs) usually via the binding of the TIMP N-terminal domain with the active-site of the 
enzyme inhibiting substrate binding 758, 759. However,  Rapti et al. reported that both 
ADAM10 and ADAM17 are inhibited by TIMP3, though the binding of the N-terminus to 
ADAM10 is insufficient for complete inhibition 760, which suggests that other inhibitory 
mechanisms may also occur. The C-terminal domain of TIMPs has been shown to stabilise 
interactions with specifc pro-MMPs such as TIMPs -2, -3 and -4 with pro-MMP2, allowing 
the potential for the binding of a second MMP at the N-terminus. Although the functional 
significance of multiple MMP binding is unclear, the formation of the TIMP2/pro-
MMP2/MT1-MMP ternary complex has been shown to be essential for the activation of 
proMMP2 761, which suggest an alternative role for TIMPs in the activation of MMPs. 
H. pylori infection has been shown to increase the abundance of TIMPs, specifically TIMP1, 
3 and 4 in human gastric corpus biopsies. Immunohistochemical analysis indicated that all 
three TIMPs were localised to glandular epithelia. Only TIMPs 3 and 4 were localised in the 
surface epithelia and TIMP3 alone showed strong immunoreactivity within the stroma, 
which suggests distinct roles and regulatory mechanisms for each anti-protease. H. felis 
infection in mice has also been shown to increase the abundance of TIMP1 and TIMP3 
mRNAs 762. TIMPs have also been shown to exert MMP independent biological functions 
such as the promotion or inhibition of cell growth, apoptosis, the promotion of 
angiognenesis and increased synaptic plasticity 763 through the direct binding of cell surface 
receptors 764.  Therefore, alterations in the ratio of MMPs:TIMPs caused by H. pylori 
infection may be a factor that helps to determine clinical outcome. 
Similarly, PAPPA2 has also been shown to cleave IGFBPs, primarily IGFBP5, whose 
concentrations are increased in the plasma during all stages of pregnancy and peak during 




The IGF-1R has been shown to be essential for cell growth and survival and IGF1R deletion 
or IGFBP5 overexpression in mice is associated with severe growth deficiency and high 
morbidity at birth 713, 766. However, aberrant activation of the IGF-1R has been associated 
with neoplasia and cancer development 767-770, whilst decreased IGF signalling has been 
shown to reduce tumour proliferation 771-773.    
During early placental development, environmental conditions are relatively hypoxic (2-4% 
oxygen) resulting in increased villus trophoblast proliferation and differentiation. Uterine 
invasion by villus trophoblasts results in direct contact between the maternal and foetal 
circulations after 10 weeks of gestation 774 and this is promoted by growth factors such as 
IGF-I which are liberated from their binding proteins by proteases 775, 776. Although both 
PAPPA and PAPPA2 cleave IGFBPs, low PAPPA expression has previously been associated 
with placental pathology 777-780, whereas high PAPPA2 expression has been associated with 
complicated pregnancies such as pre-eclampsia 722 and HELLP syndrome 726, as a 
consequence of placental hypoxia and tissue injury.  
Christians et al. previously identified low levels of PAPPA2 gene expression in a variety of 
other mouse tissues. This was strongest in the stomach, skin and embryo with expression 
also being observed in the kidney, lung, brain, heart, testis prostate and pancreas 781. 
Whole-exome sequencing of patients with lung adenocarcinoma found that an increase in 
PAPPA2 gene mutations was indicative of a better prognosis with significantly prolonged 
survival rates being observed in a Japanese population. Mutations in the PAPPA2 gene may 
decrease PAPPA2 protein expression which results in elevated levels of IGFBP5 and 
decreases subsequent IGF-I signalling 725. However, the proteolytic activity of PAPPA2 is 
relatively unknown in these tissues. 
In the work presented in this chapter, I have identified that PAPPA2 gene and protein 
expression is increased in a human gastric adenocarcinoma cell line in response to gastrin 




associated with decreased cell proliferation and increased migration and cell remodelling, 
known cofactors for gastric tumourigenesis. Metalloproteinases have been shown to share 
structural homology and also have many overlapping functions that have previously made 
clinical application difficult 782, 783. However, their potential use as biomarkers of disease 
and disease progression may be of clinical significance. 
The normal gastric mucosa progresses through a series of premalignant stages during 
cancer development from atrophy through metaplasia to dysplasia. This involves biological 
processes that have been associated with hypergastrinaemia and in part, PAPPA2 
expression. Therefore, PAPPA2 expression changes may correspond with early stages of 
neoplasia and if so could potentially provide an indication for an increased risk of gastric 
cancer development. Previously, PAPPA2 expression has been successfully detected in 
human serum as an effort to improve prenatal screening 721, 784. Future serological studies 
are therefore indicated to assess whether PAPPA2 has a potential application as a novel 










3.3 The effects of three 
novel gastrin receptor 
antagonist compounds 















Type-1 gastric neuroendocrine tumours (NETs) develop as a consequence of chronic 
autoimmune atrophic gastritis (CAG) in conjunction with hypergastrinaemia. Gastrin is a 
regulatory peptide that binds to the cholecystokinin subtype-2 receptor (CCK2R) and can 
promote tumour development via dysregulation of cell proliferation, migration and actin 
remodelling. For most patients tumour resection is potentially curative, however this is not 
always possible. Several CCK2 receptor antagonists have previously been developed, but 
very few have achieved clinical application due to low oral absorption, potency and/or 
selectivity issues. Using a variety of different cell-based assays, I have examined whether 
the three novel CCK2 receptor antagonists TR1, TR2 and TR3, inhibit gastrin-induced 
biological processes in AGSGR and AR42J cells and have compared these effects with the 
previously developed benzodiazepine analogue CCK-2 receptor antagonists YM022 and 
netazepide (YF476). All three compounds inhibited gastrin-induced cell growth, migration, 
branching morphogenesis and clonogenic survival in vitro and did not induce cellular 
toxicity or influence other cellular phenomena when administered alone. Of the three 
compounds TR2 was the most potent followed by TR1 and TR3 was the least potent. 
However, all three compounds were less potent than YM022 and netazepide. These data 
suggest that TR2, but not TR1 or TR3, could potentially be developed as a specific CCK2R 
antagonist to treat gastrin related conditions if further studies confirm that it has increased 











Gastrin is a hormone that is essential for gastric homeostasis and alterations in its 
secretion or processing may influence the initiation and progression of various diseases 130. 
The physiological functions of gastrin have been largely investigated within the stomach, 
primarily focussing on acid secretion following CCK2 receptor (CCK2R) binding which aids 
food digestion 15, 467, 717, 718. However, gastrin also plays a central role in regulating gastric 
mucosal growth and differentiation 785. Previous studies have suggested that pathological 
changes in the stomach particularly ECL-cell hyperplasia, dysplasia and subsequent 
neuroendocrine (carcinoid) formation, may develop, in part, due to elevated gastrin 
concentrations which arise as a consequence of autoimmune atrophic gastritis- induced 
hypochlorhydria 302.   
The organisation of gastric epithelia is maintained by cell proliferation, migration and 
differentiation. Proliferating cells located in the isthmus of the gastric gland migrate 
towards the surface or the base and differentiate; adopting multiple cell phenotypes 
including enterochromaffin-like (ECL), parietal, chief and endocrine cells 154. Gastrin has 
both direct and indirect influences on AGS gastric adenocarcinoma cells dependent upon 
the existence of cell surface receptors, particularly the CCK2R which has been associated 
with both pro- and anti-proliferative effects of G17 
663. Studies by Håkanson et al. examined 
the trophic effects of hypergastrinaemia on ECL cells and concluded that the gastrin/CCK2 
receptor signalling pathway was an essential regulator of cell remodelling 786 which can 
facilitate type-1 gastric neuroendocrine tumour development.  
Tumour cells acquire the ability to reproduce indefinitely, with atypical activation of 
survival pathways possibly contributing to resistance towards drug treatment. It has 
previously been shown that gastrin directly inhibits AGSGR cell proliferation by inhibiting 
progression through the cell cycle in the G1 phase 




been shown to reduce the cytotoxic effects of chemotherapeutic agents such as etoposide 
787. Abdalla reported that gastrin caused a 27% increase in peripheral blood mononuclear 
cell (PBMC) viability when treated with etoposide 788; retaining cell reproducibility and 
increasing survival. By contrast, in other cell lines, specifically rat pancreatic tumour 
(AR42J) cells, gastrin has been shown to increase cell growth by inducing the progression 
of the cell cycle into S-phase, which promotes protein and DNA synthesis 339 and down 
regulation of the CCK2 receptor has shown to inhibit cell growth and induce apoptotic 
activity 789.    
In some patients with hypergastrinaemia there is a progression from a normal mucosa to 
ECL cell dysplasia and subsequent type-1 gastric neuroendocrine (NETs) formation. The 
structure of the mucosa is maintained through reciprocal signalling between the gastric 
epithelium and stromal cells, particularly myofibroblasts, which release cytokines and 
proteases involved in the regulation of the extracellular matrix (ECM). Gastrin has 
previously shown to increase the expression of some proteases involved in tissue 
remodelling, specifically MMP1 188,  MMP7 191 and MMP9  189 which increase ECM 
degradation. Loss of ECM stability activates epithelial-to-mesenchymal transition (EMT) 
which reduces cell-cell adhesion and may contribute to tumour migration, invasion and 
angiogenesis.  
Multiple gastrin/CCK2 receptor antagonists have previously been investigated; however 
clinical application has proven disappointing due to low oral bioavailability, potency and/or 
selectivity. However two clinical trials 460, 460, have recently demonstrated that patients 
with type-1 gastric neuroendocrine tumours who received a daily oral dose of 50mg 
netazepide (YF476) for 12 weeks with a 12 week follow-up showed an approximate 30% 
reduction in tumour size and number. In addition, serum chromogranin A (a biomarker of 




pre-treatment levels after 12 weeks of follow up and serum gastrin levels remained 
unaffected. 
Therefore using a variety of in vitro assays, we set out to assess whether three novel 
potential CCK2 receptor antagonists synthesised by Trio Medicines Ltd (TR1, TR2 and TR3) 
inhibited gastrin-induced cellular phenomena and have compared their potencies against 





3.3.3 The anti-proliferative effects of gastrin are inhibited by compounds TR1, 
TR2 and TR3 in AGSGR cells. 
To investigate whether pre-treatment with three new gastrin receptor antagonists 
completely reversed the anti-proliferative effects of gastrin in vitro, SRB assays were 
performed for each drug with and without gastrin treatment. A broad range of 
concentrations (1, 10, 25, 50, 100, 500, 1000nM) of each compound was initially tested 
followed by a specific range of concentrations to further characterise the dose response 
relationship for each drug. SRB stain absorbance was measured at 570nm and cellular 
content was assessed as a percentage of the negative untreated control absorbance. To 
validate the minimum concentration at which compounds TR1, TR2 and TR3 inhibited the 
anti-proliferative effects of gastrin, haemocytometer count assays were also performed. 
Untreated and G17 10nM alone treatments were used as negative and positive controls 
respectively and 1% DMSO was used as a vehicle control.  
YM022 and netazepide (both at 60nM) completely inhibited the anti-proliferative effects of 
10nM G17 (P<0.0001) and neither YM022 nor netazepide alone (concentrations of 1-
100nM) induced cellular toxicity in AGSGR cells (Figure 38)(N=3, n=8). This was validated 
with haemocytometer counts in AGSGR cells as 60nM of either YM022 or netazepide caused 
complete reversal of the anti-proliferative effects of 10nM G17 with minimal floating cells 
being observed, indicating no significant cellular toxicity (Figure 39) (N=3, n=3). These 
drugs were therefore used as positive inhibition controls in future experiments at 
concentrations of 100nM. Complete reversal of the anti-proliferative effects of 10nM G17 
was observed when cells were pre-treated with the following minimum concentrations of 
TR1 (500nM) (P<0.001), TR2 (100nM) (P<0.0001) and TR3 (500nM) (P<0.01) (Figure 40) 
(N=4, n=8). These findings were validated using haemocytometer counts and treatment 
with TR1, TR2 and TR3 alone at concentrations 1-1000nM did not induce cellular toxicity, 





Figure 38. YM022 and netazepide both at 60nM completely reverse the inhibition of AGS
GR
 cell proliferation 
caused by 10nM G17.YM022 and netazepide alone at concentrations of 1-100nM do not induce toxicity in 
AGS
GR
 cells (A and B) (N=3, n=8). Statistical significance was determined using two-way ANOVA with Sidak 





Figure 39. YM022 (A) and netazepide (B) both at 60nM concentration completely reverse the anti-proliferative 
effects of 10nM G17 treatment with no significant cellular toxicity (N=3, n=3). Statistical significance was determined 






Figure 40. TR1 500nM (A), TR2 100nM (B) and TR3 500nM (C) completely reverse the inhibition of AGS
GR
 cell 
proliferation caused by 10nM G17. TR1, TR2 or TR3 alone at concentrations of 1-1000nM do not induce 
toxicity in AGS
GR
 cells (N=4, n=8). Statistical significance was determined using two-way ANOVA with Sidak 






Figure 41. TR1 500nM (A), TR2 100nM (B) and TR3 500nM (C) completely reverse the anti-proliferative effects of 10nM 
G17 treatment with no significant cellular toxicity (N=3, n=3). Statistical significance was determined using two-way 





3.3.4 The migratory effects of gastrin are inhibited by compounds TR1, TR2 
and TR3 in AGSGR cells 
Scratch wound migration assays were performed to investigate whether pre-treatment 
with the three new gastrin receptor antagonists reversed the migratory response 
stimulated by gastrin in AGSGR cells in vitro. For each drug a broad range of concentrations 
was initially investigated (1, 10, 25, 50, 100nM) followed by a more specific range of 
concentrations to further characterise the dose response relationship for each drug.  
Gastrin stimulated migration was completely inhibited by YM022 and netazepide both at 
50nM concentrations (Figure 42 and 44), and were therefore used as positive inhibition 
controls (N=3, n=3). 
 Gastrin-stimulated AGSGR cell migration was completely inhibited by TR1 300nM, TR2 

















Figure 42. Migratory response in control and gastrin stimulated (10nM, 8hrs) AGS
GR
 cells with and without 
YM022 (A) or netazepide (B) pre-treatment (N=3, n=3). Statistical significance was determined using two-
way ANOVA with Sidak post-hoc test and P<0.05 was considered significant (***P<0.001 and 












































Figure 43. Migratory responses in control and gastrin stimulated (10nM, 8hrs) AGS
GR
 cells with and without 
TR1 (A) TR2 (B) and TR3 (C) pre-treatment (N=3, n=3). Statistical significance was determined using two-
way ANOVA with Sidak post-hoc test and P<0.05 was considered significant (*P<0.05, **P<0.01, 































Figure 44. Scratch wounds for 0hrs and 8hrs respectively, in untreated AGSGR cells (A,C) and cells treated with 10nM 
gastrin (B, D) stimulated cell migration. Treatment with CCK2 receptor antagonists: YM022 50nM (E, G), netazepide 
50nM (I, K), TR1 300nM (M, O), TR2 80nM (Q, S) and TR3 1000nM (U, W) alone did not induce AGS
GR
 cell migration. Pre-
treatment with CCK2 receptor antagonists: YM022 50nM (F, H), netazepide 50nM (J, L), TR1 300nM (N, P), TR2 80nM (R, 





3.3.5 Gastrin-induced cellular morphological changes are inhibited by 
compounds TR1, TR2 and TR3 in AGSGR cells 
Incubation of AGSGR cells with G17 10nM induced time dependent morphological responses 
(Figure 45); with the extension of long processes being observed after 6hrs incubation. 
Therefore, branching morphogenesis assays were performed to investigate whether pre-
treatment with compounds TR1, TR2 or TR3 would inhibit this gastrin-induced cellular 
phenotype in AGSGR cells. An initial dose response was performed for a broad range of 
concentrations for each drug (1, 10, 25, 50, 100, 500nM) followed by a specific range to 
further assess the minimum inhibitory concentration. Untreated, 10nM G17 treated and 1% 
DMSO treated were used as negative, positive and vehicle controls. 
YM022 (10nM) and netazepide (25nM) completely inhibited, and netazepide 10nM partly 
inhibited gastrin stimulated branching morphogenesis in AGSGR cells (Figure 46) (N=3, n=3). 
Gastrin induced morphological changes were significantly inhibited by TR1 10nM, TR2 
50nM and TR3 10nM and completely inhibited by TR1 400nM, TR2 400nM and TR3 500nM 
(Figure 47) (N=3, n=3). 
Immunofluorescence visualisation confirmed that gastrin-induced branching 
morphogenesis was completely inhibited by pre-treatment with CCK2 receptor 
antagonists: YM022, netazepide, TR1, TR2 and TR3 (Figure 48) at the minimum 
concentrations for complete inhibition of gastrin that were shown by the branching 



































Figure 45. Phalloidin-488 staining of actin shows remodelling of the cytoskeleton and the extension of long 
processes in AGS
GR
 cells (white arrows). Untreated cells (A) and cells treated with 10nM G17 30mins (B) 
show gastrin stimulated cell spreading. Cells treated with G17 6hrs (C) and 15hrs (D) show the 







Figure 46. Branching morphogenesis in control and gastrin stimulated (10nM, 6hrs) AGS
GR
 cells with 
and without YM022 (A) and netazepide (B) pre-treatment (N=3, n=3). Each experiment was run 
three times and values are expressed as mean percentage of total cells ± SEM. Statistical 
significance was determined using two way ANOVA with Sidak post-hoc test and P<0.05 was 





Figure 47. Branching morphogenesis in control and gastrin stimulated (10nM, 6hrs) AGSGR cells 
with and without TR1 (A) TR2 (B) and TR3 (C) pre-treatment (N=3, n=3). Each experiment was 
repeated three times and values are expressed as mean percentage of total cells ± SEM. 
Statistical significance was determined using two way ANOVA with Sidak post-hoc test and P<0.05 







Figure 48. Phalloidin-594 staining of actin shows remodelling of the actin cytoskeleton and the extension of long processes in AGS
GR
 cells. Untreated AGS
GR
 cells (A) show no 
branching morphogenesis and were used as a negative control, whereas 10nM G17 6hrs stimulated the formation of long processes and was used as a positive control (B). Pre-
treatment with CCK2 receptor antagonists without 10nM G17 treatment 6hrs: netazepide (25nM, C), YM022 (10nM, E), TR1 (400nM, G), TR2 (400nM, I) and TR3 (500nM, K) did 
not induce the formation of processes. Pre-treatment with CCK2 receptor antagonists followed by 10nM G17 6hrs showed complete inhibition of branching morphogenesis: 




3.3.6 The long term effects of gastrin on clonogenic survival are inhibited by 
compounds TR1, TR2 and TR3 in AGSGR cells 
Gastrin has previously been shown to inhibit clonogenic survival and etoposide cytotoxicity 
in AGSGR cells after 6hrs treatment (Pritchard unpublished data). Therefore clonogenic 
assays were performed to assess whether pre-treatment with TR1, TR2, TR3, YM022 or 
netazepide would improve long term cell survival and reverse the inhibition of cell 
cytotoxicity in AGSGR cells.  
Pre-treatment with YM022 (25nM) or netazepide (25nM) completely reversed the 
inhibition of clonogenic survival induced by 10nM G17. YM022 and netazepide (both 1nM) 
completely reversed the inhibition of etoposide-induced cytotoxicity induced by 10nM G17 
(Figures 49 and 51) (N=3, n=3).    
Improvements in cell survival were seen with all 3 compounds at concentrations of TR1 
(600nM), TR2 (100nM) and TR3 (700nM). All 3 compounds at concentrations of 1nM 
completely reversed the inhibition of etoposide-induced cytotoxicity induced by 10nM G17 






























Figure 49. Clonogenic survival assays for YM022 (A, B) and netazepide (C, D) dose responses after 6hrs 10nM G17 treatment 
with and without 1hr 8μM etoposide treatment (N=3, n=3). Each experiment was repeated three times and values are 
expressed as mean percentage of control ± SEM. Statistical significance was determined using two way ANOVA with Sidak 







Figure 50. Clonogenic survival assays for TR1 (A, B), TR2 (C, D) and TR3 (E, F) dose responses after 6hrs 10nM G17 
treatment with and without 1hr 8μM etoposide treatment (N=3, n=3). Each experiment was repeated three times and 
values are expressed as mean percentage of control ± SEM. Statistical significance was determined using two way 




























Figure 51. Clonogenic assays of AGSGR cells stained with 0.3% crystal violet for the minimum concentrations of 
YM022, netazepide, TR1, TR2 and TR3 that completely reverse the inhibition of clonogenic survival and 




3.3.7 The proliferative effects of gastrin are inhibited by compounds TR1, TR2 
and TR3 in AR42J cells 
Rat exocrine pancreatic tumour cells (AR42J) constitutively express the CCK2R and were 
therefore used to validate the minimum concentration at which compounds TR1, TR2 and 
TR3 inhibited the proliferative effects of gastrin. Using the modified thymidine analogue 
EdU, newly synthesised DNA is fluorescently labelled with Alexa Fluor® 594 (red). EdU 
incorporation assays were performed in order to assess the cellular proliferation rate in 
response to 0.1nM gastrin, following pre-treatment with the minimum concentrations of 
TR1 (500nM), TR2 (100nM) and TR3 (500nM) that inhibited the anti-proliferative response 
of 10nM gastrin in AGSGR cells.  
Untreated, DMSO (1%) and G17 0.1nM treatments were used as negative, vehicle and 
positive controls with YM022 and netazepide (100nM) treatments used as positive 
inhibition controls. 
Significant inhibition of the proliferative effects of 0.1nM G17 (P<0.001) were seen when 
cells were pre-treated with the following minimum concentrations of TR1 (500nM), TR2 
(100nM) and TR3 (500nM). Treatment with TR1, TR2 and TR3 alone at these 
concentrations did not induce cellular toxicity as AR42J cell growth was not affected 






































Figure 52. EdU incorporation assays for TR1 (500nM), TR2 (100nM), TR3 (500nM), YM022 (100nM) and 
netazepide (100nM), in AR42J cells with and without 8hrs 0.1nM G17 treatment (N=3, n=3). Each 
experiment was repeated three times and values are expressed as mean percentage of total cells per 
three reference fields  ± SEM. Statistical significance was determined using two way ANOVA with 
































Figure 53. EdU incorporation assays for (B) TR1 (500nM), TR2 (100nM), TR3 (500nM), (C) YM022 (100nM) 
and netazepide (100nM), in AR42J cells with and without 8hrs 0.1nM G17 treatment. (A) Untreated, 
DMSO (1%) and 0.1nM G17 treatments were used as controls, mean cell number per treatment 105 ±6. 
(D) Proliferating cells with incorporated EdU were visualised with Alexa Fluor®594 (red) and non-
proliferating cells were stained using Hoechst 33342 nuclear stain (blue), representative image of 





Patients with autoimmune atrophic gastritis and pernicious anaemia develop 
hypergastrinaemia as a consequence of reduced gastric acid secretion. Elevated gastrin 
concentrations have previously been shown to induce ECL cell hyperplasia which 
predisposes some patients to progression towards ECL cell dysplasia and type 1 gastric 
neuroendocrine tumour (NET) formation. 
In localised type-1 gastric NETs, multiple polypoid tumours (<1cm diameter) may be 
successfully removed endoscopically, with an 80-100% 5-year survival rate 790. Even in 
metastatic disease endoscopic resection plays an important role in minimising tumour size. 
However, in many cases resection is not possible because of tumour multiplicity and other 
therapies must be explored. Many hormonal approaches have also been investigated 
particularly the use of somatostatin analogues such as lanreotide and octreotide, both of 
which have provided good symptomatic control with evidence of tumour regression 791-793. 
The development of new gene markers in conjunction with more effective therapies is 
expected to improve diagnosis, prognosis and response to therapy for patients with type-1 
gastric NETS.  
Gastrin receptor antagonists inhibit gastrin/CCK2 receptor binding and have the potential 
to reduce the downstream activation of biological processes such as gastric acid secretion 
155, tissue remodelling and proliferation 463, particularly of ECL cells. CCK2 receptor 
antagonists have shown promising results in patients with type-1 gastric NETs 459, 460.  
In this preclinical study, the effects of three novel gastrin receptor antagonists (TR1, TR2 
and TR3) were examined and compared to the potency of the previously established 
compounds YM022 and netazepide, using CCK2 receptor bearing cells (AGSGR and AR42J).  
Gastrin has both direct and indirect influences on AGS cells dependent upon the existence 




with the pro- and anti-proliferative effects of G17; proliferation was arrested in the G1 
phase of the cell cycle when this receptor was expressed 663.  Activation of the 
gastrin/CCK2R pathway leads to the production of several, growth regulator proteins 
including TGFα related peptides, Reg and histamine which act in a paracrine manner on 
CCK2 receptor non-bearing cells to stimulate cell growth 718, as determined by flow 
cytometry separation of Hoechst 33342 labelled AGSGR cells co-cultured with AGSGFP cells 
that only express the green fluorescent protein 663. Alternatively, gastrin has also been 
shown to modulate pancreatic cell growth in vitro using AR42J cells 794 and in vivo in rats 
795. AR42J cells treated with pentagastrin showed increased DNA and protein synthesis and 
subsequent cell proliferation via activation of the CCK2 receptor.  
Using a mouse fibroblast cell line that expresses the human CCK2 receptor (N-hCCKBR), 
YM022 proved to be a highly potent anti-proliferative drug with respect to binding affinity 
for the CCK2 receptor, inhibition of PI3kinase production, increased intracellular calcium 
and DNA synthesis as assessed by the inhibition of [methyl-3H] thymidine incorporation 
with and without gastrin 443. Similarly, in enzyme immunoassays and MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation studies, netazepide 
reduced ECL cell secretion (IC50 1.2nM) and cell growth (IC50 0.0013nM) in vitro, and was 
1000 times more potent than a previous benzodiazepine derived drug L-365,260 446. 
In spontaneously hypergastrinaemic cotton rats (Sigmodon hispidus) that are predisposed 
to developing gastric neuroendocrine tumours, Kidd et al. also reported reduced ECL cell 
secretion and hyperplasia with a 60% decrease in subsequent neoplasm formation 
following a single, subcutaneous injection of netazepide (300μmol/kg/month) for <4 
months 454.   
In this study, complete inhibition of the anti-proliferative effects of gastrin was observed in 




AR42J cells was observed in EdU incorporation assays for all 3 compounds at 
concentrations of 500nM, 100nM and 500nM for TR1, TR2 and TR3 respectively. Of the 
three compounds, TR2 had the highest potency with complete inhibition of the effects of 
G17 being observed at a concentration that was five times lower than TR1 or TR3, which 
were also both less potent than YM022 and netazepide (both 60nM). However, TR2 did not 
have a higher potency than either YM022 or netazepide. None of the compounds tested 
produced cellular toxicity, as cell growth was unaffected at concentrations of TR1 (500nM), 
TR2 (100nM) or TR3 (500nM). These results were also confirmed using haemocytometer 
counts. The minimum concentration needed for complete inhibition of G17 induced effects 
did not increase floating cell numbers suggesting that the compounds did not induce cell 
death. 
It has been established that cell migration is essential for gastric maintenance and wound 
healing. However, the ability of aberrant cells to metastasise defines the aggressive 
potential of a tumour and migration to secondary locations decreases the effectiveness of 
a treatment. Gastrin has been  shown to increase cell migration in scratch wound assays of 
AGSGR cells, in direct response to CCK2 receptor stimulation and this is partially mediated 
by PKC, MAPK and EGF-R pathways, and by matrix metalloproteinases in a paracrine 
manner 672. The EGF-R pathway is initiated by the production of prostaglandins by gastric 
epithelial cells, primarily PGE2 in response to inflammation-induced Cox-2 expression 
796.  
Intraperitoneal pre-treatment with YM022 (10, 30 and 100mg/kg) has been shown to dose 
dependently abolish gastrin induced Cox-2 overexpression and reduce PGE2 expression 
797, 
limiting cell migration in rats which had been injected with gastrin (100μg/kg). In the same 
way, the levels of epidermal growth factors (Reg I, HB-EGF, TGFα and amphiregulin) were 
significantly reduced in hypergastrinaemic INS-GAS mice, following weekly netazepide 




We found that pre-treatment of AGSGR cells with TR1 200nM, TR2 70nM or TR3 900nM 
completely inhibited gastrin-stimulated cell migration, without influencing cell migration 
when treated alone at concentrations between 1nM-1μM. Whilst TR1 and TR3 had a lower 
potency when compared with YM022 and netazepide (100nM), TR2 was 30% more potent 
that both of its predecessors.   
Hypergastrinaemia can evoke considerable tissue remodelling in the gastric epithelium. It 
has previously been reported that heregulin (neuregulin) in gastric epithelial cells 798, and 
transforming growth factor (TGF)-α in rat gastric mucus cells 799 promote the formation of 
branching morphogenesis (long tube-like projections) as part of the EGF-R pathway. CCK2 
receptor inhibition using YM022 (1μmol/kg/hr via osmotic pumps) or netazepide 
(300μmol/kg via subcutaneous injection) reduced both ECL cell density and completely 
reversed the transformed cellular morphology (gastric processes) 800. These data suggest 
that whilst gastrin is essential for the structural integrity of gastric ECL cells, under 
hypergastrinaemic conditions CCK2 receptor antagonism may provide an additional layer 
of mucosal protection against the formation of gastric neuroendocrine tumours.    
Branching morphogenesis (the formation of long, cellular processes) was completely 
inhibited by TR1, TR2 and TR3 (all at concentrations of 400nM), with no structural changes 
being detected following treatment with any of the three compounds alone (1nM-500nM). 
This time, all three drugs were less potent than YM022 and netazepide, which both 
inhibited structural remodelling at 100nM. Gastrin stimulates multiple downstream 
signalling pathways of the CCK2 receptor including MAPK, PKC and PI3K. It has previously 
been suggested that branching morphogenesis occurs in a PKC-dependent, PI3K 
independent manner in AGSGR cells however the full PKC dependent mechanism still 




affinity for the CCK2 receptor and their subsequent inhibition of downstream signalling 
pathways that may be associated with branching morphogenesis.  
Clonogenic survival assays determine a cell’s ability to retain long term reproducibility and 
chemosensitivity.  In this study AGSGR cells treated with 10nM G17 for 6hrs showed 
inhibition of cell growth by ~60%. This inhibition was completely reversed by all 3 
compounds at concentrations of TR1 600nM, TR2 200nM and TR3 700nM. Whilst TR2 was 
the most potent of the 3 compounds, it was less potent that YM022 and netazepide (both 
25nM). In AGSGR cells treated with 10nM G17 for 6hrs followed by 1hr 8µM etoposide (a 
known cytotoxic drug), chemotherapy-induced cell death was reduced ~2-fold. This 
inhibition was completely reversed by all three drugs as well as YM022 and netazepide at 
low concentrations of 1nM. Although this suggests that all three compounds are equally as 
potent as YM022 and netazepide at increasing AGSGR cell chemosensitivity, lower 
concentrations of all three compounds and YM022 and netazepide will need to be 
assessed to elucidate an appropriate dose-response. 
These studies suggest that the CCK2 receptor selective compounds TR1, TR2 and TR3 
inhibit gastrin mediated effects in vitro, in order of highest to lowest potency 
(TR2>TR1>TR3). Although complete mechanistic understanding of CCK2 receptor activation 
remains unclear and there is an abundance of previously assessed CCK2 receptor 
antagonists that have been unsuccessful, the potential increase in oral bioavailability of 
TR1, TR2 and TR3 compared with previously synthesised compounds may increase the 
potency and therapeutic utility of these compounds, particularly TR2. However, selectivity 
for the CCK2 receptor will need to be explored for potential idiosyncratic effects and 
cellular toxicology will need to be thoroughly elucidated. In vivo translation of these 
findings in both hypergastrinaemic and malignant animal models will also be required 




potential to be further developed as a treatment for hypergastrinaemia associated 



















4.1 Summary of major findings and conceptual advances 
The initial aim of this study was to identify miRNAs that were differentially expressed in 
response to gastrin. As gastrin has been shown to stimulate multiple pathways involved in 
the initiation and progression of gastric tumours via the CCK2 receptor, further 
understanding of these regulatory mechanisms may provide therapeutic insights into the 
processes involved in gastric tumourigenesis. miRNAs are non-coding RNAs that regulate 
~30% of the human genome and have previously been shown to be dysregulated both in 
vitro and in vivo during H. pylori infection, a known cause of both hypergastrinaemia and 
gastric cancer. However the specific dysregulation of miRNA profiles by gastrin remains 
unclear. 
I demonstrated that gastrin significantly altered the expression of six miRNAs from a panel 
of 84 of the most abundant and best characterised miRNAs (according to miRbase version 
19) 801-804. Of the six differentially expressed miRNAs, three were upregulated and three 
were downregulated; however only two of these proved to be significant, miR-376c (5.2 
fold) and miR-222 (2.3 fold). Due to the relatively low abundance of miR-376c in both the 
untreated and gastrin treated samples, miR-222 was chosen as a potential ‘hit’ and was 
further investigated in vitro and in vivo. miR-222 was upregulated in response to gastrin 
following CCK2R activation via the PKC and PI3K pathways in AGSGR cells. Increased miR-
222 expression was also demonstrated in hypergastrinaemic INS-GAS mice, and this 
increased further following H. felis infection. Additionally, miR-222 was upregulated in 
eight patients who had hypergastrinaemia (>400pM) and type-1 gastric NETs at baseline. 
This expression significantly reduced when patients were taking 50mg netazepide (CCK2R 
antagonist) daily and returned to baseline levels after cessation of treatment. Gastrin-
induced miR-222 overexpression reduced p27 expression, a cell cycle regulatory protein, 
and this resulted in cellular phenotypical changes that have previously been associated 




Other researchers within our research group at the University of Liverpool had previously 
demonstrated that PAPPA2 mRNA expression was increased in the same eight 
hypergastrinaemic patients as previously described, and also that this decreased whilst the 
patients were taking 50mg netazepide daily and returned to baseline after cessation of 
treatment. Further investigation showed that PAPPA2 (mRNA and protein) expressions 
were increased in response to gastrin treatment of the AGSGR cell line in vitro. Gastrin-
induced PAPPA2 overexpression also significantly increased cellular phenotypical changes 
such as migration and the extension of long processes that are associated with gastric 
tumourigenesis.  
In vitro, I investigated whether three novel CCK2R antagonists (TR1, TR2 and TR3) 
reduced/reversed gastrin-stimulated premalignant phenotypical changes including cell 
growth, structural remodelling, migration and clonogenic survival. All three compounds 
significantly inhibited gastrin-induced cellular phenomena in two cell lines with compound 
TR2 having the highest potency. In all cell based assays TR2 showed equal or slightly 
reduced potency compared to the previously developed CCK2R antagonists, YM022 and 
netazepide. Clinical application for CCK2R antagonists has to date been poor due to low 
oral bioavailability. Therefore pending further investigation, TR2 may provide promise as a 
novel CCK2R antagonist for treating gastrin-related disorders.    
4.2 Strengths and limitations of the current study  
4.2.1 Transformed cell lines 
Gastric cancer cell lines derived from human gastric tumours have made major 
contributions to our understanding of gastric cancer development and cell biology. 
Transformed cell lines allow experiments to be repeated reproducibly, grow rapidly and 




investigations of the responses of a specific cell type to various well-defined experimental 
conditions such as drug treatments and growth factors.  
In this study human gastric adenocarcinoma cells (AGS) that have been stably transfected 
with the human CCK2R (AGSGR) were used to investigate gastrin-stimulated cellular 
responses. However, AGS cells do not normally express the CCK2R and transformed AGSGR 
cells have a higher level of CCK2R expression than normal gastric ECL cells. Therefore, this 
cell line may not fully reflect the responses of physiological ECL cell populations to gastrin. 
Cell lines that natively express the CCK2R such as rat pancreatic tumour cells (AR42J) may 
more accurately represent physiological responses to gastrin and could be used to confirm 
our findings in AGSGR cells. Primary cell cultures derived from the gastric mucosa may also 
provide a better understanding of gastrin-induced cell responses within the stomach. The 
isolation and subsequent culturing of heterogeneous populations of normal gastric 
epithelial cells would more closely mimic the properties of the cells in vivo. However, 
primary gastric cells have less reproducibility than immortalised cell lines and subculturing 
has been shown to alter cellular characteristics and gene expressions over time 805. Each 
passage selects for subpopulations of cells that are more capable of proliferating ex-vivo 
such as stromal fibroblasts, which alters the physiological cell populations and may skew 
sequential results.  
3-dimensional (3D) pluripotent stem-cell derived gastric organoids 806 maintain the native 
architecture of the multiple differentiated cell types within the stomach and some of these  
would  have physiological levels of CCK2R expression. Cells within these gastroids form 
complex cell-cell and cell-matrix interactions which more accurately mimic the in vivo 
environment of the originating tissue and this would allow the investigation of pathological 
mechanisms involved with aberrant CCK2R activation. However, the tumour 




and immune cells 807, which all contribute to the process of carcinogenesis. Thus even 
experiments involving epithelial gastroids may not be fully indicative of the events which 
occur in vivo. 
4.2.2 INS-GAS mouse model 
Animal models of gastric cancer have been shown to provide reproducible methods for 
investigating disease mechanisms and treatments for malignancy, in ways that are not 
possible in humans. The physiology and anatomy of the mouse stomach is relatively similar 
to humans, however structural and size differences are still present. There is also a high 
degree of similarity between the human and murine genomes (~85%) 808. Genetically 
modified hypergastrinaemic INS-GAS mice were therefore utilised to model human gastrin-
associated cellular changes.  
Transgenic INS-GAS mice are genetically modified to overexpress the human gastrin gene 
and therefore have high circulating gastrin concentrations. Initially, young INS-GAS mice 
have increased parietal and ECL cell numbers which decrease over time leading to gastric 
atrophy. The majority of INS-GAS mice spontaneously develop gastric dysplasia and 
invasive gastric adenocarcinoma after ~20 months of age 112. In humans, atrophic gastritis 
is driven either by long-term H. pylori infection or by autoimmune mechanisms and 
hypergastrinaemia is secondary to gastric hypoacidity. Patients with hypergastrinaemia 
have an increased risk of developing both gastric adenocarcinomas and gastric NETs 
(depending upon the original aetiology) 809-812, however INS-GAS mice have only been 
shown to develop gastric adenocarcinomas. Female Japanese cotton rats (Sigmodon 
hispidus) are hypergastrinaemic wild-type rodents that have been shown to spontaneously 
develop gastric NETs after ~8 months of age 366-368. Additionally, the African Mastomys 
natalensis rodent (Z strain) has been shown to develop gastric adenocarcinomas or gastric 




gastrin is a cofactor for the development of both gastric adenocarcinomas and gastric 
neuroendocrine tumours, the use of Japanese cotton rats or Mastomys natalensis would 
help to determine the effects of hypergastrinaemia on the development of gastric 
premalignant phenotypes with neuroendocrine characteristics that mimic human 
carcinogenesis. Unfortunately, these animals were not available at the University of 
Liverpool so I was not able to conduct any such studies during this PhD. 
4.2.3 Helicobacter felis infection model 
It is well established that H. pylori infection can contribute to the development of gastric 
cancer in humans and  hypergastrinaemia may contribute in some cases 614. However, 
many H. pylori strains do not colonise various mouse strains 814, 815. H. felis has been shown 
to readily colonise the murine stomach and was therefore used as a model of bacteria-
induced gastric neoplasia in this study. H. felis has been shown to cause murine gastric 
mucosal inflammation with premalignant cellular phenotypes that are morphologically 
similar to human H. pylori pathogenesis 816. However, H. felis strains do not contain cagPAI 
or vacA genes, the most extensively characterised bacterial virulence factors that are 
strongly associated with gastric pathology in humans, and this has resulted in some 
criticism when used to model H. pylori-induced conditions.  
In this study, I demonstrated that six week H. felis infection further induced miR-222 
expression in three month old hypergastrinaemic INS-GAS mice compared with uninfected 
INS-GAS mice. Bacterial infection (H. felis) in this model has been shown to accelerate the 
gastric atrophy, metaplasia, dysplasia and gastric adenocarcinoma sequence associated 
with human pathology 817. However, previous studies have shown that wild-type mice of 
the same genetic background (FVB/N) maintained under similar conditions did not develop 
the same H. felis-induced gastric pathology 112. Therefore, it would be useful to assess miR-




be interesting to assess longer time-points in H. felis infected mouse models (up to two 
years) as extended periods of infection in wild-type and INS-GAS mice have previously 
been shown to cause gastric lesions similar to those observed in H. pylori infected humans 
818, 819.  
H. pylori strains that can successfully colonise the murine stomach have recently been 
developed such as G1.1, TN2 SS1 and B1287, of which the best characterised is the Sydney 
strain of H. pylori (SS1) 387. The mouse-adapted H. pylori strain SS1 (cagA+/vacA+) efficiently 
and rapidly colonises multiple mouse strains and can persist for long periods of time 820. 
After 8 months infection with H. pylori SS1, chronic atrophic gastritis and secondary 
hypergastrinaemia were observed in C57BL/6 mice and these increased in severity with the 
extent of colonisation 387. This is comparable to the progressive destruction of the corpus 
mucosa observed in human H. pylori infection. Similarly, Mongolian gerbils infected with H. 
pylori (G1.1 821, TN2 822 or B1287 823 strains) develop hypergastrinaemia and severe 
inflammation and this can result in the development of gastric NETs and less frequently, 
gastric adenocarcinoma 824, 825. Therefore, these rodent adapted H. pylori strains may be 
useful for future investigations as they best resemble human pathogenic H. pylori and 
closely mimic the premalignant phenotypical changes observed within the gastric mucosa 
in humans. 
4.2.4 Human samples 
For this study, samples were taken from a small number of patients from a single hospital. 
They had hypergastrinaemia and type-1 gastric NETs (n=8) and were on a daily regimen of 
50mg netazepide; they underwent intensive monitoring for more than one year. This 
strategy has both advantages and disadvantages. Small sample size studies are relatively 
quick to conduct with respect to enrolling patients, so that a particular research question 




sample size is therefore cost effective for the initial determination of an area of focus. 
However the interpretation of results may not accurately reflect the whole population and 
therefore further confirmatory studies are needed involving a larger cohort of patients 
who have differences in geographical location, age, race and sex. A placebo arm was also 
not included in the initial open label study and this will be required in any subsequent 
trials. Further investigation of the specificity of our observations also means that patients 
with different sources of hypergastrinaemia including PPI use, autoimmune atrophic 
gastritis, active H. pylori infection or Zollinger-Ellison syndrome should now be assessed. 
Biomarker expression profiles that can distinguish between sources of hypergastrinaemia 
may be of clinical value for the diagnosis and treatment of gastrin-related conditions.   
4.2.5 Investigation of miRNAs 
Several miRNAs have previously been shown to be clustered within a locus and are 
transcribed simultaneously with the host gene, forming monocistronic, dicistronic or 
polycistronic primary miRNA (pri-miRNA) transcripts 471, 557. Therefore, an increase in gene 
transcription may increase the expression of more than one miRNA. miR-222 forms a 
cluster with miR-221 and is cleaved from the same dicistronic pri-miRNA. An increase in 
miR-222 transcription may therefore also increase miR-221 transcription. miR-221 has 
previously been shown to exert independent biological effects that may also contribute to 
carcinogenesis via targeting cell cycle inhibitor proteins in prostate 826, hepatocellular 827, 
828, colorectal 829 and breast 830 cancers . The miRNA PCR array initially used in this study 
contained miR-222 and miR-221 primers separately. Therefore we were able to determine 
whether gastrin increased the transcription of both miRNAs within the cluster or each one 
individually. However, separate primer assays for miR-221 should also be used to confirm 
whether the observed cellular responses arose specifically as a result of gastrin-induced 




It has previously been suggested that one miRNA may sometimes regulate multiple targets 
and vice versa one mRNA can be targeted by numerous miRNAs 689, 831-834. This adds an 
additional layer of functional complexity and makes miRNAs potent regulators of several 
biological processes. The initial miScript™ miRNA PCR array used in this study only 
contained 84 of the most abundant and best characterised miRNAs according to miRbase 
version 19 801-804 and may therefore not have included all of the miRNAs that are affected 
by gastrin. Therefore, the use of whole genome miRNA deep sequencing (miR-seq) could 
elucidate all miRNA expression changes that may occur in association with gastrin. This 
might identify additional specific miRNA patterns/profiles that are associated with gastrin-
related conditions. However, miR-seq is an expensive and time-consuming technique that 
would not have been possible for this particular study.    
4.3 Potential translational impact 
The main causes of hypergastrinaemia are gastric atrophy and the use of PPIs; the former 
occurs most frequently after chronic H. pylori infection. Gastric atrophy is currently the 
highest (independent) known risk factor for the development of gastric tumours 218, 293, 835, 
836 and the trophic effects of increased circulating gastrin concentrations may contribute in 
some cases.  
Parallel assays that detect the serum concentrations of human pepsinogens (pepsinogen I 
and/or pepsinogen I: pepsinogen II ratios) and gastrin have been used to indicate the 
extent of atrophic gastritis 837-839. Altered expressions of this panel of biomarkers reflect 
changes in gastric morphology and the physiological function of the mucosa. However, 
serum pepsinogen testing has variable specificity and has been associated with false-
positive results 840 for the detection of premalignant lesions such as atrophy and dysplasia. 
There is also no standard cut-off value for PGI or PGI: PGII ratios 841-844 meaning that it is 




induced cellular responses, particularly those that are highly associated with an increased 
risk of gastric neoplasia have not yet been established. This study has identified miR-222 
and PAPPA2 as gastrin-regulated genes which are overexpressed in hypergastrinaemic 
conditions. This overexpression dysregulates several biological processes including 
increased gastric cellular remodelling and migration, which are strongly associated with 
malignant phenotypes. Therefore, miR-222 and PAPPA2 are promising candidate novel 
serum biomarkers for the detection of gastrin-associated clinical conditions such as type-1 
gastric NETs.  
Previously developed gastrin/CCK2 receptor antagonists have been shown to block the 
downstream signalling associated with CCK2R activation. However to date clinical 
application has proven disappointing due to low oral bioavailability, potency and/or 
selectivity. Recently, two studies have reported tumour regression in patients with 
hypergastrinaemia and type-1 gastric NETs who have taken the CCK2R antagonist, 
netazepide 459, 460. These data indicate the potential for netazepide and related compounds 
to be utilised for the treatment of gastrin-associated malignant conditions. This thesis has 
reported that three novel CCK2R antagonist drugs which are structurally similar to 
netazepide significantly inhibited gastrin-induced cellular changes which have previously 
been associated with gastric pathologies including type-1 gastric NETs. Although the most 
potent of the three novel compounds was TR2, it was still equal to or less potent than 
YM022 and netazepide. However, if it shown to have improved bioavailability and CCK2R 
selectivity in vivo, TR2 may still prove to be a new CCK2R antagonist drug that is suitable 





4.4 Future research directions 
Three potential future research directions have been highlighted during this study. Further 
research is required to evaluate the clinical potential of miR-222 and PAPPA2 as non-
invasive biomarkers of gastrin-related conditions and additional experiments are also 
necessary to assess whether TR2 is suitable to be developed as a novel treatment for 
gastrin-induced conditions.    
In Chapter 3.1, further profiling of miR-222 expression in a larger cohort of patients with 
other causes of hypergastrinaemia i.e. PPI use, H. pylori infection and type-2 gastric NETs 
with associated ZES would determine whether miR-222 expression patterns can distinguish 
between different sources of hypergastrinaemia. If distinct miR-222 expression patterns 
are associated with different sources of hypergastrinaemia this would increase the utility 
of this biomarker in various gastrin-related conditions, thus increasing the potential for 
clinical application.  
As gastrin-CCK2R binding has been shown to activate several downstream pathways 
including PI3K, MAPK and PKC pathways, further investigation of other miR-222 targets 
that may be involved in the regulation of these pathways would also be beneficial to 
understand the mechanisms involved in the development of gastrin-related pathologies. 
miR-222 has been shown to downregulate the tumour suppressor proteins TIMP3 and 
PTEN, which are involved in regulating tissue remodelling and cell cycle progression in non-
squamous cell lung carcinoma (NSCLC) and hepatocellular carcinoma (HCC) 845. It would 
therefore be interesting to investigate the expression of these target proteins in gastric 
tissues under hypergastrinaemic conditions.  
As previously mentioned, miR-222 is transcribed as a dicistronic primary transcript with 
miR-221. Thus miR-221 expression may also be increased upon CCK2R activation. In NSCLC 




been shown to target TIMP3 and PTEN 845. Further investigation of miR-221 expression 
would indicate whether dysregulation of several gastric physiological cell processes may be 
responsible for the malignant phenotypes associated with hypergastrinaemia. 
Alternatively, next-generation sequencing could identify the expression patterns of all 
gastrin-regulated miRNAs. This would provide a more accurate ‘miRNA signature’ and 
would potentially increase biomarker(s) specificity for particular gastrin-induced 
morphological changes within the stomach.  
In Chapter 3.2 experiments were only conducted in vitro and follow up studies should 
therefore include in vivo application.  Transgenic mouse models should be used to confirm 
that altered PAPPA2 expression is caused by gastrin.  For example, PAPPA2 expression 
should be assessed in hypergastrinaemic INS-GAS mice and compared with that in wild-
type FVB/N mice, with and without H. felis infection for short and long periods of time. 
PAPPA2 deficient mice 846, 847 and wild-type mice on the same genetic background could 
also be used to further explore whether gastric morphological changes occur as a result of 
gastrin-induced overexpression of PAPPA2.  
As previous studies have suggested that PAPPA2 can be detected in the blood 4, 781, 848, 
PAPPA2 enzyme-linked immunosorbent assays (ELISAs) could be employed to measure the 
circulating concentrations of PAPPA2 protein in patients with hypergastrinaemia and type-
1 gastric NETs compared with healthy controls. Immunohistochemistry would additionally 
show which cells within the stomach express PAPPA2 in health and disease. It would 
additionally be useful to investigate PAPPA2 expression in different hypergastrinaemic 
conditions such as PPI usage, H. pylori infection and type-2 gastric NETs with associated 





In Chapter 3.3, TR2 was the most potent of the three novel compounds tested in vitro. 
Further examination of gastrin-regulated gene expression (such as miR-222, PAPPA2, Mcl-1 
180, PAI-1 185, PAI-2 173 and MMP7 190) in human immortalised cell lines and primary cells by 
qPCR and western blot, at a range of doses of TR2, would now be helpful. Evaluating the 
effects of TR2 in gastric corpus organoids derived from hypergastrinaemic mice and 
humans, compared with wild-type mice and healthy humans, would also be helpful to 
assess the effects of TR2 on gastrin-induced gene expressions in a 3D model that more 
closely mimics the in vivo gastric environment. Both short and long-term in vivo studies in 
hypergastrinaemic mice are also needed to determine whether TR-2A (the pro-drug of 
TR2) affects gastric morphology, gastric acid secretion or gastrin-related gene expression. 
These experiments are required before future human clinical trials of TR2 can be 
contemplated.    
4.5 Conclusions 
Gastrin altered the expression of miRNAs which are involved in the physiological 
maintenance of the gastric mucosa, specifically miR-222. In vitro changes were validated in 
hypergastrinaemic murine models (INS-GAS) and human clinical samples obtained from 
patients with hypergastrinaemia and type-1 gastric NETs. Increased expression of miR-222, 
in response to CCK2R activation by gastrin, inhibited the production of proteins such as 
p27 that control biological processes which may contribute to gastric premalignant 
morphological changes. Similarly, gastrin increased the expression of the matrix 
remodelling protein PAPPA2 in vitro and this was shown to increase cell migration and 
tissue remodelling; prerequisites for gastric carcinogenesis. These data suggest that both 
miR-222 and PAPPA2 are gastrin-related genes which may be further developed as serum 




In vitro, treatment with the novel CCK2R antagonists, TR1, TR2 or TR3 significantly reversed 
gastrin-induced cellular phenomena including dysregulated growth, increased migration, 
clonogenic survival and increased structural remodelling, with TR2 proving the most potent 
of the three tested compounds. Although TR2 is equal to or less potent than previously 
developed CCK2R antagonists in vitro, it is still a promising drug candidate for the 
treatment of gastrin-related conditions in vivo as it may have an increased oral 
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Table 2. Mature miRNA expression patterns of all 84 mature miRNAs arrayed the pathway-
focused miScript miRNA PCR array for AGSGR cells treated with 10nM G17 24hrs compared 
with untreated controls. 
 Human mature miRNA Fold change P value 
*ǂ miR-376c-3p 0.010 5.18 
*ǂ miR-222-3p <0.000 2.34 
ǂ miR-141-3p 0.163 2.11 
 miR-32-5p 0.943 1.84 
* miR-22-3p 0.026 1.82 
* miR-142-3p 0.029 1.81 
* miR-27a-3p 0.002 1.80 
 miR-130a-3p 0.150 1.60 
 miR-210-3p 0.513 1.57 
* miR-29a-3p 0.002 1.47 
 miR-124-3p 0.409 1.37 
* miR-29c-3p 0.001 1.36 
* miR-140-3p 0.044 1.34 
 miR-424-5p 0.403 1.32 
 miR-101-3p 0.432 1.30 
 miR-146a-5p 0.415 1.29 
 miR-144-3p 0.417 1.28 
 miR-196b-5p 0.417 1.27 
 miR-185-5p 0.102 1.26 
 miR-143-3p 0.737 1.26 
 let-7c-5p 0.262 1.25 
 miR-150-5p 0.428 1.22 
 miR-302c-3p 0.166 1.20 
 miR-23a-3p 0.585 1.18 
 let-7b-5p 0.459 1.17 
 miR-155-5p 0.423 1.15 
 miR-24-3p 0.502 1.12 
 let-7d-5p 0.552 1.10 
 miR-186-5p 0.462 1.08 
 miR-223-3p 0.425 1.08 
 miR-126-3p 0.425 1.07 
 miR-122-5p 0.425 1.07 
 miR-19b-3p 0.520 1.06 
 miR-19a-3p 0.551 1.06 
 miR-28-5p 0.783 1.05 
 miR-16-5p 0.658 1.04 
 miR-125a-5p 0.708 1.03 
 miR-181a-5p 0.969 1.03 
 miR-15a-5p 0.881 1.00 
 miR-195-5p 0.855 0.98 
 miR-125b-5p 0.890 0.97 
 let-7a-5p 0.848 0.97 




 Human mature miRNA Fold change P value 
 miR-191-5p 0.917 0.95 
 let-7e-5p 0.829 0.95 
 miR-106b-5p 0.760 0.93 
 miR-302a-3p 0.672 0.93 
 miR-425-5p 0.644 0.93 
 miR-200c-3p 0.959 0.93 
 miR-30b-5p 0.697 0.92 
 let-7i-5p 0.507 0.92 
 miR-142-5p 0.710 0.90 
 miR-30a-5p 0.598 0.90 
 miR-27b-3p 0.817 0.90 
 miR-302b-3p 0.709 0.88 
 miR-20a-5p 0.384 0.88 
 miR-181b-5p 0.454 0.87 
 miR-151a-5p 0.562 0.86 
 miR-93-5p 0.187 0.86 
 miR-21-5p 0.964 0.85 
 miR-15b-5p 0.787 0.85 
 let-7f-5p 0.848 0.83 
 miR-99a-5p 0.852 0.83 
 miR-92a-3p 0.504 0.83 
 miR-30d-5p 0.390 0.82 
 miR-26a-5p 0.728 0.81 
 miR-18a-5p 0.163 0.81 
 miR-23b-3p 0.610 0.81 
 miR-17-5p 0.171 0.80 
 miR-320a 0.251 0.78 
 miR-194-5p 0.250 0.74 
 miR-374a-5p 0.472 0.74 
 miR-423-5p 0.288 0.72 
 let-7g-5p 0.338 0.72 
 miR-128-3p 0.207 0.72 
 miR-103a-3p 0.813 0.70 
 miR-26b-5p 0.617 0.69 
 miR-7-5p 0.401 0.68 
 miR-100-5p 0.418 0.60 
 miR-30e-5p 0.191 0.51 
 miR-30c-5p 0.385 0.47 
ǂ miR-96-5p 0.738 0.27 
ǂ miR-29b-3p 0.669 0.22 
ǂ miR-25-3p 0.089 0.07 
* Statistically significant versus untreated control samples (P<0.05 was considered 
significant) 
ǂ Fold regulation beyond the 2-fold boundary relative to untreated control samples 
 
